<SEC-DOCUMENT>0001193125-24-227080.txt : 20240927
<SEC-HEADER>0001193125-24-227080.hdr.sgml : 20240927
<ACCEPTANCE-DATETIME>20240927060915
ACCESSION NUMBER:		0001193125-24-227080
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240927
DATE AS OF CHANGE:		20240927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263251
		FILM NUMBER:		241330379

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d872484d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR>Registration No. 333-263251 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated May&nbsp;4, 2022) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>23,125,001 Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g872484g05g05.jpg" ALT="LOGO" STYLE="width:1.5625in;height:0.5625in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 23,125,001 of our ordinary shares and, in lieu of ordinary shares to certain investors that so
<FONT STYLE="white-space:nowrap">choose,&nbsp;pre-funded&nbsp;warrants</FONT> to purchase 1,875,023 ordinary shares. The purchase price of <FONT STYLE="white-space:nowrap">each&nbsp;pre-funded&nbsp;warrant</FONT> equals the price per share at which
ordinary shares are being sold to the public in this offering, minus $0.0001, and the exercise price of <FONT STYLE="white-space:nowrap">each&nbsp;pre-funded&nbsp;warrant</FONT> equals $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares are listed on the Nasdaq Global Market under the symbol &#147;WVE.&#148; The last reported sale price of our ordinary shares on the Nasdaq
Global Market on September&nbsp;25, 2024 was $9.01 per ordinary share. There is no established public trading market for <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants,</FONT> and we do not expect a market to develop. In
addition, we do not intend to apply for a listing of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> on the Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;<A HREF="#suptx872484_4">Risk Factors</A>&#148; on page <FONT
STYLE="white-space:nowrap">S-16</FONT> of this prospectus supplement and in the documents that are incorporated by reference into this prospectus supplement. </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER<BR><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT></B><br><B>WARRANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Wave Life Sciences Ltd., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,999,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to the section titled &#147;Underwriting&#148; for additional information regarding underwriting
compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is expected to be made on
or about September 27, 2024. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 ordinary shares. If the underwriters exercise the option in full, the total underwriting discounts and
commissions payable by us will be $13.8 million, and the total proceeds to us, before expenses, will be $215.7&nbsp;million. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint
Book-Running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Leerink Partners</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Book-Runners </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Truist Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Mizuho</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement dated September 25, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Page </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_10">DESCRIPTION OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_11">CERTAIN MATERIAL TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_12">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptx872484_16">INCORPORATION OF DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_5">INDUSTRY AND MARKET DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_8">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_10">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_11">DESCRIPTION OF RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_12">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_13">COMPARISON OF SHAREHOLDER RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_14">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_15">ENFORCEMENT OF CIVIL LIABILITIES UNDER UNITED STATES SECURITIES
LAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_16">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_17">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_18">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_19">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a &#147;shelf&#148; registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263251)</FONT> that we initially filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on March&nbsp;3, 2022, and was declared
effective on May&nbsp;4, 2022. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and
also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more
general information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a
conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should
rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in the
accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on
the information we have provided or incorporated by reference in this prospectus. We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson or
other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only
the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus is accurate only as of the date on the front of the document and that any
information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference in this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus supplement nor the accompanying
prospectus is a &#147;prospectus&#148; as defined in the Securities and Futures Act 2001 of Singapore (the &#147;SFA&#148;), and accordingly, statutory liability under the SFA in relation to the content of prospectuses will not apply. This
prospectus supplement and the accompanying prospectus have not been lodged with or registered as a prospectus by the Monetary Authority of Singapore. Accordingly, this prospectus supplement, the accompanying prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of our ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may not be circulated or distributed, nor may our ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
(as defined in Section&nbsp;4A of the SFA) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018 or (iii)&nbsp;otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with the conditions set forth in the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trustee of a trust (where the trustee is not an accredited investor) whose sole purpose is to hold
investments and each beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based
derivatives contracts (each as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that
trust has acquired the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to an offer made under Section&nbsp;275 of the SFA, except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person as defined in Section&nbsp;275(2) of the SFA, or (in the
case of such corporation) where the transfer arises from an offer referred to in Section&nbsp;275(1A) of the SFA or (in the case of such trust) where the transfer arises from an offer referred to in Section&nbsp;276(4)(c)(ii) of the SFA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reference to the SFA is a reference to the Securities and
Futures Act 2001 of Singapore and a reference to any term as defined in the SFA or any provision in the SFA is a reference to that term as modified or amended from time to time including by such of its subsidiary legislation as may be applicable at
the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notification under Section</B><B></B><B>&nbsp;309B(1) of the SFA</B>: The Company has determined, and hereby notifies all persons
(including relevant persons (as defined in Section&nbsp;309A(1) of the SFA)) that the ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are prescribed capital markets products (as defined in the Securities and Futures
(Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in the MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice
<FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this prospectus supplement and the
accompanying prospectus, the recipient hereof and thereof represents and warrants that such recipient is entitled to receive it in accordance with the restrictions set forth above and agrees to be bound by the limitations contained herein. Any
failure to comply with these limitations may constitute a violation of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references to &#147;Wave,&#148; the
&#147;Company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; or similar terms refer to Wave Life Sciences Ltd. and our wholly-owned subsidiaries. References in this prospectus to &#147;S$&#148; refer to Singapore
dollars, &#147;&yen;&#148; refer to Japanese yen, and &#147;&#128;&#148; refer to euros. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd.
names, the Wave Life Sciences mark, and the other trademarks, trade names and service marks of Wave Life Sciences Ltd. appearing in this prospectus supplement or the accompanying prospectus are the property of Wave Life Sciences Ltd. Wave has
applied to register certain of its trademarks in the United States. This prospectus supplement and the accompanying prospectus also contain additional trade names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other
companies. We do not intend our use or display of other parties&#146; trademarks, trade names or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the
trademarks and trade names in this prospectus supplement and the accompanying prospectus are referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols,
but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For investors outside the United States</I>: Neither we nor any of the underwriters have taken any action that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to
inform themselves about and to observe any restriction relating to this offering and the distribution of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This
summary does not contain all of the information that you should consider before deciding to invest in our ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. You should read this entire prospectus supplement and the
accompanying prospectus carefully, including the &#147;Risk Factors&#148; section contained in this prospectus supplement, our consolidated financial statements and the related notes thereto and the other documents and information incorporated by
reference in this prospectus supplement and the accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (&#147;RNA&#148;) medicines (also known as
oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, combines multiple modalities, chemistry innovation and deep insights into human
genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of <FONT STYLE="white-space:nowrap">RNA-targeting</FONT> modalities includes RNA editing, splicing, antisense silencing and RNA interference
(&#147;RNAi&#148;), providing us with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our lead programs are in rare and prevalent diseases, including
<FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency (&#147;AATD&#148;), obesity, Duchenne muscular dystrophy (&#147;DMD&#148;), and Huntington&#146;s disease (&#147;HD&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded on the recognition that there was a significant, untapped opportunity to use chemistry innovation to tune the pharmacological properties of
oligonucleotides. Today, we have more than a decade of experience challenging convention related to oligonucleotide design and pioneering novel chemistry modifications to optimize the pharmacological properties of our molecules. We have seen
preclinically and in clinical trials that these chemistry modifications enhance potency, distribution, and durability of effect of our molecules. Our novel chemistry also allows us to avoid using complex delivery vehicles, such as lipid
nanoparticles and viruses, and instead use clinically proven conjugates (<I>e.g.</I>, <I>N</I>-acetylgalactosamine or (&#147;GalNAc&#148;)) or free uptake for delivery to a variety of cell and tissue types. We maintain strong and broad intellectual
property, including for our novel chemistry modifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> chemistry capabilities have also unlocked new areas of biology, such as harnessing adenosine deaminases acting on RNA (&#147;ADAR&#148;) enzymes for
messenger RNA (&#147;mRNA&#148;) correction and upregulation, selectively silencing a mutant allele, and more. By opening up new areas of biology, we have also opened up new opportunities to slow, stop or reverse disease and have expanded the
possibilities offered through our platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inspiration for our multimodal platform is based on the recognition that the biological machinery (i.e.,
enzymes) needed to address human disease already exists within our cells and can be harnessed for therapeutic purposes with the right tools. We believe that we have built the most versatile toolkit of
<FONT STYLE="white-space:nowrap">RNA-targeting</FONT> modalities in the industry, with multiple means of repairing, restoring, or reducing proteins and designing <FONT STYLE="white-space:nowrap">best-fit</FONT> solutions based on the unique biology
of a given disease target. We are actively advancing programs in all of our modalities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g872484g11g11.jpg" ALT="LOGO" STYLE="width:3.1875in;height:2.28906in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intentionally focus on targeting the transcriptome using oligonucleotides rather than other nucleic acid modalities such
as gene therapy and DNA editing. This focus enables us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage diversity of expression across cell types by modulating the many regulatory pathways that impact gene
expression, including transcription, endogenous RNA interference pathways, splicing, and translation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address diseases that have historically been difficult to treat with small molecules or biologics;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Access a variety of tissue types or cell types throughout the body and modulate the frequency of dosing for broad
distribution in tissues over time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avoid the risk of permanent <FONT STYLE="white-space:nowrap">off-target</FONT> genetic changes and other
challenges associated with DNA editing or gene therapy approaches; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage well-established industry manufacturing processes and regulatory, access, and reimbursement pathways.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a robust and diverse pipeline of potential <FONT STYLE="white-space:nowrap">first-or</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> programs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GalNAc-conjugated oligonucleotides for hepatic and metabolic diseases including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AATD: <FONT STYLE="white-space:nowrap">WVE-006</FONT> is a GalNAc-conjugated SERPINA1 RNA editing
oligonucleotide; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obesity: <FONT STYLE="white-space:nowrap">WVE-007</FONT> is a GalNAc-conjugated RNAi oligonucleotide targeting
inhibin <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>E (&#147;INHBE&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unconjugated oligonucleotides for muscle, CNS and other disease areas including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DMD: <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is an exon 53 splicing oligonucleotide; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HD: <FONT STYLE="white-space:nowrap">WVE-003</FONT> is an allele-selective oligonucleotide designed to lower
mutant huntingtin (&#147;mHTT&#148;) protein and preserve healthy, wild-type huntingtin (&#147;wtHTT&#148;) protein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
building a pipeline of novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-to-I</FONT></FONT> RNA editing oligonucleotides (&#147;AIMers&#148;). Our RNA editing capability affords us the dexterity to address both rare diseases,
as well as those diseases impacting large patient populations. AIMers are designed to target single bases on an RNA transcript and recruit proteins that exist in the body, called ADAR enzymes, which naturally possess the ability to change an adenine
(A)&nbsp;to an inosine (I), which cells read as guanine (G). This approach enables both the correction of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-to-A</FONT></FONT> point mutations and the modulation of RNA to either
upregulate protein expression, modify protein-protein interactions, or alter RNA </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
folding and processing. AIMers enable simplified delivery and avoid the risk of permanent changes to the genome and irreversible <FONT STYLE="white-space:nowrap">off-target</FONT> effects with <FONT
STYLE="white-space:nowrap">DNA-targeting</FONT> approaches. AIMers are short in length, fully chemically modified, and use our novel chemistry, which make them distinct from other ADAR-mediated editing approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, we announced a strategic collaboration with GlaxoSmithKline Intellectual Property (No. 3) (&#147;GSK&#148;) to advance transformative
oligonucleotide therapeutics, including <FONT STYLE="white-space:nowrap">WVE-006.</FONT> The collaboration combines GSK&#146;s novel genetic insights, as well as its global development and commercial capabilities, with our PRISM platform and
oligonucleotide expertise. The collaboration will enable us to continue building a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> oligonucleotide-based therapeutics and unlock new areas of
disease biology, as well as realize the full value of <FONT STYLE="white-space:nowrap">WVE-006</FONT> as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for AATD that has the
potential to simultaneously address both liver and lung manifestations of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our GSK collaboration has three components: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A discovery collaboration which enables us to advance up to three programs leveraging targets informed by
GSK&#146;s novel insights, the first of which is our INHBE program <FONT STYLE="white-space:nowrap">(WVE-007)</FONT> for obesity and other metabolic disorders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A discovery collaboration which enables GSK to advance up to eight programs leveraging PRISM and our
oligonucleotide expertise and discovery capabilities, the first two of which were selected in April 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An exclusive global license for GSK to <FONT STYLE="white-space:nowrap">WVE-006,</FONT> our AATD program, that
uses our proprietary AIMer technology. We will maintain development responsibilities for <FONT STYLE="white-space:nowrap">WVE-006</FONT> through completion of <FONT STYLE="white-space:nowrap">RestorAATion-2,</FONT> at which point development and
commercial responsibilities will transition to GSK. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Current Programs </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g872484g08n08.jpg" ALT="LOGO" STYLE="width:6.30556in;height:2.74532in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional details regarding our lead therapeutic programs are set forth below. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><I><FONT STYLE="white-space:nowrap">Alpha-1</FONT> antitrypsin deficiency (&#147;AATD&#148;)</I> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our AATD program is the first to leverage our novel RNA editing capability and uses GalNAc-conjugated AIMers (RNA editing oligonucleotides) and endogenous ADAR
enzymes to correct a single base in the mutant SERPINA1 mRNA. By correcting the single RNA base mutation that causes a majority of AATD cases with the Pi*ZZ genotype (approximately 200,000 in the United States and Europe), RNA editing may provide an
ideal approach for increasing circulating levels of wild-type <FONT STYLE="white-space:nowrap">Alpha-1</FONT> antitrypsin (&#147;AAT&#148;) protein and reducing mutant protein aggregation in the liver, thus simultaneously addressing both the lung
and liver manifestations of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">WVE-006</FONT> is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> in AATD and is the most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for RNA editing. In the fourth quarter of 2023, we initiated our
RestorAATion clinical program investigating <FONT STYLE="white-space:nowrap">WVE-006</FONT> as a treatment for AATD. The RestorAATion clinical program includes both healthy volunteers
<FONT STYLE="white-space:nowrap">(&#147;RestorAATion-1&#148;),</FONT> as well as patients with AATD who have the homozygous Pi*ZZ mutation <FONT STYLE="white-space:nowrap">(&#147;RestorAATion-2&#148;)</FONT> and is designed to provide an efficient
path to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> as measured by restoration of wild-type <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin
<FONT STYLE="white-space:nowrap">(&#147;M-AAT&#148;)</FONT> protein in serum. <FONT STYLE="white-space:nowrap">RestorAATion-2</FONT> is a Phase 1b/2a open label study designed to evaluate the safety, tolerability, pharmacodynamics (PD) and
pharmacokinetics (PK) of <FONT STYLE="white-space:nowrap">WVE-006</FONT> in individuals with AATD who have the homozygous Pi*ZZ mutation. The trial includes both single ascending dose (&#147;SAD&#148;) and multiple ascending dose (&#147;MAD&#148;)
portions. In the third quarter of 2024, we initiated dosing in the single dose portion of the first dose cohort of <FONT STYLE="white-space:nowrap">RestorAATion-2.</FONT> We expect to deliver <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> data in patients with AATD in the fourth quarter of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our GSK collaboration, GSK
received an exclusive global license for <FONT STYLE="white-space:nowrap">WVE-006,</FONT> with clinical development and commercial responsibilities transitioning to GSK after we complete the <FONT STYLE="white-space:nowrap">RestorAATion-2</FONT>
trial. Under the terms of the collaboration, we are eligible to receive up to $525&nbsp;million in development, launch, and commercial milestone payments, as well as double-digit tiered royalties up to the high teens, as a percentage of net sales
for <FONT STYLE="white-space:nowrap">WVE-006.</FONT> In December 2023, we announced that we achieved the first <FONT STYLE="white-space:nowrap">WVE-006</FONT> milestone in our collaboration with GSK, resulting in a $20&nbsp;million payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical data show that treatment with <FONT STYLE="white-space:nowrap">WVE-006</FONT> resulted in serum AAT protein levels of up to 30 micromolar in an
established AATD mouse model <FONT STYLE="white-space:nowrap">(NSG-PiZ).</FONT> <FONT STYLE="white-space:nowrap">WVE-006</FONT> also led to restoration of approximately 50% wild-type <FONT STYLE="white-space:nowrap">M-AAT</FONT> protein in serum and
a <FONT STYLE="white-space:nowrap">3-fold</FONT> increase in neutrophil elastase inhibition activity, indicating that the restored <FONT STYLE="white-space:nowrap">M-AAT</FONT> protein was functional. Our AATD AIMers are highly specific to SERPINA1
RNA <I>in vitro</I> and <I>in vivo</I> based on transcriptome-wide analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are successful in the clinic with
<FONT STYLE="white-space:nowrap">WVE-006,</FONT> this would validate our clinical approach to AATD and demonstrate the feasibility of RNA editing as a therapeutic modality in humans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Obesity and Other Metabolic Disorders </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our first
wholly owned program to emerge from our collaboration with GSK is <FONT STYLE="white-space:nowrap">WVE-007,</FONT> a GalNAc-small interfering RNA (&#147;siRNA&#148;) that is designed to silence the Inhibin
<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>E gene (&#147;INHBE&#148;) to induce lipolysis <FONT STYLE="white-space:nowrap">(fat-burning)</FONT> while preserving muscle mass to restore and maintain a healthy metabolic profile. There are
approximately 174&nbsp;million people in the United States and Europe with obesity, and therapeutic options beyond <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonists are needed. <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor
agonists lead to weight loss at the expense of muscle, suppress the general reward system, and are associated with a poor tolerability profile and 68% <FONT STYLE="white-space:nowrap">drop-off</FONT> after one year. Heterozygous INHBE <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> human carriers exhibit a healthy metabolic profile, including reduced
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">waist-to-hip</FONT></FONT> ratio and reduced odds of developing type 2 diabetes or coronary artery disease, and reduction of INHBE by 50% or more is expected to restore a healthy
metabolic profile. In connection with our </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2023 Research and Development Day, we shared <I>in vivo</I> proof of concept data in diet-induced obesity mice demonstrating INHBE silencing well beyond the anticipated 50% therapeutic threshold,
which led to substantially lower body weight and reduction of visceral fat as compared to controls. These are the first data to demonstrate INHBE silencing <I>in vivo</I> in an animal model is consistent with the phenotypes of heterozygous <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> carriers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">WVE-007</FONT>
utilizes our next generation GalNAc-siRNA format. In preclinical diet-induced obesity (&#147;DIO&#148;) mouse models, our INHBE GalNAc-siRNA has demonstrated highly potent INHBE silencing (ED50 &lt; 1 mg/kg), durable silencing following one, <FONT
STYLE="white-space:nowrap">low-single</FONT> digit dose supporting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">every-six-month</FONT></FONT> or annual subcutaneous dosing in humans, weight loss with no loss of muscle mass and
reduction in fat mass, with preferential effect to the visceral fat, consistent with the profile of INHBE LoF in human genetics. In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study in DIO mice, we
have observed a weight loss effect from a single dose of our INHBE GalNAc-siRNA similar to semaglutide. In addition, treatment with our INHBE GalNAc-siRNA upon cessation of semaglutide treatment curtailed expected rebound weight gain. Additionally,
in a separate ongoing study in DIO mice, when administered in combination with semaglutide, a single dose of our INHBE GalNAc-siRNA doubled the weight loss observed with semaglutide alone and this effect was sustained throughout the duration of the
study. We plan to share additional preclinical data later this year and expect to initiate a clinical trial for <FONT STYLE="white-space:nowrap">WVE-007</FONT> in the first quarter of 2025 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><I>Duchenne muscular dystrophy (&#147;DMD&#148;)</I> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
DMD, we are advancing <FONT STYLE="white-space:nowrap">WVE-N531,</FONT> which is designed to skip exon 53 within the dystrophin gene &#150; a therapeutic approach that would address approximately <FONT STYLE="white-space:nowrap">8-10%</FONT> of DMD
cases. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is designed to cause the cellular splicing machinery to skip over exon 53 during <FONT STYLE="white-space:nowrap">pre-mRNA</FONT> processing, which restores the dystrophin mRNA reading frame
and enables production of a truncated, but functional, dystrophin protein. Exon skipping produces dystrophin from the endogenous dystrophin gene (not micro or mini dystrophin expressed from a foreign vector), under the control of native
gene-regulatory elements, resulting in normal expression. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is our first splicing candidate incorporating PN backbone (&#147;PN&#148;) chemistry to be assessed in the clinic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022 (data <FONT STYLE="white-space:nowrap">cut-off:</FONT> December&nbsp;6, 2022), we announced a positive update from Part A of the Phase 1b/2a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> open label trial of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> in three boys with DMD amenable to exon 53 skipping. High muscle concentrations of <FONT
STYLE="white-space:nowrap">WVE-N531</FONT> and exon skipping were observed six weeks after initiating multi-dosing at 10 mg/kg every other week, achieving
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in the trial. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> also appeared safe and well-tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, we shared an analysis of muscle biopsy data from the Part A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial indicating that <FONT STYLE="white-space:nowrap">WVE-N531</FONT> was present in myogenic stem cells, which are integral to muscle regeneration.
This is the first demonstration of uptake in myogenic stem cells in a clinical study and supports the potential differentiation of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> from other therapeutics, including gene therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, we initiated dosing of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> in <FONT STYLE="white-space:nowrap">FORWARD-53,</FONT> the Phase 2
portion of the open-label trial (&#147;Part B&#148;). In Part B, boys are being dosed at 10 mg/kg every other week, and we plan to assess dystrophin protein after 24 and 48 weeks of dosing. The primary endpoint will be dystrophin protein levels, and
the trial will also evaluate pharmacokinetics, digital and functional endpoints, and safety and tolerability. See &#147;-Recent Developments&#148; regarding our announcement of positive interim data from FORWARD-53. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><I>Huntington&#146;s disease (&#147;HD&#148;)</I> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In HD, we are currently advancing <FONT STYLE="white-space:nowrap">WVE-003,</FONT> a stereopure allele-selective oligonucleotide designed to selectively target
an undisclosed single nucleotide polymorphism (&#147;SNP&#148;), &#147;mHTT SNP3&#148;, associated with the disease-causing mHTT mRNA transcript within the Huntingtin (&#147;HTT&#148;) gene. Approximately 40% of the HD population carries SNP3
according to published literature (Carroll et al., Molecular Therapy, 2011), and up to 80% of HD may be addressed in the future with other <FONT STYLE="white-space:nowrap">SNP-targeted</FONT> candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently no disease modifying therapies for HD, which affects over 200,000 individuals across all disease stages in the United States and Europe.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">WVE-003</FONT> incorporates our proprietary PN chemistry. Targeting mRNA with SNP3 allows us to lower expression of
transcript from the mutant allele, while leaving the healthy transcript relatively intact, thereby preserving wild-type (healthy) huntingtin (&#147;wtHTT&#148;) protein, which is important for neuronal function. Only an allele-selective approach to
mHTT lowering has the potential to both protect the reservoir of wtHTT protein and decrease the mHTT to wtHTT ratio in neurons, potentially releasing wtHTT from the inhibitory actions of mHTT. Our allele-selective approach may also enable us to
address HD patient populations in early stages of disease prior to onset of clinical symptoms. In preclinical studies, <FONT STYLE="white-space:nowrap">WVE-003</FONT> showed dose-dependent and selective reduction of mHTT mRNA <I>in vitro</I>, as
well as potent and durable knockdown of mHTT mRNA and protein <I>in vivo</I> in mouse models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the third quarter of 2023, we achieved a milestone in
our collaboration with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;), which pertained to the positive results from a <FONT STYLE="white-space:nowrap">non-clinical</FONT> study of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in <FONT
STYLE="white-space:nowrap">non-human</FONT> primates and resulted in a payment of $7.0&nbsp;million to us. This study showed significant tissue exposure levels of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in the deep brain regions, including
striatum and bolstered our existing datasets that confirm the ability of our oligonucleotides to distribute to the areas of the CNS important for HD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">SELECT-HD</FONT> trial was a global, multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in
people with a confirmed diagnosis of HD who are in the early stages of the disease and carry SNP3 in association with their cytosine-adenine-guanine (&#147;CAG&#148;) expansion. Additional objectives included assessing pharmacokinetics and
exploratory pharmacodynamic and clinical endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2024, we announced positive clinical data from the Phase 1b/2a
<FONT STYLE="white-space:nowrap">SELECT-HD</FONT> study of <FONT STYLE="white-space:nowrap">WVE-003.</FONT> Results from the multi-dose portion of the trial, which evaluated three doses of 30mg <FONT STYLE="white-space:nowrap">WVE-003</FONT>
administered every eight weeks, showed clear translation of target engagement to clinic with statistically significant, potent, durable and allele-selective reductions in cerebrospinal fluid (&#147;CSF&#148;) mHTT of up to 46% and preservation of
healthy protein. This cohort also revealed a statistically significant correlation between mHTT reductions and slowing of caudate atrophy, indicating a potential benefit of allele-selective mHTT reductions. Structural brain magnetic resonance
imaging (&#147;MRI&#148;) changes such as caudate atrophy are well-characterized measures of disease progression and neurodegeneration in HD. <FONT STYLE="white-space:nowrap">WVE-003</FONT> was generally safe and well-tolerated, with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> adverse events (&#147;AEs&#148;) and no Serious AEs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
submitted an <FONT STYLE="white-space:nowrap">opt-in</FONT> package to our partner, Takeda, and initiated engagement with regulators on a clinical development path to accelerated approval. We expect to receive a decision from Takeda on their option
right, as well as feedback from regulators by <FONT STYLE="white-space:nowrap">year-end.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Discovery Pipeline </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing new targets across multiple disease areas to expand our pipeline of wholly owned programs. Our compelling preclinical data indicates our
oligonucleotides can distribute to various tissues and cells without </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complex delivery vehicles, enabling us to address a wide variety of diseases, including pulmonary and renal diseases. Within RNA editing, we have demonstrated preclinically that we can edit to
correct monogenic diseases by restoring or correcting protein function for the treatment of AATD. Building on our work in AATD, we have demonstrated our ability to address more prevalent diseases by editing RNA to upregulate or increase the
stability of the mRNA transcript, thereby increasing endogenous protein production. Utilizing our proprietary &#147;edit-verse,&#148; which is powered by genetic datasets and deep learning models, we have identified several RNA editing targets that
leverage easily accessible biomarkers, offer efficient paths to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in humans, and represent meaningful commercial opportunities. We demonstrated
preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data on several of these new targets in 2023, achieving at least <FONT STYLE="white-space:nowrap">2-fold</FONT> mRNA upregulation in liver
and kidney targets and more than 60% mRNA correction in liver and lung targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our collaboration with GSK, we are leveraging GSK&#146;s novel
genetics insights to expand our wholly owned pipeline, with the first being our INHBE program. In addition, we and GSK are actively working on multiple target validation programs for our <FONT STYLE="white-space:nowrap">GSK-partnered</FONT>
programs, for which all of our costs and expenses are prepaid by GSK. In April 2024, GSK selected its first two programs to advance to development candidates following achievement of target validation, triggering an aggregate initiation payment of
$12&nbsp;million from GSK. These programs utilize our next generation GalNAc-siRNA format and are in hepatology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to select five new clinical
candidates by the end of 2025, including <FONT STYLE="white-space:nowrap">WVE-007,</FONT> our INHBE candidate for obesity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2024, we announced positive interim data from the ongoing Phase 2 <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> study of <FONT
STYLE="white-space:nowrap">WVE-N531,</FONT> which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. The interim analysis was conducted after 24 weeks of 10
mg/kg dosing every two weeks (Q2W), and <FONT STYLE="white-space:nowrap">WVE-N531</FONT> demonstrated substantial dystrophin expression and that it was safe and well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eleven boys amenable to exon 53 skipping (age <FONT STYLE="white-space:nowrap">5-11;</FONT> 10 ambulatory and 1
<FONT STYLE="white-space:nowrap">non-ambulatory)</FONT> are enrolled in the ongoing, open-label <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> trial. The study is designed to administer 10 mg/kg infusions of
<FONT STYLE="white-space:nowrap">WVE-N531</FONT> Q2W and muscle biopsies are taken after 24 and 48 weeks of dosing. Results from this interim analysis include: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety and Tolerability </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">WVE-N531</FONT> was safe and well tolerated. Treatment-related adverse events
(four events total in three participants) were mild in intensity. There were no serious adverse events and no study discontinuations due to any causes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no oligonucleotide class-related safety events. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dystrophin: Dystrophin results from a <FONT STYLE="white-space:nowrap">pre-specified</FONT> analysis of
ambulatory boys showed: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mean absolute muscle content-adjusted dystrophin expression was 9.0% (range:
<FONT STYLE="white-space:nowrap">4.6-13.9%)</FONT> and mean absolute unadjusted dystrophin expression was 5.5% of normal (range: <FONT STYLE="white-space:nowrap">3.3-8.3%),</FONT> as measured by Western Blot. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The dystrophin expression was quantified from two isoforms consistent with those observed in Becker muscular
dystrophy patients who display milder disease. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exon skipping: Mean exon skipping was 57% (range: <FONT STYLE="white-space:nowrap">31-75%)</FONT> as measured by <FONT
STYLE="white-space:nowrap">RT-PCR.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Localization: <FONT STYLE="white-space:nowrap">WVE-N531</FONT> was detected in myocyte nuclei in all participants
and in myogenic stem cells in the majority of participants. Myogenic stem cells are the progenitor cells for new myoblasts, which give rise to new myocytes and ultimately aid in skeletal muscle regeneration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Improvements in muscle health: Participants showed multiple indicators of improvement in muscle health, including
an increase in the mean percentage of myocytes with internalized nuclei and an improvement in myofiber size and diameter between the previously completed Part A study and <FONT STYLE="white-space:nowrap">FORWARD-53.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Serum biomarkers for muscle health: Creatine kinase (CK) and aspartate aminotransferase (AST) are serum
biomarkers that are elevated in the presence of muscle damage. In the interim data, there were significant decreases in CK and AST levels from baseline. The reduction in CK was numerically larger than is typically seen with the introduction of
steroids in DMD. Changes in CK and AST were highly correlated (p&lt;0.0001). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Muscle concentration: Mean muscle concentration was ~41,000 ng/g (~5,900 nM). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical data for <FONT STYLE="white-space:nowrap">WVE-N531</FONT> demonstrate significantly higher drug
concentrations in the heart and diaphragm versus skeletal muscle, suggesting the <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> data from skeletal muscle biopsies may be underrepresenting activity in heart and diaphragm. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Half-life: The muscle tissue half-life of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is estimated to be 61
days. Along with muscle concentration, this supports a monthly dosing regimen for <FONT STYLE="white-space:nowrap">WVE-N531</FONT> moving forward. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2025, we expect to complete the <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> trial and receive feedback from regulators on a
pathway to accelerated approval. We are also advancing a broader DMD pipeline of oligonucleotides for skipping other exons, with the goal of providing new and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment options for up to 40% of boys with DMD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Relating to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company, and our business and ability to execute our business strategy are subject to a
number of significant risks of which you should be aware before you decide to buy our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Among these important risks are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biotechnology company with a history of losses, and we expect to continue to incur losses
for the foreseeable future, and we may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional funding, which may not be available on acceptable terms, or at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management has broad discretion over the use of proceeds received from sales of our securities and our
collaborations with third parties and the proceeds may not be used effectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our operating history as a clinical-stage biotechnology company may make it difficult for shareholders to
evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We, or third parties upon whom we depend, may face risks related to local and global health epidemics, which may
delay our ability to complete our ongoing clinical trials, initiate additional clinical trials, delay regulatory activities and have other adverse effects on our business and operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The approach we are taking to discover and develop RNA medicines is novel and may never lead to marketable
products. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to conduct clinical trials successfully due to various process-related factors that could
negatively impact our business plans. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we cannot successfully manufacture our product candidates for our research and development and preclinical
activities, or manufacture sufficient amounts of our product candidates to meet our clinical requirements and timelines, our business may be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results of preclinical studies and early clinical trials may not be predictive of results of subsequent clinical
trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of
necessary regulatory approvals could be delayed or prevented. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be
unable to commercialize our product candidates and our ability to generate revenue will be materially impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. If we
or our collaborators fail to comply with continuing U.S. and foreign requirements, our approvals, if obtained, could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The pharmaceutical industry is intensely competitive. If we are unable to compete effectively with existing
drugs, new treatment methods and new technologies, we may be unable to successfully commercialize any drugs that we develop. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks associated with our operations outside of the United States and developments in international trade by the
U.S. and foreign governments could adversely affect our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to execute our business strategy optimally if we are unable to maintain our existing
collaborations or enter into new collaborations with partners that can provide sales, marketing and distribution capabilities and funds for the development and commercialization of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct some aspects of our compound formulation,
research, preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If any of our product candidates are approved for marketing and commercialization and we are unable to develop
sales, marketing and distribution capabilities on our own, or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such future products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to attract and retain qualified key management and scientists, staff, consultants and advisors,
our ability to implement our business plan may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to obtain and enforce market exclusivity for our technologies or product candidates,
development and commercialization of our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We license patent rights from third-party owners or licensees. If such owners or licensees do not properly or
successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other companies or organizations may challenge our or our licensors&#146; patent rights or may assert patent
rights that prevent us from developing and commercializing our products. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intellectual property rights of third parties could adversely affect our ability to commercialize our product
candidates, and we might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are incorporated in Singapore and our shareholders may have more difficulty in protecting their interests than
they would as shareholders of a corporation incorporated in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are subject to the laws of Singapore, which differ in certain material respects from the laws of the United
States. The public market may not be liquid enough for our shareholders to sell their ordinary shares quickly or at market price, or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market price of our ordinary shares is likely to be highly volatile, and our shareholders may lose some or
all of their investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you purchase ordinary shares in this offering, you will suffer immediate dilution of your investment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management will have broad discretion over the use of the net proceeds from this offering, and you may not
agree with how we use the proceeds and the proceeds may not be invested successfully. If we are unable to adequately address these and other risks we face, our business, financial condition, operating results and prospects may be adversely affected.
For additional information about the risks we face, please see the information contained in or incorporated by reference under &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-16</FONT> of this prospectus supplement and page 6 of
the accompanying prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History and Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. was incorporated under the name Wave Life Sciences Pte. Ltd. (Registration No.: 201218209G) under the laws of Singapore on
July&nbsp;23, 2012. On November&nbsp;16, 2015, we closed our initial public offering. In preparation for our initial public offering, on November&nbsp;5, 2015, Wave Life Sciences Pte. Ltd. converted from a private limited company to a public limited
company known as Wave Life Sciences Ltd., or Wave. Wave has four wholly-owned subsidiaries: Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), a Delaware corporation (formerly Ontorii, Inc.); Wave Life Sciences Japan, Inc. (&#147;Wave
Japan&#148;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.); Wave Life Sciences Ireland Limited (&#147;Wave Ireland&#148;), a company organized under the laws of Ireland; and Wave Life Sciences UK Limited (&#147;Wave
UK&#148;), a company organized under the laws of the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered office is located at 7 Straits View
<FONT STYLE="white-space:nowrap">#12-00,</FONT> Marina One East Tower, Singapore 018936, and our telephone number at that address is +65 6236 3388. Our principal office for Wave USA is located at 733 Concord Avenue, Cambridge, MA 02138, and our
telephone number at that address is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-617-949-2900.</FONT></FONT></FONT> Our registered office for Wave Japan is 2438
<FONT STYLE="white-space:nowrap">Miyanoura-cho,</FONT> <FONT STYLE="white-space:nowrap">Kagoshima-shi,</FONT> Kagoshima pref. <FONT STYLE="white-space:nowrap">891-1394,</FONT> Japan. Our registered office for Wave Ireland is One Spencer Dock, North
Wall Quay, Dublin 1, Ireland. Our registered office for Wave UK is 1 Chamberlain Square CS, Birmingham B3 3AX, United Kingdom. Our corporate website address is <I>http://www.wavelifesciences.com</I>. The information on our website is not part of
this prospectus supplement or the accompanying prospectus or incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider any information contained on, or that can be accessed through, our
website in deciding whether to purchase our ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and all amendments to such reports are made available free of charge through the &#147;For Investors&nbsp;&amp; Media&#151;SEC
Filings&#148; section of our website as soon as reasonably practicable after they have been filed or furnished with the SEC. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares offered by us </P></TD>
<TD>23,125,001 ordinary shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants offered by us </P></TD>
<TD>We are also offering, in lieu of ordinary shares to certain investors, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 1,875,023 ordinary shares. The purchase price of each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals the price per share at which the ordinary shares are being sold to the public in this offering, minus $0.0001, and the exercise price of each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be $0.0001 per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time after its original issuance and on or prior to 5:00 p.m. (New York
City time) on the five-year anniversary of the original issuance date, subject to an ownership limitation. See &#147;Description of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants.&#148; This prospectus supplement also relates to the
offering of the ordinary shares issuable upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares to be outstanding after this offering </P></TD>
<TD>145,604,290 ordinary shares (or 149,354,290 ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Series A preferred shares outstanding before and after this offering </P></TD>
<TD>3,901,348 shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Total ordinary shares and Series A preferred shares to be outstanding after this offering </P></TD>
<TD>149,505,638 shares (or 153,255,638 ordinary shares and Series A preferred shares if the underwriters exercise their option to purchase 3,750,000 additional ordinary shares in full) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ordinary shares </P></TD>
<TD>We have granted the underwriters an option to purchase up to an additional 3,750,000 ordinary shares at the offering price from us within 30 days of the date of this prospectus supplement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $187.4&nbsp;million, or approximately $215.7&nbsp;million if the underwriters exercise their option to purchase additional ordinary shares in full, after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital, capital expenditures and general and administrative expenses. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>An investment in our ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants involves a high degree of risk. See &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-16</FONT> and other information included
in or incorporated by reference in this prospectus supplement and the accompanying prospectus. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market symbol </P></TD>
<TD>&#147;WVE&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of ordinary shares to be outstanding after this offering is based on an aggregate of 122,479,289
ordinary shares outstanding as of June&nbsp;30, 2024, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,901,348 ordinary shares issuable upon the conversion of our Series A preferred shares outstanding as of
June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,093,656 ordinary shares issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,453,490 ordinary shares issued and sold after June&nbsp;30, 2024 pursuant to our open market sales agreement
with Jefferies LLC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20,574,934 ordinary shares issuable upon the exercise of share options outstanding as of June&nbsp;30, 2024, at a
weighted average exercise price of $5.75 per share, of which 8,136,928 ordinary shares were exercisable as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">660,750 restricted share units (&#147;RSUs&#148;) outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,866,279 ordinary shares reserved for future issuance under the 2021 Equity Incentive Plan (the &#147;2021
Plan&#148;) as of June&nbsp;30, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,388,958 ordinary shares reserved for future issuance under our 2019 Employee Share Purchase Plan
(&#147;ESPP&#148;) as of June&nbsp;30, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;30, 2024 through September&nbsp;15, 2024, we granted
options to purchase an aggregate of 402,900 ordinary shares and issued 201,450 RSUs. Except as otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, vesting of outstanding RSUs, or other issuance of shares under the 2021 Plan or ESPP, or conversion of Series A preferred shares, each as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;15, 2024 our issued ordinary share capital comprises 125,215,882 ordinary shares. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks described below and discussed in the section titled &#147;Risk Factors&#148; contained in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), each of which is incorporated by
reference in this prospectus supplement and the accompanying prospectus in their entirety, together with other information in this prospectus supplement and the accompanying prospectus, and the information and documents incorporated by reference in
this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in our ordinary shares and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. If any of the following events actually occur, our business, financial condition, results of operations or cash flow could be harmed. This could cause the trading price of our ordinary shares to
decline and you may lose all or part of your investment. The risks below and incorporated by reference in this prospectus supplement and the accompanying prospectus are not the only ones we face. Additional risks not currently known to us or that we
currently deem immaterial may also affect our business operations. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase
ordinary shares in this offering, you will suffer immediate dilution of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price of our ordinary shares is
substantially higher than the net tangible book value per share of our ordinary shares. Therefore, if you purchase our ordinary shares in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share
after giving effect to this offering. If you purchase ordinary shares in this offering, you will incur an immediate and substantial dilution in net tangible book value of $6.68 per share. For a further description of the dilution that you will
experience immediately after this offering, see the section titled &#147;Dilution.&#148; In addition, in the past, we have issued options to acquire ordinary shares at prices significantly below the offering price, have issued <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants with an exercise price of $0.0001 per share, have granted restricted share units, and have issued shares under our ESPP at a discount to market prices. To the extent these outstanding options or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants are ultimately exercised, these restricted share units vest or we otherwise issue shares under the 2021 Plan or ESPP, you will incur additional dilution. Furthermore, <FONT
STYLE="white-space:nowrap">if&nbsp;the&nbsp;pre-funded&nbsp;warrants</FONT> offered hereby, are exercised, you will experience further dilution. For more information, see &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have broad discretion over the use of the net proceeds from this offering, and you may not agree with how we use the proceeds and
the proceeds may not be invested successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion as to the use of the net proceeds from this offering and
could use them for purposes other than those contemplated at the time of this offering. Accordingly, you are relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of
your investment decision, to assess whether the proceeds will be used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for Wave. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our ordinary shares. We anticipate that we will retain our earnings, if any, for
future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our ordinary shares will provide a return to shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a significant number of our ordinary shares in the public markets, or the perception that
such sales could occur, could depress the market price of our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of our ordinary shares in the public
markets could depress the market price of our ordinary shares and impair our ability to raise capital through the sale of additional equity securities. We, our directors and our executive officers have agreed not to sell, dispose of or hedge any
ordinary shares or securities convertible into or exchangeable for shares of ordinary shares during the period from the date of this prospectus supplement continuing through and including the date 60 days after the date of this prospectus
supplement, subject to certain exceptions. J.P. Morgan Securities LLC and Leerink Partners LLC may, in their discretion, release the restrictions on any such shares at any time without notice. In addition, certain of our shareholders have the right
to require us to register the sales of their shares under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) under agreements between us and such shareholders, and we have an effective registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that has registered the resale of shares held by certain of our shareholders. We cannot predict the effect that future sales of our ordinary shares would have on the market price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering, and we do not expect a
market to develop. In addition, we do not intend to apply to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading system, including the Nasdaq Global Market. Without an
active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not receive a significant
amount or any additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant is exercisable for $0.0001 per ordinary share underlying such warrant which may be paid by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but
instead would receive upon such exercise the net number of ordinary shares determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Accordingly, we will not receive a significant amount or any
additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased in this offering will have no rights as ordinary shareholders until such holders exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our
ordinary shares</I></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants acquire our ordinary shares upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will have no rights with respect to the ordinary shares underlying such <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants. Upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be entitled to exercise the rights of an ordinary shareholder only as to matters for which the record date occurs after the exercise date.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial holders of our ordinary shares may not be permitted to exercise
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant which, upon giving effect to such exercise, would cause (i)&nbsp;the aggregate number of ordinary shares beneficially owned by the
holder (together with its affiliates) to exceed, at the election of such holder, 4.99%, 9.99% or 19.99% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii)&nbsp;the combined voting power of our
securities beneficially owned by the holder (together with its affiliates) to exceed, at the election of such holder, 4.99%, 9.99% or 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless such percentage is increased upon 61 days&#146; prior notice to us, provided however,
this percentage may not exceed 19.99%. As a result, you may not be able to exercise your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for our ordinary shares at a time when it would be financially beneficial for you to do so. In such
circumstance you could seek to sell your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents we have filed with the SEC that are incorporated by reference contain
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act that involve substantial risks and uncertainties. In some cases, forward-looking statements are identified
by the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;future,&#148; &#147;goals,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;ongoing,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;strategy,&#148; &#147;will&#148; and &#147;would&#148; or
the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe
that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement, the accompanying prospectus and the documents that we have filed with the SEC that are incorporated by reference, such statements are based
on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our future operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial position, revenues, costs, expenses, uses of cash and capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need for additional financing or the period for which our existing cash resources will be sufficient to meet
our operating requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, progress, number, scope, cost, duration, timing or results of our research and development
activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits that may be derived from any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, prospects, plans, goals, expectations, forecasts or objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our collaborations with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any payment that our collaboration partners may make to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors in the industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our liquidity and working capital requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected impact of new accounting standards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and our expectations regarding the impact of any local and global health epidemics on our business, including our
research and development activities, preclinical studies and clinical trials, supply of drug product, and workforce; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intended use of proceeds for this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should refer to the section titled &#147;Risk Factors&#148; of this prospectus supplement and in our other filings with the SEC for a discussion of
important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure that the forward-looking statements in this prospectus
supplement, the accompanying prospectus or the documents we have filed with the SEC that are incorporated by reference will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.
In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements as
predictions of future events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus, the documents that we have incorporated by
reference herein and therein and the documents we have filed as exhibits to the registration statement, of which this prospectus supplement is a part, completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds we will receive in this offering will be approximately $187.4&nbsp;million, or approximately $215.7&nbsp;million if the
underwriters exercise their option to purchase 3,750,000 additional ordinary shares in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We will receive nominal proceeds, if any, from the
exercise <FONT STYLE="white-space:nowrap">of&nbsp;the&nbsp;pre-funded&nbsp;warrants.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for
general corporate purposes, including, but not limited to, working capital, capital expenditures and general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected
use of the net proceeds from this offering represents our current intentions based upon our present plans and business conditions. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors, including the
relative success and cost of our research, preclinical and clinical development programs, whether we are able to enter into future collaborations, and any unforeseen delays or cash needs. As a result, our management will have broad discretion in the
application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue these planned trials and activities or other
development activities if the net proceeds from this offering and the other sources of cash are less than, or do not last as long as, expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending
their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest- bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our ordinary shares. We currently anticipate that we will retain any future earnings for the operation and
expansion of our business. Accordingly, we do not currently anticipate declaring or paying any cash dividends on our ordinary shares for the foreseeable future. Any future determination relating to our dividend policy will be made at the discretion
of our board of directors and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions (including in the agreements governing our credit facilities), capital requirements, business
prospects and other factors our board of directors may deem relevant. We may, by ordinary resolution, declare dividends, but (without prejudice to the powers of the Company to pay interest on share capital as provided in our constitution) no
dividend is payable (i)&nbsp;except out of the profits of the Company or (ii)&nbsp;in excess of the amount recommended by our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2024: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to give effect to the issuance and sale by us of 23,125,001 ordinary shares in this
offering at the public offering price of $8.00 per share <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> to purchase up to 1,875,023 of our ordinary shares at the public offering price of $7.9999 <FONT
STYLE="white-space:nowrap">per&nbsp;pre-funded&nbsp;warrant</FONT> (which equals the public offering price per ordinary share less the $0.0001 per share exercise price of each
<FONT STYLE="white-space:nowrap">such&nbsp;pre-funded&nbsp;warrant)</FONT> (and excluding ordinary shares issued and any proceeds received upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or any resulting accounting
associated with the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This table should be read together with our consolidated financial statements and related notes and the other financial information included or incorporated
by reference in this prospectus supplement and the accompanying prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(In thousands except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value, 3,901,348 shares issued and outstanding actual and as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value, 122,479,289 shares issued and outstanding, actual; shares issued
and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">950,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,138,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,089,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,089,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of ordinary shares to be outstanding after this offering is based on an aggregate of 122,479,289 ordinary shares
outstanding as of June&nbsp;30, 2024, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,901,348 ordinary shares issuable upon the conversion of our Series A preferred shares outstanding as of
June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,093,656 ordinary shares issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,453,490 ordinary shares issued and sold after June&nbsp;30, 2024 pursuant to our open market sales agreement
with Jefferies LLC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20,574,934 ordinary shares issuable upon the exercise of share options outstanding as of June&nbsp;30, 2024, at a
weighted average exercise price of $5.75 per share, of which 8,136,928 ordinary shares were exercisable as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">660,750 RSUs outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,866,279 ordinary shares reserved for future issuance under the 2021 Plan as of June&nbsp;30, 2024; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,388,958 ordinary shares reserved for future issuance under the ESPP as of June&nbsp;30, 2024.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our ordinary shares, your ownership interest will be diluted immediately to the extent of the difference between the offering price per
ordinary share and the as adjusted net tangible book value per ordinary share after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, our historical net tangible
book value was $5.1 million, or $0.04 per ordinary share. Historical net tangible book value per share represents the amount of our total tangible assets less total liabilities and Series A preferred shares, divided by the number of outstanding
ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of 23,125,001 ordinary shares in this offering at the public offering price of $8.00 per share <FONT
STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants&nbsp;to</FONT> purchase up to 1,875,023 of our ordinary shares at the public offering price of $7.9999 <FONT STYLE="white-space:nowrap">per&nbsp;pre-funded&nbsp;warrant&nbsp;(which</FONT>
equals the public offering price per ordinary share less the $0.0001 per share exercise price of <FONT STYLE="white-space:nowrap">each&nbsp;such&nbsp;pre-funded&nbsp;warrant)&nbsp;(and</FONT> excluding ordinary shares issued and any proceeds
received upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or any resulting accounting associated with the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us, our net tangible book value as of June&nbsp;30, 2024 would have been $192.6 million or $1.32 per share. This amount represents an immediate increase in net tangible book value of $1.28 per
share to our existing shareholders and an immediate dilution in net tangible book value of $6.68 per share to new investors purchasing our ordinary shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> in this offering. We
determine dilution by subtracting the net tangible book value per share after the offering from the amount of cash that a new investor paid for an ordinary share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis to new investors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after the offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in as adjusted net tangible book value per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase an additional 3,750,000 ordinary shares at the public offering
price of $8.00 per share, the as adjusted net tangible book value per share after giving effect to this offering would be $1.48 per share, representing an immediate increase to existing shareholders of $1.44 per share, and immediate dilution in net
tangible book value of $6.52 per share to investors participating in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">holders&nbsp;of&nbsp;pre-funded&nbsp;warrants&nbsp;exercise&nbsp;the&nbsp;pre-funded&nbsp;warrants,&nbsp;the</FONT></FONT> as adjusted net tangible book value per share of our
ordinary shares after giving effect to this offering would be $1.31 per share, and the dilution in net tangible book value per share to investors purchasing ordinary shares in this offering would be $6.69 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table and discussion above does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,901,348 ordinary shares issuable upon the conversion of our Series A preferred shares outstanding as of
June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,093,656 ordinary shares issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,453,490 ordinary shares issued and sold after June&nbsp;30, 2024 pursuant to our open market sales agreement
with Jefferies LLC; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20,574,934 ordinary shares issuable upon the exercise of share options outstanding as of June&nbsp;30, 2024, at a
weighted average exercise price of $5.75 per share, of which 8,136,928 ordinary shares were exercisable as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">660,750 RSUs outstanding as of June&nbsp;30, 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,866,279 ordinary shares reserved for future issuance under the 2021 Plan as of June&nbsp;30, 2024; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,388,958 ordinary shares reserved for future issuance under the ESPP as of June&nbsp;30, 2024.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised, outstanding RSUs
vest, or shares are otherwise issued under the 2021 Plan or ESPP or upon conversion of Series A preferred shares, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may
result in further dilution to our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_10"></A>DESCRIPTION OF
<FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by this prospectus supplement. The following description is subject in all respects to the provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be issued as individual warrant agreements to the investors. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be filed as an exhibit to our Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file with the SEC in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term and Exercisability
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance and on or prior to 5:00 p.m.
(New York City time) on the five-year anniversary of the original issuance date. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly
executed exercise notice and by payment in full of the exercise price in immediately available funds for the number of ordinary shares purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may elect to
exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant through a cashless exercise, in which the holder would receive upon such exercise the net number of ordinary shares determined according to the formula set forth in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. No fractional ordinary shares will be issued in connection with the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Limitations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless and until the Shareholder Approval (as defined below) is obtained, we may not effect the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not
be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which, upon giving effect to such exercise, would cause (i)&nbsp;the aggregate number of our ordinary shares beneficially owned by the holder
(together with its affiliates) to exceed, at the election of such holder, 4.99%, 9.99% or 19.99% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii)&nbsp;the combined voting power of our
securities beneficially owned by the holder (together with its affiliates) to exceed, at the election of such holder, 4.99%, 9.99% or 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, any holder may increase or decrease such percentage to any other percentage not
exceeding 19.99%, in the case of an increase, upon 61 days&#146; prior notice from the holder to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the written request of the holder delivered to
us and subsequent to December 31, 2024, we shall use commercially reasonable efforts to obtain shareholder approval (the &#147;Shareholder Approval&#148;), at our next regularly scheduled annual general meeting of shareholders, for the issuance of
the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant shares upon the exercise of all or any portion of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants such that such issuance of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant shares will comply with the Listing Rules of the Nasdaq Stock Market, including, without limitation, Listing Rule 5635, and with applicable Singapore law. In the event that the holder
requests the Shareholder Approval, we use commercially reasonable efforts to obtain Shareholder Approval at our next regularly scheduled annual general meeting, and Shareholder Approval is not obtained at such meeting for any reason, then the holder
may again request Shareholder Approval each year pursuant to and subject to the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, at each of our subsequent regularly scheduled annual general meetings that occur prior to the
termination date of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. We shall not be obligated to seek the Shareholder Approval at any shareholder meeting other than our regularly scheduled annual shareholder meeting and such written
request of the holder must be received by us at least 90 days in advance of such annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price per whole share of our ordinary shares purchasable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is
$0.0001 per ordinary share. The exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the number of our ordinary shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is
subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications or similar events affecting our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transferability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants may be offered for sale, sold, transferred or assigned without our consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not plan on applying to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Market, any other national
securities exchange or any other nationally recognized trading system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fundamental Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and generally including any
reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of
more than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding ordinary shares, upon consummation of such a fundamental transaction, the holders of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be entitled to receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants the kind and amount of securities, cash or other property that the holders would
have received had they exercised the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Rights as a Shareholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except by virtue of such holder&#146;s ownership of our ordinary shares, the holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant does not
have the rights or privileges of a holder of our ordinary shares, including any voting rights, until the holder exercises the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. In the event of certain distributions, including cash
dividends, if any, to all holders of our ordinary shares for no consideration, the holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant shall be entitled to participate in such distributions to the same extent as if a holder of our
ordinary shares, subject to not exceeding the ownership limitations described above under &#147;&#151;Exercise Limitations,&#148; in which case such distribution shall be held in abeyance for the benefit of such holder until the earlier of such time
as the ownership limitations would not be exceeded or the warrant is exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_11"></A>CERTAIN MATERIAL TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion sets forth a summary of material U.S. federal income tax consequences to U.S. Holders (as defined below) of the purchase, ownership and
disposition of the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), its legislative history, final, temporary and
proposed regulations thereunder, published rulings and court decisions, all as currently in effect and all subject to change at any time, possibly with retroactive effect. We cannot assure you that a change in law will not alter significantly the
tax considerations described in this summary. We have not sought and do not expect to seek any rulings from the U.S. Internal Revenue Service (the &#147;IRS&#148;) regarding the matters discussed below. There can be no assurance that the IRS will
not take positions concerning the tax consequences of the purchase, ownership or disposition of our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that differ from those discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion addresses only material U.S. federal income tax considerations to U.S. Holders that acquire their ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering and that hold those ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as capital assets (generally, property held for investment) and does not
purport to be a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. In addition, this
discussion does not address the U.S. federal income tax consequences to any special class of U.S. Holders, including without limitation, holders of (directly, indirectly or constructively and including any future acquisitions of ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants) 10% or more of the total voting power or value of our ordinary shares (except as discussed below), dealers in securities or currencies, banks, <FONT STYLE="white-space:nowrap">tax-exempt</FONT>
organizations, qualified retirement plans, individual retirement accounts and other <FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts, life insurance companies, financial institutions, broker-dealers, regulated investment companies, real
estate investment trusts, traders in securities that elect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings, persons that hold securities that are a
hedge or that are hedged against currency or interest rate risks or that are part of a straddle, conversion or &#147;integrated&#148; transaction, persons that are not U.S. Holders (as defined below), persons who acquired our ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to the exercise of an employee share option or otherwise as compensation, S corporations, partnerships or other entities classified as pass-through entities for U.S. federal income tax
purposes (and investors therein) and U.S. Holders whose functional currency for U.S. federal income tax purposes is not the U.S. dollar. This discussion does not address the effect of the U.S. federal alternative minimum tax, or U.S. federal gift,
estate or generation-skipping transfer tax, or any state, local or foreign tax laws on a holder of ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;if a court within the U.S. can exercise primary supervision over its administration, and one or
more U.S. persons have the authority to control all of the substantial decisions of that trust, or (ii)&nbsp;that was in existence on August&nbsp;20, 1996, and validly elected under applicable U.S. Treasury Regulations to continue to be treated as a
domestic trust. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership or an entity or arrangement that is treated as a partnership for U.S. federal income tax purposes
holds our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the U.S. federal income tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the
partnership. Partnerships that hold our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and partners in such partnerships should consult their own tax advisors regarding the particular U.S. federal, state, local and
foreign tax consequences of owning and disposing of ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you are considering the purchase of our ordinary shares or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, you should consult your own tax advisors concerning the particular U.S. federal income tax consequences to you of the purchase, ownership and disposition of our ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, as well as the consequences to you arising under other U.S. federal tax laws and the laws of any applicable state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other taxing
jurisdiction and any applicable tax treaty in light of your particular circumstances. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although it is not entirely free from doubt, a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should be treated as an
ordinary share for U.S. federal income tax purposes and a U.S. Holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should generally be taxed in the same manner as a U.S. Holder of such an ordinary share, as described below.
Accordingly, no gain or loss should be recognized (other than with respect to cash paid in lieu of a fractional share) upon the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and, upon exercise, the holding period of a <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the ordinary share received. Similarly, the tax basis of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share received upon exercise,
increased by the exercise price per share. If a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant expires without being exercised, the U.S. Holder thereof should recognize a capital loss in an amount equal to such U.S. Holder&#146;s tax
basis in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. This loss will be long-term capital loss if, at the time of the expiration, the U.S. Holder&#146;s holding period in the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant is longer than one year. The deductibility of capital losses is subject to limitations. In addition, a U.S. Holder may, in its discretion, elect to undertake a cashless exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants into ordinary shares. The U.S. federal income&nbsp;tax&nbsp;treatment of a&nbsp;cashless&nbsp;exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants into ordinary shares is unclear, and the&nbsp;tax&nbsp;consequences of
a&nbsp;cashless&nbsp;exercise could differ from the consequences upon the exercise of <FONT STYLE="white-space:nowrap">a&nbsp;pre-funded&nbsp;warrant&nbsp;described</FONT> in the preceding paragraph. U.S. Holders should consult their
own&nbsp;tax&nbsp;advisors regarding the U.S. federal income tax consequences of a&nbsp;cashless&nbsp;exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, characterizing <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as ordinary shares for U.S. federal income tax purposes is not binding on
the IRS, and the IRS may treat our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as warrants to acquire our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In that case,
the amount and character of a U.S. Holder&#146;s gain with respect to an investment in <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could change, and a U.S. Holder may not be entitled to timely make the &#147;qualified electing
fund&#148; election described below with respect to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to mitigate PFIC consequences in the event that we are classified as a PFIC. Based on the foregoing, the amount and character of a U.S.
Holder&#146;s gain with respect to an investment in our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could be materially different than the discussion set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market-to-market</FONT></FONT> election will likely not be available with
respect to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in the event that we are classified as a PFIC because the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are not treated as &#147;marketable stock&#148; as they
are not expected to be &#147;regularly traded&#148; (as such terms are defined below). Similarly, assuming we are not treated as a &#147;qualified foreign corporation&#148; (within the meaning of applicable U.S. Treasury Regulations and other IRS
guidance), dividends received with respect to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will likely not qualify for the lower rates of tax applicable to &#147;qualified dividend income&#148; (as described below) because the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants are not &#147;readily tradable&#148; on an established securities market in the United States (within the meaning of applicable U.S. Treasury Regulations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, each U.S. Holder should consult his, her or its tax advisor regarding the risks associated with the acquisition of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to this offering (including potential alternative characterizations). Except where specifically noted, the remainder of this discussion assumes a
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is treated as an ordinary share for U.S. federal income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the section titled &#147;Dividend Policy,&#148; we do not currently anticipate declaring or paying dividends to holders of our ordinary shares
or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for the foreseeable future. However, subject to the discussion below of the passive foreign investment company (&#147;PFIC&#148;) rules, if we do make distributions of cash or other
property in respect of our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, other than certain pro rata distributions of ordinary shares, the U.S. dollar amount of the gross amount of any such distribution will be
taxable as a dividend, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such income will be includable in your gross income on the day actually or constructively
received by you. The amount of any distribution of property other than cash will be the fair market value of that property on the date of distribution. To the extent the amount of the distribution exceeds our current and accumulated earnings and
profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of your tax basis in your ordinary shares or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and then, to the extent such excess amount exceeds your tax basis in your ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, as capital gain. We, however, may
not calculate earnings and profits in accordance with U.S. federal income tax principles. In that case, we intend to treat the full amount of any distribution by us to U.S. Holders as a dividend for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder may be entitled, subject to certain limitations, to a credit against its U.S. federal income tax liability, or to a deduction, if elected, in
computing its U.S. federal taxable income, for nonrefundable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income taxes withheld from dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
amount of the dividend will generally be treated as foreign-source dividend income to U.S. Holders. However, if we are treated as a &#147;United States-owned foreign corporation,&#148; a portion of dividends paid by us may be treated as U.S. source
for purposes of determining the foreign tax credit limitation. We will be treated as a United States-owned foreign corporation if 50% or more of the total value or total voting power of all classes of our shares is owned, directly, indirectly or by
attribution, by 10% U.S. Shareholders (as defined below). We do not believe that we are currently treated as a United States-owned foreign corporation, but there is no assurance that we will not be treated as such as a result of this offering or
otherwise in the future. U.S. Treasury Regulations that were issued in 2022 also require <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income tax laws to meet certain requirements in order for taxes imposed under such laws to be eligible for
credit. We have not determined whether these requirements have been met with respect to any such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> withholding taxes. A recent notice from the IRS indicates, however, that the U.S. Department of the
Treasury (&#147;Treasury&#148;) and the IRS are considering proposing amendments to such U.S. Treasury Regulations and allows, subject to certain conditions, taxpayers to defer the application of many aspects of such U.S. Treasury Regulations for
taxable years ending before the date that notice or other guidance withdrawing or modifying the temporary relief is issued (or any later date specified in such notice or other guidance). For purposes of the foreign tax credit limitation, dividends
paid by us generally will constitute &#147;passive category income.&#148; The rules relating to the foreign tax credit or deduction, if elected, are complex and U.S. Holders should consult their tax advisors concerning their availability in their
particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders of our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that are corporations
generally will not be entitled to claim a &#147;dividends received deduction&#148; with respect to dividends paid on the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends received by a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder with respect to our ordinary shares, including an individual, may
qualify for the lower rates of tax applicable to &#147;qualified dividend income,&#148; provided that (i)&nbsp;we are not a PFIC for our taxable year in which the dividend is paid or in the preceding taxable year, (ii)&nbsp;certain holding period
and other requirements are met and (iii)&nbsp;our ordinary shares are readily tradable on an established securities market in the United States. As discussed above, assuming we are not treated as a &#147;qualified foreign </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporation&#148; (within the meaning of applicable U.S. Treasury Regulations and other IRS guidance), dividends received by U.S. Holders with respect to <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will likely not qualify for the lower rates of tax applicable to &#147;qualified dividend income.&#148;&nbsp;You should consult your own tax advisors regarding the availability of the lower tax
rates applicable to qualified dividend income for any dividends that we pay with respect to the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, as well as the effect of any change in applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Constructive Distributions on <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may, in some circumstances, be deemed to have received a distribution subject to
U.S. federal income tax as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or number of ordinary shares issuable upon exercise of such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. In addition, in certain circumstances, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are not entitled to any distributions until such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is exercised. Upon the exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, a U.S. Holder shall be entitled to receive distributions declared on our ordinary shares
prior to the exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. It is possible that such entitlement to distributions may cause the declaration of a distribution on our ordinary shares to be currently taxable to U.S.
Holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisors regarding the proper treatment of
any adjustments to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposition of the Ordinary Shares or <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will recognize gain or loss on a sale, exchange or other taxable disposition of our
ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in an amount equal to the difference between the amount realized (in U.S. dollars) on the sale, exchange or taxable disposition and your tax basis (in U.S. dollars) in
the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Subject to the PFIC rules discussed below, such gain or loss generally will be capital gain or loss. If you are a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder, including an individual, that has held the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for more than one year, you may be eligible for reduced tax
rates. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any gain or loss that you recognize on a disposition of our ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants generally will be treated as U.S.-source income or loss for foreign tax credit limitation purposes. You should consult your own tax advisors regarding the proper treatment of gain or loss, as
well as the availability of a foreign tax credit, in your particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the current and anticipated value of our assets and the current and expected composition of our income and assets, we do not believe we were a PFIC
for U.S. federal income tax purposes for our most recent taxable year ending December&nbsp;31, 2023 nor expect to be treated as a PFIC for U.S. federal income tax purposes for our current taxable year ending December&nbsp;31, 2024; however, there
can be no assurance that we will not be considered a PFIC for any taxable year. The determination of PFIC status is based on an annual determination that cannot be made until the close of a taxable year, involves extensive factual investigation,
including ascertaining the fair market value of all of our assets on a quarterly basis and the character of each item of income that we earn, and is subject to uncertainty in several respects. Moreover, our ability to earn specific types of income
that we currently treat as <FONT STYLE="white-space:nowrap">non-passive</FONT> for purposes of the PFIC rules is uncertain with respect to future years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, we cannot assure you that we will not be treated as a PFIC for our current taxable year ending December&nbsp;31, 2024, or for any future taxable
year or that the IRS will not take a contrary position. Mintz, Levin, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cohn, Ferris, Glovsky and Popeo, P.C., our U.S. tax counsel, therefore expresses no
opinion with respect to our PFIC status for any taxable year or our expectations relating to such status set forth in this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> corporation will be treated as a PFIC for U.S. federal income tax purposes for any taxable year if, applying applicable look-through rules with respect to certain subsidiary entities (as discussed in more
detail below), either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 75% of its gross income for such year is passive income; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 50% of the value of its assets (determined based on a quarterly average) during such year is
attributable to assets that produce or are held for the production of passive income. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For these purposes, we will be treated as owning
a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% by value of the stock or shares. Subject to various exceptions, passive income
generally includes dividends, interest, capital gains, royalties and rents (other than certain royalties and rents derived in the active conduct of a trade or business and not derived from a related person). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must make a separate determination each year as to whether we are a PFIC. As a result, our PFIC status may change. Because PFIC status must be determined
annually based on tests which are factual in nature, our PFIC status in future years will depend on our income, assets and activities in those years. Furthermore, because the value of our gross assets is likely to be determined in large part by
reference to our market capitalization and the value of our goodwill, a decline in the value of our shares could affect the determination of whether we are a PFIC. There can be no assurance that we will not be considered a PFIC for any taxable year.
If we are a PFIC for any taxable year during which you hold ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, we generally will continue to be treated as a PFIC for all succeeding years during which you hold the
ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, if we cease to be a PFIC, you may avoid some of the adverse effects of the PFIC regime by making a &#147;deemed sale&#148; election with respect to the ordinary
shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are or become a PFIC in a taxable year in which we pay a
dividend or the prior taxable year, the preferential tax rates discussed above with respect to dividends paid to <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders would not apply. In addition, if we are a PFIC for any taxable year
during which you hold ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, in the absence of a &#147;qualifying electing fund&#148; election (which, as noted below, may not be available to you), you will be subject to
special tax rules with respect to any &#147;excess distribution&#148; that you receive and any gain you realize from a sale or other disposition (including, under certain circumstances, a pledge) of the ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless you make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election as discussed below. Distributions (including constructive
distributions with respect to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants) you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable
years or your holding period for the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be treated as an excess distribution. Under these special tax rules: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over your holding period for the ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which
we became a PFIC, will be treated as ordinary income, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for individuals or
corporations, as appropriate, for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax liability for amounts allocated to years prior to the year of disposition or &#147;excess distribution&#148; cannot be offset by any net operating
losses for such years, and gains (but not losses) realized on the sale of the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants cannot be treated as capital, even if you hold the ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants as capital assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are treated as a PFIC with respect to you for any taxable year, to the
extent any of our subsidiaries are also PFICs, you will be deemed to own shares in such lower-tier PFICs that are directly or indirectly owned by us in the proportion that the value of the ordinary shares you own bears to the value of all of our
ordinary shares, and you may be subject to the rules described in the preceding paragraphs with respect to the shares of such lower-tier PFICs you are deemed to own. You should consult your own tax advisor regarding the application of the PFIC rules
to any of our subsidiaries including as a result of the changes included as part of the Tax Cuts and Jobs Act (the &#147;Tax Act&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain circumstances, a U.S. Holder of shares in a PFIC may avoid the adverse tax consequences described
above by making a &#147;qualified electing fund&#148; election to include in income its pro rata share of the corporation&#146;s income on a current basis. However, you may make a qualified electing fund election with respect to your ordinary shares
or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants only if we agree to furnish you annually with a PFIC annual information statement as specified in the applicable U.S. Treasury Regulations. As discussed above, a timely qualified
electing fund election may not be available with respect to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, a U.S. Holder
of &#147;marketable stock&#148; (as defined below) in a PFIC may make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such stock to elect out of the tax treatment discussed
above. If you make a valid <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for the ordinary shares you will include in income each year an amount equal to the excess, if any, of the fair market
value of the ordinary shares as of the close of your taxable year over your adjusted basis in such ordinary shares. You are allowed a deduction for the excess, if any, of the adjusted basis of the ordinary shares over their fair market value as of
the close of the taxable year. However, deductions are allowable only to the extent of any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains on the ordinary shares included in your income for
prior taxable years. Amounts included in your income under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, as well as gain on the actual sale or other disposition of the ordinary shares, are
treated as ordinary income. Ordinary loss treatment also applies to the deductible portion of any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> loss on the ordinary shares, as well as to any loss
realized on the actual sale or disposition of the ordinary shares, to the extent that the amount of such loss does not exceed the net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains previously
included for such ordinary shares. Your basis in the ordinary shares will be adjusted to reflect any such income or loss amounts. If you make such an election, the tax rules that apply to distributions by corporations that are not PFICs would apply
to distributions by us, except that the preferential tax rate discussed above under the heading &#147;&#151;Dividends and Other Distributions&#148; would not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for &#147;marketable
stock,&#148; which is stock that is traded in other than<I> de minimis</I> quantities on at least 15 days during each calendar quarter &#147;regularly traded&#148; on a qualified exchange or other market, as defined in applicable U.S. Treasury
Regulations. The Nasdaq Global Market is a qualified exchange. We anticipate that our ordinary shares will continue to be regularly traded on the Nasdaq Global Market, and therefore, in 2024 and any subsequent year in which our ordinary shares
continue to be regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election would be available to a U.S. Holder of our ordinary shares if we are or become a PFIC. As discussed above,
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;market-to-market&#148;</FONT></FONT> election will likely not be available with respect to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. If any of our
subsidiaries are or become PFICs, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will not be available with respect to the shares of such subsidiaries that are treated as owned by you.
Consequently, you could be subject to the PFIC rules with respect to income of the lower-tier PFICs the value of which already had been taken into account indirectly via
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax
advisors regarding the availability and advisability of making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in any year in which we are a PFIC, you will also be subject to
annual information reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PFIC rules are complex, and you should consult your own tax advisors regarding the application of the PFIC
rules to your investment in our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the availability, application and consequences of the elections discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposition of Foreign Currency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders are
urged to consult their tax advisors regarding the tax consequences of receiving, converting or disposing of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency received as dividends on our ordinary shares or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (if any) or on the sale or other disposition of our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Controlled Foreign Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes included in the Tax Act can impact the tax treatment of a U.S. person treated as a 10% U.S. Shareholder (as defined below). The Tax Act eliminated
the prohibition on &#147;downward attribution&#148; from <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons to U.S. persons under Section&nbsp;958(b)(4) of the Code for purposes of determining constructive stock ownership under the controlled
foreign corporation (&#147;CFC&#148;) rules. As a result, our U.S. subsidiary will be deemed to own all of the stock of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries held by the Company for CFC purposes. To the extent one of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries is treated as a CFC for any taxable year, each U.S. person treated as a 10% U.S. Shareholder (as defined below) with respect to such CFC that held our ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants directly or indirectly through one or more <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities (including the Company) as of the last day of such taxable year that the subsidiary was a CFC
generally would be required to include in gross income as ordinary income its pro rata share of certain investment income of the CFC (with certain adjustments), regardless of whether that income was actually distributed to such U.S. person. A
&#147;10% U.S. Shareholder&#148; of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation includes any U.S. person that owns (or is treated as owning) stock of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation possessing 10%
or more of the total voting power or total value of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation&#146;s stock. To the extent that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiary is treated as a CFC and as a PFIC
for any taxable year, such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiary will be treated as a CFC and not as a PFIC with respect to any 10% U.S. Shareholder. Failure to comply with these reporting and tax paying obligations may subject
a 10% U.S. Shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder&#146;s U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any
assurances that we will assist investors in determining whether any investor is treated as a 10% U.S. Shareholder with respect to any such CFC or furnish to any 10% U.S. Shareholders information that may be necessary to comply with the
aforementioned reporting and tax paying obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>YOU ARE STRONGLY URGED TO CONSULT YOUR OWN TAX ADVISORS TO DETERMINE WHETHER YOUR OWNERSHIP OF
THE ORDINARY SHARES OR <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS WILL CAUSE YOU TO BECOME A 10% U.S. SHAREHOLDER AND THE IMPACT OF SUCH A CLASSIFICATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless an exception applies, information reporting to the IRS generally will be required with respect to payments on the ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants (including constructive distributions with respect <FONT STYLE="white-space:nowrap">to&nbsp;pre-funded&nbsp;warrants)</FONT> and proceeds of the sale of the ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants paid to U.S. Holders, other than corporations and other exempt recipients. Backup withholding, currently at the rate of 24%, may apply to those payments if such a holder fails to provide a
taxpayer identification number to the paying agent and to certify that no loss of exemption from backup withholding has occurred. The amounts withheld under the backup withholding rules are not an additional tax and may be refunded or credited
against the holder&#146;s U.S. federal income tax liability, if any, provided the required information is furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain U.S.
Holders who are individuals that hold certain foreign financial assets (which may include the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), or who have a beneficial interest in or signatory authority over certain
foreign financial accounts, are required to report information relating to such assets or accounts, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should consult
your own tax advisor regarding the application of the information reporting and backup withholding requirements to your particular situation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders that are
individuals, estates or trusts are required to pay up to an additional 3.8% tax on, among other things, interest, dividends and gains from the sale or other disposition of capital assets. Special rules apply and certain elections are available for
certain U.S. Holders that are subject to the 3.8% tax on net investment income and hold shares in a PFIC. Each U.S. Holder that is an individual, estate or trust should consult its own tax advisors regarding the effect, if any, of this tax provision
on their ownership and disposition of ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders may be required to report information relating to an interest in our ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants, subject to certain exceptions (including an exception for ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their
tax advisors regarding the effect, if any, of this requirement on their ownership and disposition of the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Reporting Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder
(including a U.S. <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entity) that acquires equity of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation may be required to file a Form 926 or a similar form with the IRS under certain
circumstances. Penalties may be imposed upon a U.S. Holder that fails to comply with the reporting requirements. U.S. Holders should consult their tax advisors regarding the applicability of this requirement to the acquisition or disposition of the
ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Reportable Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder sells or disposes of the ordinary shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants at a loss or otherwise incurs certain
losses that meet certain thresholds, such U.S. Holder may be required to file a disclosure statement with the IRS. Failure to comply with these and other reporting requirements could result in the imposition of significant penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>POTENTIAL PURCHASERS OF OUR ORDINARY SHARES OR <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS TO
DETERMINE THE U.S. FEDERAL, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INCOME, GIFT, ESTATE OR GENERATION- SKIPPING TRANSFER, AND OTHER TAX AND TAX TREATY CONSIDERATIONS OF PURCHASING, OWNING AND DISPOSING OF OUR ORDINARY
SHARES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Singapore Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material Singapore income tax, stamp duty and estate duty considerations relevant to the purchase, ownership and
disposition of our ordinary shares by an investor who is not tax resident or domiciled in Singapore and who does not carry on business or otherwise have a presence in Singapore. The statements made herein regarding taxation are based on certain
aspects of the tax laws of Singapore and administrative guidelines issued by the relevant authorities in force as of the date hereof and are subject to any changes in such laws or administrative guidelines, or in the interpretation of those laws or
guidelines, occurring after such date, which changes could be made on a retroactive basis. The statements made herein do not describe all of the tax considerations that may be relevant to all our shareholders, some of which (such as dealers in
securities) may be subject to different rules. The statements are not intended to be and do not constitute legal or tax advice and no assurance can be given that courts or fiscal authorities responsible for the administration of such laws will agree
with the interpretation adopted therein. Each prospective investor should consult an independent tax advisor regarding all Singapore income and other tax consequences applicable to them from owning or disposing of our ordinary shares in light of the
investor&#146;s particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxation Under Singapore Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Distributions with Respect to Ordinary Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
the basis that a company is not tax resident in Singapore for Singapore tax purposes, dividends paid by the company should generally be considered as sourced outside Singapore (unless our ordinary shares are held as part of a trade or business
carried on in Singapore in which event the holders of such shares may be taxed on the dividends as they are derived). </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign-sourced dividends received or deemed received in Singapore by an individual not resident in
Singapore would be exempt from Singapore income tax. This exemption will also apply in the case of a Singapore tax resident individual who receives such foreign-sourced income in Singapore (except where such income is received through a partnership
in Singapore). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign-sourced dividends received or deemed received by corporate investors in Singapore will be liable for Singapore tax. However, if
the conditions for the exemption of specified foreign-sourced income are met, foreign-sourced dividends received by corporate investors resident in Singapore would be exempt from Singapore tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign-sourced dividends received or deemed received in Singapore on or after June&nbsp;1, 2003 by a Singapore resident corporate taxpayer is exempt from
tax, provided certain prescribed conditions are met, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such income is subject to tax of a similar character to income tax under the law of the jurisdiction from which
such income is received; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time the income is received in Singapore, the highest rate of tax of a similar character to income tax
(by whatever name called) levied under the law of the territory from which the income is received on any gains or profits from any trade or business carried on by any company in that territory at that time is not less than 15%; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Comptroller of Income Tax is satisfied that the tax exemption would be beneficial to the person resident in
Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of dividends paid by a company resident in a territory from which the dividends are received, the &#147;subject
to tax condition&#148; in (a)&nbsp;above is considered met where tax is paid in that territory by such company in respect of its income out of which such dividends are paid or tax is paid on such dividends in that territory from which such dividends
are received. Certain concessions and clarifications have also been announced by the Inland Revenue Authority of Singapore (&#147;IRAS&#148;) with respect to the above conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Gains upon Disposition of Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current Singapore tax law, there is no tax on capital gains. As such, any profits from the disposal of our ordinary shares would not ordinarily be
taxable in Singapore. However, there are no specific laws or regulations which deal with the characterization of whether a gain is income or capital in nature. If the gains from the disposal of ordinary shares are construed to be of an income nature
(which could be the case if, for instance, the gains arise from activities which the IRAS regards as carrying on a trade or business in Singapore), the disposal profits would be taxable as income rather than capital gains. As the precise status of
each prospective investor will vary from one another, each prospective investor should consult an independent tax advisor on the Singapore income tax and other tax consequences that will apply to their individual circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain conditions being satisfied, gains derived by a company from the disposal of our ordinary shares between the period of June&nbsp;1, 2012 and
December&nbsp;31, 2027 (inclusive of both dates) will not be subject to Singapore income tax, if the divesting company holds a minimum shareholding of 20% of our ordinary shares and these shares have been held for a continuous minimum period of 24
months. For disposals during the period from June&nbsp;1, 2012 and May&nbsp;31, 2022 (inclusive of both dates), this exemption would not apply to the disposal of unlisted shares in a company that is in the business of trading or holding immovable
properties in Singapore (excluding property development). For disposals during the period from June&nbsp;1, 2022 and December&nbsp;31, 2027 (inclusive of both dates), this exemption would not apply to the disposal of unlisted shares in a company
that is in the business of trading, holding or developing immovable properties in Singapore or abroad. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, shareholders who apply, or who are required to apply, the Singapore Financial Reporting
Standard 39 (&#147;FRS 39&#148;), Financial Reporting Standard 109 (&#147;FRS 109&#148;) or Singapore Financial Reporting Standard (International) 9 (Financial Instruments) (&#147;SFRS(I) 9&#148;) (as the case may be), for the purposes of Singapore
income tax may be required to recognize gains or losses (not being gains or losses in the nature of capital) in accordance with the provisions of FRS 39, FRS 109 or SFRS(I) 9 (as modified by the applicable provisions of Singapore income tax law)
even though no sale or disposal of our ordinary shares is made. Singapore corporate shareholders who may be subject to such tax treatment should consult their own accounting and tax advisors regarding the Singapore income tax consequences of their
acquisition, holding and disposal of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stamp Duty </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no Singapore stamp duty payable in respect of the issuance or holding of our ordinary shares. Singapore stamp duty will be payable if there is an
instrument of transfer of our ordinary shares executed in Singapore or if there is an instrument of transfer executed outside of Singapore which is received in Singapore. Under Singapore law, stamp duty is not applicable to electronic transfers of
our shares effected on a book entry basis outside Singapore. We therefore expect that no Singapore stamp duty will be payable in respect of ordinary shares purchased by U.S. holders in this offering assuming that they are acquired solely in book
entry form through the facility outside Singapore established by our transfer agent and registrar outside Singapore. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where shares evidenced in
certificated form are transferred and an instrument of transfer is executed (whether physically or in the form of an electronic instrument) in Singapore or outside Singapore and which is received in Singapore, Singapore stamp duty is payable on the
instrument of transfer for the sale of our ordinary shares at the rate of 0.2% of the consideration for, or market value of, the transferred shares, whichever is higher. The Singapore stamp duty is borne by the purchaser unless there is an agreement
to the contrary. Where the instrument of transfer is executed outside of Singapore and is received in Singapore, Singapore stamp duty must be paid within 30 days of receipt of the instrument of transfer in Singapore. Electronic instruments that are
executed outside Singapore are treated as received in Singapore in any of the following scenarios: (a)&nbsp;it is retrieved or accessed by a person in Singapore; (b)&nbsp;an electronic copy of it is stored on a device (including a computer) and
brought into Singapore; or (c)&nbsp;an electronic copy of it is stored on a computer in Singapore. Where the instrument of transfer is executed in Singapore, Singapore stamp duty must be paid within 14 days of the execution of the instrument of
transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goods and Services Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issue
or transfer of ownership of our ordinary shares would be exempt from Singapore goods and services tax, or GST. Hence, no GST would be incurred on the subscription or subsequent transfer of our ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of our ordinary shares by a <FONT STYLE="white-space:nowrap">GST-registered</FONT> investor belonging in Singapore for GST purposes to another person
belonging in Singapore is an exempt supply not subject to GST. Any input GST incurred by the </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GST-registered</FONT>
investor in making the exempt supply is generally not recoverable from the Singapore Comptroller of GST. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where our ordinary shares are sold by a <FONT
STYLE="white-space:nowrap">GST-registered</FONT> investor in the course of or furtherance of a business carried on by such investor contractually to and for the direct benefit of a person belonging outside Singapore, the sale should generally,
subject to satisfaction of certain conditions, be considered a taxable supply subject to GST at 0%. Subject to the normal rules for input tax claims, any input GST incurred by the <FONT STYLE="white-space:nowrap">GST-registered</FONT> investor in
making such a supply in the course of or furtherance of a business carried out by such investor may be fully recoverable from the Singapore Comptroller of GST. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each prospective investor should consult an independent tax advisor on the recoverability of input GST
incurred on expenses in connection with the purchase and sale of our ordinary shares if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Services consisting of arranging, brokering,
underwriting or advising on the issue, allotment or transfer of ownership of our ordinary shares rendered by a <FONT STYLE="white-space:nowrap">GST-registered</FONT> person to an investor belonging in Singapore for GST purposes in connection with
the investor&#146;s purchase, sale or holding of our ordinary shares will be subject to GST at the current standard rate of 9%. Similar services rendered by a <FONT STYLE="white-space:nowrap">GST-registered</FONT> person contractually to and for the
direct benefit of an investor belonging outside Singapore should generally, subject to the satisfaction of certain conditions, be subject to GST at 0%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the implementation of reverse charge from January&nbsp;1, 2020, the &#147;directly benefit&#148; condition for
<FONT STYLE="white-space:nowrap">zero-rating</FONT> (i.e. GST at 0%) will be amended to allow the <FONT STYLE="white-space:nowrap">zero-rating</FONT> of a supply of services to the extent that the services directly benefit a person belonging outside
Singapore or a <FONT STYLE="white-space:nowrap">GST-registered</FONT> person in Singapore. Under the reverse charge regime, a <FONT STYLE="white-space:nowrap">GST-registered</FONT> partially exempt business that is not entitled to full input tax
claims will be required to account for GST on all services that it procures from overseas suppliers (except for certain services which are specifically exempt from reverse charge) and the import of <FONT STYLE="white-space:nowrap">low-value</FONT>
goods. A non <FONT STYLE="white-space:nowrap">GST-registered</FONT> person whose total value of imported services and <FONT STYLE="white-space:nowrap">low-value</FONT> goods for a <FONT STYLE="white-space:nowrap">12-month</FONT> period exceeds
S$1&nbsp;million and is not entitled to full input tax claims even if such person was <FONT STYLE="white-space:nowrap">GST-registered</FONT> may become liable for GST registration and be required to account for GST both on its taxable supplies and
imported services and <FONT STYLE="white-space:nowrap">low-value</FONT> goods subject to reverse charge. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Estate Duty </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore estate duty has been abolished with effect from February&nbsp;15, 2008 in relation to the estate of any person whose death has occurred on or after
February&nbsp;15, 2008. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Treaties Regarding Withholding Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no comprehensive avoidance of double taxation agreement between the United States and Singapore which applies to withholding taxes on
dividends or capital gains. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_12"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering the ordinary shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants described in this prospectus supplement through a number
of underwriters. J.P. Morgan Securities LLC and Leerink Partners LLC (the &#147;Representatives&#148;) are acting as joint&nbsp;book-running&nbsp;managers of the offering and as representatives of the underwriters. We have entered into an
underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the
underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of ordinary shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> listed next to its name in the following table:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT></B><br><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,018,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">562,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,468,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,125,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,875,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all the ordinary shares
<FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> offered by us if they purchase any ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants.</FONT> The underwriting agreement also provides that if
an underwriter defaults, the purchase commitments <FONT STYLE="white-space:nowrap">of&nbsp;non-defaulting&nbsp;underwriters</FONT> may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the ordinary shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> directly to the public at the
initial public offering prices set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $0.2888 per ordinary share or per pre-funded warrant. After the initial offering of the
ordinary shares to the public, if all of the ordinary shares are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of any ordinary shares or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters
have an option to buy up to 3,750,000 additional ordinary shares from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus
supplement to exercise this option to purchase additional shares. If&nbsp;any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table
above. If any additional shares are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per ordinary share <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> less the
amount paid by the underwriters to us per ordinary share <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant.</FONT> The underwriting fee is $0.48 per ordinary share and pre-funded warrant. The following table shows the per share and
total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Ordinary</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-</FONT></B><br><B>Funded</B><br><B>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;with&nbsp;Option to<BR>Purchase&nbsp;Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,000,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,800,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,993,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,199,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including printing fees and legal and accounting
expenses, but excluding the underwriting discounts and commissions, will be approximately $500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made
available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their
online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 60 days after the date of this prospectus supplement <FONT STYLE="white-space:nowrap">(the&nbsp;&#147;Lock-up&nbsp;Period&#148;),</FONT> without first
obtaining the written consent of the Representatives, we have agreed that we will not (i)&nbsp;sell, offer to sell, contract to sell or lend any ordinary shares or Related Securities (as defined below); (ii) effect any short sale, or establish or
increase any &#147;put equivalent position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(h)&nbsp;under</FONT> the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in <FONT
STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)&nbsp;under</FONT> the Exchange Act) of any ordinary shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any ordinary shares or Related Securities; (iv)&nbsp;in
any other way transfer or dispose of any ordinary shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any ordinary shares or
Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any ordinary shares or Related Securities; (vii)&nbsp;file any registration statement under the
Securities Act in respect of any ordinary shares or Related Securities (other than as contemplated by this prospectus supplement); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; provided, however, that we may
(A)&nbsp;effect the transactions contemplated herein, (B)&nbsp;issue ordinary shares, options or other rights to receive or purchase or, or issue ordinary shares upon exercise of options or vesting of restricted share units or performance share
units, pursuant to any share or stock option, share or stock bonus or other share or stock plan or arrangement incorporated by reference into this prospectus supplement provided that any directors or officers who are recipients thereof have provided
to the Representatives a <FONT STYLE="white-space:nowrap">signed&nbsp;lock-up&nbsp;agreement,</FONT> (C)&nbsp;file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8&nbsp;to</FONT> register ordinary shares issuable pursuant
to the terms of a stock option, stock bonus or other stock plan or arrangement incorporated by reference into this prospectus supplement or any amendment to any such plan or arrangement and (D)&nbsp;issue ordinary shares or Related Securities, or
enter into an agreement to issue ordinary shares or Related Securities, in connection with any merger, joint venture, strategic alliances, commercial or other collaborative transaction or the acquisition or license of the business, property,
technology or other assets of another individual or entity or the assumption of an employee benefit plan in connection with a merger or acquisition; provided that the aggregate number of ordinary shares or Related Securities that we may issue or
agree to issue pursuant to this clause (D)&nbsp;shall not exceed 7% of our total outstanding share capital immediately following the issuance of the securities offered in connection with this prospectus supplement; and provided further that the
recipients thereof provide to the Representatives a <FONT STYLE="white-space:nowrap">signed&nbsp;lock-up&nbsp;agreement.</FONT> For purposes of the foregoing, &#147;Related Securities&#148; shall mean any options or warrants or other rights to
acquire ordinary shares or any securities exchangeable or exercisable for or convertible into ordinary shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period,</FONT> without first obtaining the written consent of the Representatives, our executive
officers and directors have agreed that they will not (i)&nbsp;sell or offer to sell any ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;Lock-up&nbsp;Securities</FONT> (as defined below) currently or hereafter owned either of record or
beneficially (as defined <FONT STYLE="white-space:nowrap">in&nbsp;Rule&nbsp;13d-3&nbsp;under</FONT> the Exchange Act) by <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> or such family member, (ii)&nbsp;enter into any swap,
(iii)&nbsp;make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;Lock-up&nbsp;Securities</FONT> or cause to be
filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or (iv)&nbsp;publicly announce any intention to do any of the foregoing. For purposes of the <FONT
STYLE="white-space:nowrap">foregoing,&nbsp;&#147;Lock-up&nbsp;Securities&#148;</FONT> shall mean any options, contracts or warrants or other rights to acquire ordinary shares or any securities exchangeable or exercisable for or convertible into
ordinary shares (including, without limitation, ordinary shares or such other securities which may be deemed to be beneficially owned by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undersigned in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock&nbsp;option or warrant), or to acquire other securities or rights
ultimately exchangeable or exercisable for or convertible into ordinary shares (including, without limitation, ordinary shares or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and
regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant). The foregoing restrictions shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i. transactions relating to ordinary shares or other securities acquired in (x)&nbsp;this offering from the underwriters (other than any
Company directed securities purchased in this offering by an officer or director of the Company) and (y)&nbsp;open market transactions after the completion of this offering,<I>&nbsp;provided</I><I></I>&nbsp;that no public announcement and no filing
under Section&nbsp;16(a) of the Exchange Act or other regulatory authority in respect thereof will be required or will be voluntarily made during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period</FONT> in connection with subsequent
sales of ordinary shares or other securities acquired in this offering or such open market transactions during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">ii. transfers of ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;Lock-up&nbsp;Securities</FONT> as a bona fide gift or charitable
contribution; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iii. distributions of ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;Lock-up&nbsp;Securities</FONT> to limited
partners, members, stockholders or holders of similar equity interests in <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> and (y)&nbsp;transfers or disposition of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
signatory&#146;s ordinary shares or <FONT STYLE="white-space:nowrap">Lock-up</FONT> Securities to any corporation, partnership, limited liability company or other legal entity all of the beneficial ownership interests of which are held by <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> or any family member in a transaction not involving a disposition for value; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iv. transfers of ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;Lock-up&nbsp;Securities</FONT> by will or intestacy or to any family
member or to a trust whose beneficiaries consist exclusively of one or more of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> and/or a family member; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">v. transfers of ordinary shares pursuant to a domestic order or negotiated divorce settlement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vi. the exercise of a stock option granted under a stock incentive plan incorporated by reference in this prospectus supplement by <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory,</FONT> and the receipt by <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> from the Company of ordinary shares upon such exercise, insofar as such option is
outstanding as of the date of this prospectus supplement,<I>&nbsp;provided</I><I></I>&nbsp;that the underlying ordinary shares shall continue to be subject to the restrictions on transfer set forth in
<FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> and<I>&nbsp;provided, further</I>&nbsp;that, if required, any public report or filing under Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto
that the filing relates to the exercise of a stock option, that no ordinary shares were sold by the reporting person and that ordinary shares received upon exercise of the stock option are subject to
<FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> with the underwriters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vii. the disposition of ordinary shares to
the Company, or the withholding of ordinary shares by the Company, in a transaction exempt from Section&nbsp;16(b) of the Exchange Act solely in connection with the payment of taxes due with respect to the vesting of restricted stock units granted
under a stock incentive plan or pursuant to a contractual employment arrangement incorporated by reference in this prospectus supplement, insofar as such restricted stock unit is outstanding as of the date of this prospectus
supplement,<I>&nbsp;provided</I><I></I>&nbsp;that no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">viii. transfers to the Company in connection with the repurchase of ordinary shares in connection with the termination of <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory&#146;s</FONT> employment with the Company pursuant to contractual agreements with the Company as in effect as of the date of this prospectus supplement,<I>&nbsp;provided</I><I></I>&nbsp;that
no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">ix. the establishment of a trading plan and/or other written instruction pursuant to
<FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;under</FONT> the Exchange Act (a &#147;Plan&#148;) for the transfer of ordinary shares,<I>&nbsp;provided</I>&nbsp;that (a)&nbsp;such Plan does not provide for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the transfer of ordinary shares during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period</FONT> and (b)&nbsp;the entry into such Plan is not publicly disclosed, including in any
filings under the Exchange Act, during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period,</FONT> except as required under applicable securities laws, in which case, any public announcement or filing under the Exchange Act made by any
person regarding the establishment of such Plan during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period</FONT> shall include a statement that <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> is not permitted to
transfer, sell or otherwise dispose of ordinary shares under such Plan during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">x. if <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> is an individual, sales pursuant to a Plan established before
the date of this prospectus supplement;<I>&nbsp;provided</I>, that any filing made under the Exchange Act in connection with such a sale shall disclose that the sale was made pursuant to a Plan entered into on a date before the date of this
prospectus supplement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xi. pursuant to a bona fide third party tender offer for all outstanding ordinary shares of the Company,
merger, consolidation or other similar transaction made to all holders of our securities involving a change of control of the Company (including, without limitation, the entering into
<FONT STYLE="white-space:nowrap">any&nbsp;lock-up,&nbsp;voting</FONT> or similar agreement pursuant to which <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> may agree to transfer, sell, tender or otherwise dispose of ordinary
shares or other such securities in connection with such transaction, or vote any ordinary shares or other such securities in favor of any such transaction),<I>&nbsp;provided</I><I></I>&nbsp;that in the event that such tender offer, merger,
consolidation or other such transaction is not completed, such securities held by <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> shall remain subject to the provisions of
<FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided however</I>&nbsp;(A)&nbsp;in the case of any
transfer or distribution pursuant to clause&nbsp;(ii), (iii), (iv) and (v), it shall be a condition to such transfer that such transfer shall not involve a disposition for value and each donee, transferee or distributee executes and delivers to the
Representatives an agreement in form and substance satisfactory to the Representatives stating that such donee, transferee or distributee is receiving and holding such ordinary shares
<FONT STYLE="white-space:nowrap">and/or&nbsp;Lock-up&nbsp;Securities</FONT> subject to the provisions of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> and agrees not to sell or offer to sell such ordinary shares <FONT
STYLE="white-space:nowrap">and/or&nbsp;Lock-up&nbsp;Securities,</FONT> engage in any swap or engage in any other activities restricted under <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> except in accordance with <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> (as if such donee, transferee or distributee had been an original signatory hereto), and (B)&nbsp;in the case of any transfer or distribution pursuant to clause&nbsp;(iii), (iv) and
(v), prior to the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period,</FONT> no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor, transferee, distributor or
distributee) shall be required, or made voluntarily (other than any such disclosure required to be made by applicable law or regulation, including, without limitation, one or more filings on Form&nbsp;4, Form&nbsp;5, Schedule&nbsp;13G or
Schedule&nbsp;13D, in each case, in accordance with applicable law and made after the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling ordinary
shares in the open market for the purpose of preventing or retarding a decline in the market price of the ordinary shares while this offering is in progress. These stabilizing transactions may include making short sales of ordinary shares, which
involves the sale by the underwriters of a greater number of ordinary shares than they are required to purchase in this offering, and purchasing ordinary shares on the open market to cover positions created by short sales. Short sales may be
&#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional ordinary shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of
that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional ordinary shares, in whole or in part, or by purchasing ordinary shares in the open market. In making this determination,
the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional ordinary shares.
A naked short position is more likely to be created if the underwriters are concerned that there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be downward pressure on the price of the ordinary shares in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a
naked short position, they will purchase ordinary shares in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, pursuant to
Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the ordinary shares, including the imposition of penalty bids. This means that if the representatives
of the underwriters purchase ordinary shares in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount
received by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market price of the ordinary shares or preventing or retarding a
decline in the market price of the ordinary shares, and, as a result, the price of the ordinary shares may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue
them at any time. The underwriters may carry out these transactions on the Nasdaq Global Market, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition,
from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity
securities or loans, and may do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this
prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering
material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that
jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus
supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant State&#148;), no securities have been offered or will be offered
pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another
Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that securities may be offered to the public in that Relevant State at any time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation),
subject to obtaining the prior consent of the representative for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Article
1(4) of the Prospectus Regulation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>&nbsp;that no such offer of securities shall require us or any of the representatives to
publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any securities in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;Prospectus
Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in
relation to the securities which has been approved by the Financial Conduct Authority, except that the securities may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation),
subject to obtaining the prior consent of the representative for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within
Section&nbsp;86 of the Financial Services and Markets Act 2000 (the &#147;FMSA&#148;),<I>&nbsp;provided</I>&nbsp;that no such offer of the securities shall require us or any representative to publish a prospectus pursuant to Section&nbsp;85 of the
FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the securities in the United Kingdom means the communication
in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities and the expression &#147;UK Prospectus
Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to
Prospective Investors in Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT
STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT
STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus supplement does not constitute a public offering
prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in
the Dubai International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial
Services Authority (DFSA). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to
which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this
document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to its use in the Dubai International Financial Centre (DIFC), this document is
strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the
securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the United Arab Emirates
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the DIFC)
other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities. Further, this prospectus supplement does not constitute a public offer of securities in the United Arab Emirates
(including the DIFC) and is not intended to be a public offer. This prospectus supplement has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the DFSA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Israel </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase ordinary securities under the Israeli Securities Law, 5728 &#150; 1968, which requires a prospectus to be published and authorized by the Israel
Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728 &#150; 1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to
certain conditions (the &#147;Addressed Investors&#148;); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 &#150; 1968, subject to certain
conditions (the &#147;Qualified Investors&#148;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has
not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#150; 1968. We have not and will not distribute this prospectus supplement or make, distribute or
direct an offer to subscribe for our ordinary shares to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728
&#150; 1968. In particular, we may request, as a condition to be offered ordinary shares, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within
one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#150; 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Law, 5728 &#150; 1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 &#150; 1968 and the
regulations promulgated thereunder in connection with the offer to be issued ordinary shares; (iv)&nbsp;that the ordinary shares that will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 &#150; 1968: (a) for its
own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 &#150; 1968; and (v)&nbsp;that it is
willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed
Investor&#146;s name, address and passport number or Israeli identification number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized and do not authorize the making of any offer
of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no
purchaser of the securities, other than the underwriters, is authorized to make any further offer of securities on our behalf or on behalf of the underwriters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
securities have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the securities nor any interest therein may be offered or sold, directly or indirectly, in
Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the
Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of
Hong Kong (the &#147;SFO&#148;)) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions)
Ordinance (Cap. 32) of Hong Kong (the &#147;CO&#148;) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be
in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the
securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus have not been lodged with or registered as a prospectus by the Monetary Authority of Singapore. Accordingly, this prospectus supplement, the accompanying prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the ordinary shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> may not be circulated or distributed, nor may the ordinary
shares <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants</FONT> be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to
an institutional investor (as defined in Section&nbsp;4A of the SFA) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person
pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA and (where applicable) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulation&nbsp;3 of the Securities and Futures (Classes of Investors) Regulations 2018 or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable
provision of the SFA, in each case subject to compliance with the conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the ordinary shares <FONT
STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants</FONT> are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trustee of a trust (where the trustee is not an accredited investor) whose sole purpose is to hold
investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ordinary shares <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants</FONT>
pursuant to an offer made under Section&nbsp;275 of the SFA, except: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person as defined in Section&nbsp;275(2) of the SFA, or (in the
case of such corporation) where the transfer arises from an offer referred to in Section&nbsp;275(1A) of the SFA or (in the case of such trust) where the transfer arises from an offer referred to in Section&nbsp;276(4)(c)(ii) of the SFA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation&nbsp;37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notification under Section</B><B></B><B>&nbsp;309B(1) of the
SFA</B>: The Company has determined, and hereby notifies all persons (including relevant persons (as defined in Section&nbsp;309A(1) of the SFA)) that the ordinary shares and&nbsp;pre- funded&nbsp;warrants are prescribed capital markets products (as
defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in the MAS <FONT STYLE="white-space:nowrap">Notice&nbsp;SFA&nbsp;04-N12:&nbsp;Notice</FONT> on the Sale of Investment
Products and MAS <FONT STYLE="white-space:nowrap">Notice&nbsp;FAA-N16:&nbsp;Notice</FONT> on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchasers are
advised to seek legal advice prior to the resale of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities
and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i)&nbsp;the offer of the securities under this prospectus supplement is
only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii)&nbsp;this
prospectus supplement is made available in Australia only to those persons as set forth in clause (i)&nbsp;above, and (iii)&nbsp;the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the
offeree is such a person as set forth in clause (i)&nbsp;above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its
transfer to the offeree under this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Bermuda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale
of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable
Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as
issued by the board of the Saudi Arabian Capital Market Authority (CMA) pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for
any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do
not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the British
Virgin Islands </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or
subscription by or on our behalf. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant
BVI Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement will not be circulated or distributed in the PRC and the securities will not be offered or sold, and will not be offered or sold to
any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus supplement nor any
advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Korea </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder (the FSCMA), and the securities have been and will be offered in Korea as a
private placement under the FSCMA. None of the securities may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea
or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the FETL). The securities have not been
listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the securities shall comply with all applicable regulatory requirements (including but not limited to
requirements under the FETL) in connection with the purchase of the securities. By the purchase of the securities, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the
securities pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Malaysia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No prospectus or other offering material or document in connection with the offer and sale of the securities has been or will be registered with the Securities
Commission of Malaysia (the Commission) for the Commission&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia
other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the securities, as principal, if the offer is on terms that the securities may only be
acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million
(or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding
twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets
exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee
or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be
specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the securities is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities.
The distribution in Malaysia of this prospectus supplement is subject to Malaysian laws. This prospectus supplement does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase,
invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Taiwan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in
circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to
offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in
South Africa </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the
South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies Act)) is being made in connection with the issue of the securities in South Africa. Accordingly, this
document does not, nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or
filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The securities are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or
to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;96&nbsp;(1)&nbsp;(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the offer, transfer, sale, renunciation or delivery is to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(ii) the South African Public Investment Corporation;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(iii) persons or entities regulated by the Reserve Bank of South Africa;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(iv) authorised financial service providers under South African law;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(v) financial institutions recognised as such under South African law;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(vi) a wholly owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each
case duly registered as such under South African law); or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(vii) any combination of the person in (i)&nbsp;to (vi); or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;96&nbsp;(1)&nbsp;(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of
South Africa pursuant to section 96(2)(a) of the South African Companies Act.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information made available in this prospectus supplement should not be considered as &#147;advice&#148; as defined in the
South African Financial Advisory and Intermediary Services Act, 2002. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the ordinary shares, including the ordinary shares underlying <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants,</FONT>
offered by us in this offering and certain other matters of Singapore law will be passed upon for us by WongPartnership LLP, Singapore. The validity of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> offered by us in this
offering and selected legal matters as to U.S. law in connection with this offering will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts. Selected intellectual property matters will be passed upon
for us by Choate Hall&nbsp;&amp; Stewart LLP, Boston, Massachusetts. The underwriters are being represented by White&nbsp;&amp; Case LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_14"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of Wave Life Sciences Ltd. as of December&nbsp;31, 2023 and 2022, and for the years then ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP,
independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, and file annual, quarterly and current reports, proxy statements and other information with
the SEC. SEC filings are available at the SEC&#146;s website at <I>http://www.sec.gov. </I>Our ordinary shares are listed on the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement we filed with the SEC under the Securities Act. This prospectus supplement and the accompanying
prospectus omit certain information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated
subsidiaries and the securities we are offering. Statements in this prospectus supplement and the accompanying prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not
intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC&#146;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>http://www.wavelifesciences.com</I>, through which you can access our SEC filings. The information set forth on our website
is not part of this prospectus supplement or the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptx872484_16"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement, and subsequent information that we file later with the SEC will automatically update and
supersede this information. We filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with the SEC with respect to the securities we may offer pursuant to this prospectus supplement. This
prospectus supplement omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may
offer pursuant to this prospectus supplement. Statements in this prospectus supplement regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each
statement is qualified in all respects by that reference. The documents we are incorporating by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023 that we filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000095017024026876/wve-20231231.htm">March&nbsp;6, 2024</A>, as amended by the Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> that we
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312524122488/d689252d10ka.htm">April&nbsp;29, 2024</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2024 and June&nbsp;30, 2024 that we filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000095017024057457/wve-20240331.htm">May&nbsp;
10, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000095017024093341/wve-20240630.htm">August&nbsp;8, 2024</A>, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312524002437/d681715d8k.htm">January&nbsp;4,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/d771392d8k.htm">June&nbsp;25, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312524199020/d746777d8k.htm">August&nbsp;
12, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/d876211d8k.htm">September 24, 2024</A> (in each case, except for information contained therein which is furnished rather than filed); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our ordinary shares contained in our Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> that we filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312515371452/d57859d8a12b.htm">November&nbsp;9, 2015</A>, including any amendment or report filed for the purpose of
updating such description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Exchange Act after the date of this prospectus supplement and prior to the termination or completion of the offering of securities under this prospectus supplement shall also be deemed to be incorporated by reference in this prospectus supplement
and to be a part hereof from the date of filing such reports and other documents. The SEC file number for each of the documents listed above is <FONT STYLE="white-space:nowrap">001-37627.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement
will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference
into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request, orally or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no
cost, by contacting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wave Life Sciences Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">733 Concord Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, MA
02138, USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ATTN: Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may
also access these documents on our website, <I>http://www.wavelifesciences.com</I>. The information contained on, or that can be accessed through, our website is not a part of this prospectus supplement or the accompanying prospectus. We have
included our website address in this prospectus supplement solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on information contained in, or incorporated by reference into, this prospectus
supplement or the accompanying prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus supplement or the accompanying prospectus or incorporated by reference in this prospectus
supplement or the accompanying prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do
so or to anyone to whom it is unlawful to make such offer or solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g872484g30t61.jpg" ALT="LOGO" STYLE="width:1.35667in;height:1.07333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>ORDINARY SHARES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT
SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up
to $500,000,000 of any combination of the securities described in this prospectus, either individually or in units. We may also offer ordinary shares upon conversion of or exchange for the debt securities; or ordinary shares or debt securities upon
the exercise of warrants or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus describes the general terms of these securities and the general manner in which these
securities will be offered. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and
may also supplement, update or amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus supplement,
carefully before you invest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our securities may be sold directly by us to you, through agents designated from time to time or to or
through underwriters or dealers. For additional information on the methods of sale, you should refer to the section titled &#147;Plan of Distribution&#148; in this prospectus and in the applicable prospectus supplement. If any underwriters or agents
are involved in the sale of our securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in a
prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares are listed on The Nasdaq Global Market under the symbol &#147;WVE.&#148; On March&nbsp;1, 2022, the last reported sale
price of our ordinary shares was $2.39 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Global Market or any securities market or other securities exchange of
the securities covered by the prospectus supplement. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider
carefully the risks that we have described on page 6 of this prospectus under the caption &#147;<A HREF="#cov872484_3">Risk Factors</A>&#148; We may include specific risk factors in supplements to this prospectus under the caption &#147;Risk
Factors&#148; This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is May&nbsp;4, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_5">INDUSTRY AND MARKET DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_8">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_10">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_11">DESCRIPTION OF RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_12">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_13">COMPARISON OF SHAREHOLDER RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_14">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_15">ENFORCEMENT OF CIVIL LIABILITIES UNDER UNITED STATES SECURITIES
LAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_16">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_17">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_18">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#cov872484_19">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate offering amount of up to
$500,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series
of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the
offering of the securities, you should refer to the registration statement, including its exhibits. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus. However, no
prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements and the documents incorporated by reference
into this prospectus, includes all material information relating to the offering of securities under this prospectus. You should carefully read this prospectus, the applicable prospectus supplement, the information and documents incorporated herein
by reference and the additional information under the heading &#147;Where You Can Find More Information&#148; before making an investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have
not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained
or incorporated by reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it
is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement is accurate only as of the date on the front of the document and that any information we have incorporated herein by reference is accurate
only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be
deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as
accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not a &#147;prospectus&#148; as defined in the Securities
and Futures Act 2001 of Singapore, or the SFA, and accordingly, statutory liability under the SFA in relation to the content of prospectuses will not apply. This prospectus has not been registered as a prospectus by the Monetary Authority of
Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of our securities may not be circulated or distributed, nor may our securities be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the SFA) pursuant to
Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018 or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other applicable provision of the SFA, in each case subject to compliance with the conditions set forth in the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where securities or securities-based derivatives contracts are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) a trustee of a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each as defined in
Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities or
securities-based derivatives contracts pursuant to an offer made under Section&nbsp;275 of the SFA, except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person as defined in Section&nbsp;275(2) of the SFA, or (in the
case of such corporation) where the transfer arises from an offer referred to in Section&nbsp;275(1A) of the SFA or (in the case of such trust) where the transfer arises from an offer referred to in Section&nbsp;276(4)(c)(ii) of the SFA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference to the SFA is a reference to the
Securities and Futures Act 2001 of Singapore and a reference to any term as defined in the SFA or any provision in the SFA is a reference to that term as modified or amended from time to time including by such of its subsidiary legislation as may be
applicable at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By accepting this prospectus, the recipient hereof represents and warrants that such recipient is
entitled to receive it in accordance with the restrictions set forth above and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent
there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references to &#147;Wave,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;our,&#148;
&#147;us&#148; or similar terms refer to Wave Life Sciences Ltd. and our wholly-owned subsidiaries. References in this prospectus to &#147;S$&#148; refer to Singapore dollars, &#147;&yen;&#148; refer to Japanese yen and &#147;&#128;&#148; refer to
euros. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd. names, the Wave Life Sciences mark, and the other trademarks, trade
names and service marks of Wave Life Sciences Ltd. appearing in this prospectus are the property of Wave Life Sciences Ltd. Wave has applied to register certain of its trademarks in the United States. This prospectus also contains additional trade
names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other companies. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not be
construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the
<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of what we believe to be the most important aspects of our business and the offering of our securities under
this prospectus. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notes to the consolidated financial statements and other information incorporated by reference from our other filings with
the SEC or included in any applicable prospectus supplement. Investing in our securities involves risks. Therefore, carefully consider the risk factors set forth in any prospectus supplements and in our most recent annual and quarterly filings with
the SEC, as well as other information in this prospectus and any prospectus supplements and the documents incorporated by reference herein or therein, before purchasing our securities. Each of the risk factors could adversely affect our business,
operating results and financial condition, as well as adversely affect the value of an investment in our securities. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Wave Life Sciences
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating
diseases. Using PRISM&#153;, our proprietary discovery and drug development platform that enables the precise design, optimization and production of novel stereopure oligonucleotides, we aspire to develop best-in-class medicines that target the
transcriptome to treat genetically defined diseases with a high degree of unmet need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing oligonucleotides that target
ribonucleic acid, or RNA, and harness existing cellular machinery to reduce the expression of disease-promoting RNA or proteins, restore the production of functional proteins, or modulate protein expression. By intervening at the RNA level, we have
the potential to address diseases that have historically been difficult to treat with small molecules or biologics, while retaining the ability to titrate dose, modulate duration of effect, and avoid risk of permanent off-target genetic changes and
other challenges associated with DNA editing or gene therapy approaches. Oligonucleotides have additional advantages as a therapeutic class, including the ability to access multiple tissue types and the ability to modulate the frequency of dosing to
ensure broad distribution within tissues over time. Oligonucleotides also have well-established manufacturing processes and validated test methods based on decades of improvements, as well as established regulatory, access and reimbursement
pathways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach is based on the scientific insight that the biological machinery necessary to address genetic diseases already
exists in human cells and can be controlled with the right tools. We have built a genetic toolkit comprised of multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage
learnings and optimizations from our PRISM platform and allow us to design built-for-purpose molecules to optimally address disease biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our A-to-I RNA base editing oligonucleotides, or AIMers, represent our newest therapeutic modality. AIMers are designed to correct single base
mutations on RNA transcript, thereby avoiding permanent changes to the genome that occur with DNA-targeting approaches. Rather than using an exogenous editing enzyme, AIMers recruit proteins that exist in the body, called ADAR (adenosine deaminases
acting on RNA) enzymes, which naturally possess the ability to change an adenine (A)&nbsp;to an inosine (I), which cells read as guanine (G). This approach enables simplified delivery and avoids the risk of irreversible off-target effects with
DNA-targeting approaches. AIMers are short in length, fully chemically modified, and use novel chemistry, including proprietary PN backbone modifications and chiral control, which make them distinct from other ADAR-mediated editing approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PRISM platform is built on the recognition that a significant opportunity exists to tune the pharmacological properties of oligonucleotide
therapeutics by leveraging three key features of these molecules: </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sequence, chemistry, and stereochemistry. Our unique ability to control stereochemistry, which is a reality of chemically modified oligonucleotides, provides the resolution necessary to optimize
pharmacological profiles. PRISM therefore enables us to design stereopure oligonucleotides, which are comprised of molecules with atoms precisely and purposefully arranged in three-dimensional orientations at each linkage. These differ from the
mixture-based oligonucleotides currently on the market or in development by others. Additionally, to mitigate pharmacological risks and potential manufacturing challenges, our approach focuses on designing short, chemically modified oligonucleotides
without the need for complex delivery vehicles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our work in developing stereopure oligonucleotides has enabled the continued evolution of
PRISM and our drug discovery process of selecting genetically defined targets, identifying a sequence and applying the therapeutic modality we determine is best suited for the disease biology. We use our PRISM platform engine to screen candidates
and optimize the pharmacologic profile based on predefined design principles, which reflect a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties.
Through continued exploration of these interactions using iterative analysis of&nbsp;<I>in vitro</I>&nbsp;and&nbsp;<I>in vivo</I>&nbsp;outcomes and machine learning-driven predictive modeling, we also continue to refine our design principles that we
deploy across subsequent programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, we publicly introduced our novel PN backbone chemistry modifications, which have been
shown preclinically to increase potency, distribution and durability of effect across various modalities. PN chemistry has been incorporated into all of our current clinical, preclinical and discovery-stage programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a robust and diverse pipeline of PN-modified, stereopure oligonucleotides, including our clinical silencing and splicing programs as
well as our AIMers. Our lead clinical development programs are designed to treat genetic diseases within the central nervous system, including amyotrophic lateral sclerosis, or ALS, frontotemporal dementia, or FTD, Huntington&#146;s disease, or HD,
and muscular dystrophies, including Duchenne muscular dystrophy, or DMD. These programs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">WVE-004 (silencing), our C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">WVE-003 (silencing), our mHTT SNP3 molecule for the treatment of HD, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">WVE-N531 (splicing), our exon 53 molecule for the treatment of DMD. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With RNA base editing, our initial focus is on using GalNAc-conjugated AIMers to treat hepatic diseases and our lead program is designed to
treat alpha-1antitrypsin deficiency, or AATD. We expect to select an AATD AIMer development candidate and initiate IND-enabling toxicology studies in the third quarter of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to invest in PRISM to further evolve and apply the expanding capabilities and promise of our unique platform. We have also
established and continue to enhance our internal current good manufacturing practices manufacturing capabilities to increase control and visibility of our drug substance supply chain, while continuing to innovate oligonucleotide manufacturing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History and Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were incorporated under the name Wave Life Sciences Pte. Ltd. (Registration No.: 201218209G) under the laws of Singapore on July&nbsp;23, 2012. On November&nbsp;16, 2015, we closed our initial public offering. In preparation for our initial public
offering, on November&nbsp;5, 2015, Wave Life Sciences Pte. Ltd. converted from a private limited company to a public limited company known as Wave Life Sciences Ltd., or Wave. Wave has four wholly-owned subsidiaries: Wave Life Sciences USA, Inc.,
or Wave USA, a Delaware corporation (formerly Ontorii, Inc.); Wave Life Sciences Japan, Inc., or Wave Japan, a company organized under the laws of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Japan (formerly Chiralgen., Ltd.); Wave Life Sciences Ireland Limited, or Wave Ireland, a company organized under the laws of Ireland; and Wave Life Sciences UK Limited, or Wave UK, a company
organized under the laws of the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered office is located at 7 Straits View #12-00, Marina One East Tower,
Singapore 018936, and our telephone number at that address is +65 6236 3388. Our principal office for Wave USA is located at 733 Concord Avenue, Cambridge, MA 02138, and our telephone number at that address is +1-617-949-2900. Our registered office
for Wave Japan is 2438 Miyanoura-cho, Kagoshima-shi, Kagoshima pref. 891-1394, Japan. Our registered office for Wave Ireland is One Spencer Dock, North Wall Quay, Dublin 1 D01 X9R7, Ireland. Our registered office for Wave UK is 1 Chamberlain Square
CS, Birmingham, B3 3AX, United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate website address is www.wavelifesciences.com. The information on our website is not
part of this prospectus or incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website in deciding whether to purchase our ordinary shares. Our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the &#147;For Investors&nbsp;&amp; Media&#151;Financial Information&#148; section of our
website as soon as reasonably practicable after they have been filed or furnished with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offerings Under This Prospectus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this prospectus, we may offer ordinary shares, various series of debt securities and/or warrants or rights, either individually or in
units, with a total value of up to $500,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each
time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exercise prices, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by
reference into this prospectus. However, no prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve
the right to accept or reject all or part of any proposed purchase of securities. If we offer securities through agents or underwriters, we will include in the applicable prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those agents or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of any securities unless it is accompanied by a prospectus supplement. </B></P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves significant risk. The prospectus supplement applicable to each offering of our securities may contain a
discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#147;Risk Factors&#148; in the
applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks,
uncertainties and assumptions discussed under the heading &#147;Risk Factors&#148; included in our most recent annual report on Form 10-K, as revised or supplemented by our subsequent quarterly reports on Form 10-Q or our current reports on Form 8-K
on file with the SEC, all of which are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any accompanying prospectus supplement and the documents we have filed with the SEC that are incorporated by reference
contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties&nbsp;that relate to
future events or to our future operations or financial performance. In some cases, forward-looking statements are identified by the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;future,&#148; &#147;goals,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;ongoing,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;strategy,&#148; &#147;target,&#148; &#147;will&#148; and &#147;would&#148; or the negative of these terms, or other comparable terminology intended to identify statements about the
future, although not all forward-looking statements contain these identifying words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe that we
have a reasonable basis for each forward-looking statement contained in this prospectus, any accompanying prospectus and the documents that we have filed with the SEC that are incorporated by reference, such statements are based on a combination of
facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and
capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, progress, number, scope, cost, duration, timing or results of our research and development
activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits that may be derived from any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, prospects, plans, goals, expectations, forecasts or objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our collaborations with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any payment that our collaboration partners may make to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected uses of the net proceeds from any offering of our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors in the industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our liquidity and working capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected impact of new accounting standards; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of COVID-19 and variants thereof, on our research and development
activities, preclinical studies and clinical trials, supply of drug product, and our workforce. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the
section titled &#147;Risk Factors&#148; of this prospectus and in our other filings with the SEC for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
statements. As a result of these factors, we cannot assure that the forward-looking statements in this prospectus, any accompanying prospectus or the documents we have filed with the SEC that are incorporated by reference will prove to be accurate.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or
warranties by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our
beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be
limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are
cautioned not to unduly rely upon these statements as predictions of future events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any accompanying
prospectus supplement, the documents that we have incorporated by reference herein and therein and the documents we have filed as exhibits to the registration statement, completely and with the understanding that our actual future results may be
materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_5"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain industry data and market data included in this prospectus, any accompanying prospectus supplement and the documents we have filed with
the SEC that are incorporated herein by reference were obtained from independent third-party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. All of management&#146;s
estimates presented herein are based upon management&#146;s review of independent third-party surveys and industry publications prepared by a number of sources and other publicly available information. All of the market data used in this prospectus,
any accompanying prospectus supplement and the documents we have filed with the SEC that are incorporated herein by reference involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We
believe that the information from these industry publications and surveys is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled
&#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any time debt securities are offered pursuant to this prospectus, we will provide a table setting forth our ratio of earnings to fixed charges
on a historical basis in the applicable prospectus supplement, if required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will receive any proceeds in connection with securities which may be offered pursuant to this prospectus. Unless
otherwise indicated in the applicable prospectus supplement, we intend to use the net proceeds from the sale of securities under this prospectus for our operations and for other general corporate purposes, including, but not limited to, clinical
trial costs and other research and development expenses; continued investment in our drug development platform; and working capital, capital expenditures and general and administrative expenses. We have not determined the amounts we plan to spend on
any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any
purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade, interest-bearing securities or apply them to the reduction of short-term indebtedness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_8"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this
section, references to &#147;shareholders&#148; mean those persons whose names and number of shares are entered in our register of members. Only persons who are registered in our register of members are recognized under Singapore law as shareholders
of our company with legal standing to institute shareholder actions against us or otherwise seek to enforce their rights as shareholders. Our branch register of members is maintained by our transfer agent, Computershare Trust Company, N.A., or
Computershare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares offered in any offering pursuant to this prospectus and any accompanying prospectus supplement are expected to
be held through the Depository Trust Company, or DTC. Accordingly, DTC or its nominee, Cede&nbsp;&amp; Co., will be the shareholder on record registered in our register of members. The holder of our shares held in book-entry through DTC or its
nominee may become a registered shareholder by exchanging its interest in our shares for certificated shares and being registered in our register of members for such shares. The procedures by which a holder of book-entry interests held through DTC
or its nominee may exchange such interests for certificated shares are determined by DTC and Computershare, in accordance with their internal policies and guidelines regulating the withdrawal and exchange of book-entry interests for certificated
shares, and following such an exchange Computershare will perform the procedures to register the shares in the register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Companies Act 1967 of Singapore (&#147;Singapore Companies Act&#148;), if (a)&nbsp;the name of any person is without sufficient cause entered in or omitted from the register of members; or (b)&nbsp;default is made or there is unnecessary delay in
entering in the register of members the fact of any person having ceased to be a member, the person aggrieved or any member of the public company or the company itself, may apply to the Singapore courts for rectification of the register of members.
The Singapore courts may either refuse the application or order rectification of the register of members, and may direct the company to pay any damages sustained by any party to the application. The Singapore courts will not entertain any
application for the rectification of a register of members in respect of an entry which was made in the register of members more than 30 years before the date of the application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, there were outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">59,841,116 ordinary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,901,348 Series A preferred shares held by one shareholder of record; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,875,350 ordinary shares issuable upon vesting of outstanding restricted share units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,958,160 ordinary shares issuable upon the exercise of outstanding share options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,132,882 ordinary shares reserved for issuance in connection with future grants under our equity incentive plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">882,474 ordinary shares reserved for issuance under our 2019 Employee Share Purchase Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our share capital and provisions of our constitution (formerly known as our memorandum and articles of
association) are summaries and are qualified by reference to the Singapore Companies Act and our constitution. A copy of our constitution has been filed with the SEC as an exhibit to the registration statement of which this prospectus forms a part.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2021, our issued and paid-up ordinary share capital consists of 59,841,116 ordinary shares. We currently have only one class of issued ordinary shares, which have identical rights in all respects and rank equally with one another.
Our ordinary shares have no par value and there is no authorized share capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under Singapore law. There is a provision in our constitution which provides that we may issue shares with such preferred, deferred or other special rights or such restrictions, whether in regard
to dividend, voting, return of capital or otherwise as our board of directors may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our shares presently issued are fully
paid-up, and existing shareholders are not subject to any calls on these shares. Although Singapore law does not recognize the concept of &#147;non-assessability&#148; with respect to newly-issued shares, we note that any purchaser of our shares who
has fully paid up all amounts due with respect to such shares will not be subject under Singapore law to any personal liability to contribute to the assets or liabilities of our company in such purchaser&#146;s capacity solely as a holder of such
shares. We believe that this interpretation is substantively consistent with the concept of &#147;non-assessability&#148; under most, if not all, U.S. state corporation laws. All of our shares are in registered form. We cannot, except in the
circumstances permitted by the Singapore Companies Act, grant any financial assistance for the acquisition or proposed acquisition of our own shares. Except as described below under &#147;&#151;Takeovers,&#148; there are no limitations imposed by
the Singapore Companies Act or by our constitution on the right of shareholders not resident in Singapore to hold or vote ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer
Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares
are listed for quotation on The Nasdaq Global Market under the symbol &#147;WVE.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Singapore Companies Act, new shares may be issued only with the prior approval of our shareholders in a general meeting. General
approval may be sought from our shareholders in a general meeting for the issue of shares. Approval, if granted, will lapse at the earlier of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conclusion of the next annual general meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expiration of the period within which the next annual general meeting is required by law to be held (i.e.,
within six months after the end of each financial year), </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but any approval may be revoked or varied by the company in a general meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shareholders have provided such general authority to issue new ordinary shares until the conclusion of our 2022 annual general
meeting. Such approval will lapse in accordance with the preceding paragraph if our shareholders do not grant a new approval at our 2022 annual general meeting. Subject to this and the provisions of the Singapore Companies Act and our constitution,
our board of directors may allot and issue or grant options over or otherwise dispose of new ordinary shares to such persons on such terms and conditions and with the rights and restrictions as they may think fit to impose. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Preferred Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, we have 3,901,348 Series A preferred shares outstanding. These shares are currently held by one of
our largest shareholders, Shin Nippon Biomedical Laboratories, Ltd. The terms of the Series A preferred shares as set out in our constitution include (1)&nbsp;no voting rights at any general meeting other than in limited circumstances, (2)&nbsp;a
liquidation preference equal to $0.002 per Series A preferred share, (3)&nbsp;no entitlement to dividends and (4)&nbsp;the right to convert the Series A preferred shares at any time on a one-for-one basis into ordinary shares at the discretion of
the holder in accordance with the constitution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Series A preferred shares are not entitled to vote at any general
meeting. The only instances in which the holders of the Series A preferred shares are able to vote at a general meeting would be if (but only if) the matters to be discussed at the meeting relate to or there is intent to pass resolutions on
(i)&nbsp;abrogating or changing the rights attached to the Series A preferred shares; and (ii)&nbsp;for the winding up of the Company. Such resolutions would require the unanimous approval of the holders of the Series A preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Preferred Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Singapore Companies Act, different classes of shares in a public company may be issued only if (a)&nbsp;the issue of the class or classes of shares is provided for in the constitution of the public company and (b)&nbsp;the constitution of the public
company sets out in respect of each class of shares the rights attached to that class of shares. Our constitution provides that we may issue shares of a different class with preferred, deferred or other special rights, or such restrictions, whether
in regard to dividend, voting, return of capital or otherwise as our board of directors may determine. Under Singapore law, our preferred shareholders will have the right to attend any general meeting and in a poll at such general meeting, to have
at least one vote for every preferred share held: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon any resolution concerning the voluntary winding-up of our company under Section&nbsp;160 of the Insolvency,
Restructuring and Dissolution Act 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon any resolution which varies the rights attached to such preferred shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of preferred shares issued after August&nbsp;15, 1984, but before the commencement of Section&nbsp;96
of the Companies (Amendment) Act 2014, when the dividends to be paid on our preferred shares or any part thereof are more than twelve months in arrears and unpaid, for the period they remain in arrears and unpaid. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, subject to the Singapore Companies Act and the prior approval in a general meeting of our shareholders, issue preferred shares which
are, or at our option or are to be, subject to redemption provided that such preferred shares may not be redeemed out of capital unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all the directors have made a solvency statement in relation to such redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have lodged a copy of the statement with the Accounting and Corporate Regulatory Authority of Singapore.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, such shares must be fully paid-up before they are redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we have no preferred shares outstanding other than the Series A preferred shares described above. At
present, we have no plans to issue additional preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights under our Share Purchase Agreement with Pfizer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our Share Purchase Agreement dated as of May&nbsp;5, 2016 with an affiliate of Pfizer Inc., or the Pfizer Affiliate, under
which the Pfizer Affiliate purchased 1,875,000 ordinary shares from us, or the Pfizer Shares, subject to certain conditions and limitations, we agreed to provide certain demand registration rights to the Pfizer Affiliate in order to register all or
a portion of the Pfizer Shares purchased by the Pfizer Affiliate. We also provided the Pfizer Affiliate with certain &#147;piggyback&#148; registration rights, subject to certain conditions and limitations, such that when we propose to register our
ordinary shares for our account, the Pfizer Affiliate will have the right to include some or all of the Pfizer Shares in such registration. The Share Purchase Agreement also contains other customary terms and conditions of the parties with respect
to the registration of the Pfizer Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights under our Share Purchase Agreement with Takeda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;19, 2018, we entered into a Share Purchase Agreement with Takeda Pharmaceutical Company Limited, or Takeda, pursuant to which
Takeda purchased 1,096,892 of our ordinary shares, or the Takeda Shares. In connection with the Share Purchase Agreement, Takeda and we agreed upon certain rights and restrictions as set forth in the Investor Agreement, dated as of April&nbsp;2,
2018, or the Investor Agreement. The Takeda Shares are subject to a lock-up restriction, such that Takeda will not, and will also cause its affiliates not to, without our prior approval, sell, transfer or otherwise dispose of the Takeda Shares until
certain specified periods of time after the effective date of the Investor Agreement. For a certain period following the expiration of the lock-up period, subject to certain conditions and limitations, we agreed to provide certain demand
registration rights to Takeda in order to register all or a portion of the Takeda Shares purchased by Takeda. We also provided Takeda with certain &#147;piggyback&#148; registration rights for a certain period following the expiration of the lock-up
period, subject to certain conditions and limitations, such that when we propose to register our ordinary shares for our account, Takeda will have the right to include some or all of the Takeda Shares in such registration. The Investor Agreement
also contains other customary terms and conditions of the parties with respect to the registration of Takeda Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of Ordinary Shares
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable securities laws in relevant jurisdictions and our constitution, our ordinary shares are freely transferable. Our
constitution provides that shares may be transferred by a duly signed instrument of transfer in any usual or common form or in a form approved by the directors and The Nasdaq Stock Market. The directors may decline to register any transfer unless,
among other things, evidence of payment of any stamp duty payable with respect to the transfer is provided together with other evidence of ownership and title as the directors may reasonably require to show the right of the transferor to make the
transfer. We will replace lost or destroyed certificates for shares upon notice to us and upon, among other things, the applicant furnishing evidence and indemnity as the directors may require and the payment of all applicable fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election and Re-election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
may, by ordinary resolution, remove any director before the expiration of his or her period of office, notwithstanding anything in our constitution or in any agreement between us and such director. We may also, by an ordinary resolution, appoint
another person in place of a director removed from office pursuant to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our constitution, subject to the Singapore
Companies Act, any director shall retire at the next annual general meeting and shall then be eligible for re-election at that meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors shall have the power, at any time and from time to time, to appoint any person to be a director either to fill a casual
vacancy or as an additional director so long as the total number of directors shall not at any time exceed the maximum number (if any) fixed by or in accordance with our constitution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
required to hold an annual general meeting each calendar year and within six months after the end of each financial year. The directors may convene an extraordinary general meeting whenever they think fit and they must do so upon the written request
of shareholders holding not less than 10% of the total number of paid-up shares as of the date of deposit of the requisition carrying the right to vote at a general meeting. In addition, two or more shareholders holding not less than 10% of our
total number of issued shares (excluding our treasury shares) may call a meeting of our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act
provides that a shareholder is entitled to attend any general meeting and speak on any resolution put before the general meeting. Unless otherwise required by law or by our constitution, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resolutions put forth at general meetings may be decided by ordinary resolution, requiring the affirmative vote of a majority of the shareholders present in person or represented by proxy at the
meeting and entitled to vote on the resolution. An ordinary resolution suffices, for example, for appointments of directors. A special resolution, requiring an affirmative vote of not less than three-fourths of the shareholders present in person or
represented by proxy at the meeting and entitled to vote on the resolution, is necessary for certain matters under Singapore law, such as an alteration of our constitution. A shareholder entitled to attend and vote at a meeting of the company, or at
a meeting of any class of shareholders of the company, is entitled to appoint another person or persons, whether a shareholder of the company or not, as the shareholder&#146;s proxy to attend and vote instead of the shareholder at the meeting. Under
the Singapore Companies Act, a proxy appointed to attend and vote instead of the shareholder also has the same right as the shareholder to speak at the meeting, but unless the constitution of the company otherwise provides, (i)&nbsp;a proxy is not
entitled to vote except on a poll, (ii)&nbsp;a shareholder is not entitled to appoint more than two proxies to attend and vote at the same meeting and (iii)&nbsp;where a shareholder appoints two proxies the appointments are invalid unless the
shareholder specifies the proportions of the shareholder&#146;s holdings to be represented by each proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing,
a registered shareholder entitled to attend and vote at a meeting of the company held pursuant to an order of court under Section&nbsp;210(1) of the Singapore Companies Act, or at any adjourned meeting under Section&nbsp;210(3) of the Singapore
Companies Act, is, unless the court orders otherwise, entitled to appoint only one proxy to attend and vote at the same meeting, and except where the aforementioned applies, a registered shareholder having a share capital who is a relevant
intermediary (as defined under the Singapore Companies Act) may appoint more than two proxies in relation to a meeting to exercise all or any of the shareholder&#146;s rights to attend and to speak and vote at the meeting, but each proxy must be
appointed to exercise the rights attached to a different share or shares held by the shareholder (which number and class of shares shall be specified), and at such meeting, the proxy has the right to vote on a show of hands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only registered shareholders of our company, and their proxies, will be entitled to attend, speak and vote at any meeting of shareholders.
Under the Singapore Companies Act, public companies may issue non-voting shares and shares that confer special, limited or conditional voting rights, such that the holder of a share may vote on a resolution before a general meeting of the company
if, in accordance with the provisions of Section&nbsp;64A of the Singapore Companies Act, the share confers on the holder a right to vote on that resolution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided under our
constitution and the Singapore Companies Act, voting at any meeting of shareholders is by show of hands unless a poll has been demanded prior to the declaration of the result of the show of hands by, among others, (i)&nbsp;the chairman or
(ii)&nbsp;at least one shareholder present in person or by proxy or by attorney or, in the case of a corporation, by a representative entitled to vote thereat, in each case representing in the aggregate not less than 5% of the total voting rights of
all shareholders having the right to vote at the general meeting, provided that no poll shall be demanded in respect of an election of a chairman or relating to any adjournment of such meeting. On a poll every shareholder who is present in person or
by proxy or by attorney, or in the case of a corporation, by a representative, has one vote for every share held by such shareholder. Proxies need not be shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only those shareholders who are registered in our register of members as holders of ordinary shares will be entitled to vote at any meeting of
shareholders. Therefore, DTC, or its nominee, will grant an omnibus proxy to DTC participants holding our shares in book-entry form through a broker, bank, nominee, or other institution that is a direct or indirect participant in the DTC. Such
shareholders will have the right to instruct their broker, bank, nominee or other institution holding these shares on how to vote such shares by completing the voting instruction form provided by the applicable broker, bank, nominee, or other
institution. Whether voting is by a show of hands or by a poll, DTC&#146;s vote will be voted by the chairman of the meeting according to the results of the DTC&#146;s participants&#146; votes (which results will reflect the instructions received
from shareholders that own our shares electronically in book-entry form). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Minority Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of minority shareholders of Singapore companies are protected, among other things, under Section&nbsp;216 of the Singapore Companies
Act, which gives the Singapore courts a general power to make any order, upon application by any shareholder of a company, as they think fit to remedy any of the following situations: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the affairs of a company are being conducted or the powers of the board of directors are being exercised in a
manner oppressive to, or in disregard of the interests of, one or more of the shareholders, including the applicant; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company takes an action, or threatens to take an action, or the shareholders pass a resolution, or propose to
pass a resolution, which unfairly discriminates against, or is otherwise prejudicial to, one or more of the shareholders, including the applicant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Singapore courts have wide discretion as to the remedy they may grant, and the remedies listed in the Singapore Companies Act itself are not
exclusive. In general, Singapore courts may, with a view to bringing to an end or remedying the matters complained of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct or prohibit any act or cancel or modify any transaction or resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulate the conduct of the affairs of the company in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize civil proceedings to be brought in the name of, or on behalf of, the company by a person or persons and
on such terms as the court may direct; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for the purchase of a minority shareholder&#146;s shares by the other shareholders or by the company
itself; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a purchase of shares by the company provide for a reduction accordingly of the company&#146;s
capital; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the company be wound up. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to any preferential
rights of holders of any outstanding preferred shares, holders of our ordinary shares will be entitled to receive dividends and other distributions in cash, shares or property as may be declared by our company from time to time. We may, by ordinary
resolution, declare dividends at a general meeting of shareholders, but we are restricted from paying dividends in excess of the amount recommended by our board of directors. Pursuant to Singapore law and our constitution, no dividend may be paid
except out of our profits. To date, we have not declared any cash dividends on our ordinary shares and have no current plans to pay cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bonus and Rights Issues </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a general
meeting, our shareholders may, upon the recommendation of the directors, capitalize any reserves or profits and distribute them as bonus shares, credited as paid-up, to the shareholders in proportion to their shareholdings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Singapore Companies Act and our constitution, our directors may also issue rights to take up additional
ordinary shares to our shareholders in proportion to their respective ownership. Such rights are subject to any condition attached to such issue and the regulations of any stock exchange on which our shares are listed, as well as U.S. federal and
blue sky securities laws applicable to such issue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Takeovers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Singapore Code on Take-overs and Mergers applies to, among other things, the acquisition of voting shares of Singapore-incorporated listed
public companies or unlisted public companies with more than 50 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders and net tangible assets of S$5 million or more. Any person acquiring, whether by a series of transactions over a period of time or not, either on his or her own or together with
parties acting in concert with such person, 30% or more of our voting shares, or, if such person holds, either on his or her own or together with parties acting in concert with such person, between 30% and 50% (both amounts inclusive) of our voting
shares, and if such person (or parties acting in concert with such person) acquires additional voting shares representing more than 1% of our voting shares in any six-month period, must, except with the consent of the Securities Industry Council in
Singapore, extend a mandatory takeover offer for the remaining voting shares in accordance with the provisions of the Singapore Code on Take-overs and Mergers. Responsibility for ensuring compliance with the Singapore Code on Take-overs and Mergers
rests with parties (including company directors) to a take-over or merger and their advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Parties acting in concert&#148;
comprise individuals or companies who, pursuant to an agreement or understanding (whether formal or informal), cooperate, through the acquisition by any of them of shares in a company, to obtain or consolidate effective control of that company.
Certain persons are presumed (unless the presumption is rebutted) to be acting in concert with each other. They are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company, its parent company, subsidiaries and fellow subsidiaries, the associated companies of any of the
company and its related companies, subsidiaries and fellow subsidiaries, companies whose associated companies include any of these companies and any person who has provided financial assistance (other than a bank in the ordinary course of business)
to any of the foregoing for the purchase of voting rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company with any of its directors (together with their close relatives, related trusts and companies controlled
by any of the directors, their close relatives and related trusts); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company with any of its pension funds and employee share schemes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person with any investment company, unit trust or other fund whose investment such person manages on a
discretionary basis, but only in respect of the investment account which such person manages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a financial or other professional advisor, including a stockbroker, with its client in respect of the
shareholdings of the advisor and persons controlling, controlled by or under the same control as the advisor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors of a company (together with their close relatives, related trusts and companies controlled by any of
such directors, their close relatives and related trusts) which is subject to an offer or where the directors have reason to believe a bona fide offer for their company may be imminent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual and (i)&nbsp;such person&#146;s close relatives, (ii)&nbsp;such person&#146;s related trusts,
(iii)&nbsp;any person who is accustomed to act in accordance with such person&#146;s instructions, (iv)&nbsp;companies controlled by the individual, such person&#146;s close relatives, related trusts or any person who is accustomed to act in
accordance with such person&#146;s instructions and (v)&nbsp;any person who has provided financial assistance (other than a bank in the ordinary course of business) to any of the foregoing for the purchase of voting rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions, a mandatory offer must be in cash or be accompanied by a cash alternative at not less than the highest price
paid by the offeror or parties acting in concert with the offeror during the offer period and within the six months prior to its commencement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Singapore Code on Take-overs and Mergers, where effective control of a company is acquired or consolidated by a person, or persons
acting in concert, a general offer to all other shareholders is normally required. An offeror must treat all shareholders of the same class in an offeree company equally. A fundamental requirement is that shareholders in the company subject to the
takeover offer must be given sufficient information, advice and time to consider and decide on the offer. These legal requirements may impede or delay a takeover of our company by a third-party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may submit an application to the Securities Industry Council of Singapore for a waiver
from the Singapore Code on Take-overs and Mergers so that the Singapore Code on Take-overs and Mergers will not apply to our company for so long as we are not listed on a securities exchange in Singapore. We will make an appropriate announcement if
we submit the application and when the result of the application is known. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation or Other Return of Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a winding-up or other return of capital, subject to any special rights attaching to the Series A preferred shares or to any other class of
shares, holders of ordinary shares will be entitled to participate in any surplus assets in proportion to their shareholdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of
Liability and Indemnification Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;172 of the Singapore Companies Act, any provision exempting or indemnifying
the officers of a company (including directors) against any liability that would otherwise attach to them in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void. However, a company is not
prohibited from (a)&nbsp;purchasing and maintaining for any such individual insurance against liability incurred by him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the company, or
(b)&nbsp;indemnifying the individual against liability incurred by him or her to a person other than the company except when the indemnity is against any liability (i)&nbsp;of the individual to pay a fine in criminal proceedings, (ii)&nbsp;of the
individual to pay a penalty in respect of non-compliance with any requirements of a regulatory nature (howsoever arising), (iii)&nbsp;incurred by the individual in defending criminal proceedings in which he or she is convicted, (iv)&nbsp;incurred by
the individual in defending civil proceedings brought by the company or a related company in which judgment is given against him or her, or (v)&nbsp;incurred by the individual in connection with an application for relief under Section&nbsp;76A(13)
or Section&nbsp;391 of the Singapore Companies Act in which the court refuses to grant him or her relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Singapore
Companies Act and every other Singapore statute for the time being in force concerning companies and affecting us, our constitution provides that each of our directors and other officers and those of our subsidiaries and affiliates shall be entitled
to be indemnified by us or such subsidiary against any liability incurred by him or her arising out of or in connection with any acts, omissions or conduct, actual or alleged, by such individual acting in his or her capacity as either director,
officer, secretary or employee of us or the relevant subsidiary, except to such extent as would not be permitted under applicable Singapore laws or which would otherwise result in such indemnity being void in accordance with the provisions of the
Singapore Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Singapore Companies Act and every other Singapore statute for the time being in force and
affecting our company, we may indemnify our directors and officers against costs, charges, fees and other expenses that may be incurred by any of them in defending any proceedings (whether civil or criminal) relating to anything done or omitted or
alleged to be done or omitted by such person acting in his or her capacity as a director, officer or employee of our company, in which judgment is given in his or her favor, or in which he or she is acquitted or in which the courts have granted
relief pursuant to the provisions of the Singapore Companies Act, provided that such indemnity shall not extend to any liability which by law would otherwise attach to him or her in respect of any negligence, default, breach of duty or breach of
trust of which he may be guilty in relation to our company, or which would otherwise result in such indemnity being voided under applicable Singapore laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No director or officer of our company shall be liable for any acts, omissions, neglects, defaults or other conduct of any other director or
officer, and to the extent permitted by Singapore law, our company shall contribute to the amount paid or payable by a director or officer in such proportion as is appropriate to reflect the relative fault of such director or officer, taking into
consideration any other relevant equitable considerations, including acts of other directors or officers and our company, and the relative fault of such parties in respect thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to the Singapore Companies Act and every other Singapore statute for
the time being in force and affecting our company, no director, managing director or other officer shall be liable for the acts, receipts, neglects or defaults of any other director or officer, or for joining in any receipt or other act for
conformity, or for any loss or expense incurred by us, through the insufficiency or deficiency of title to any property acquired by order of the directors for us or for the insufficiency or deficiency of any security upon which any of our moneys are
invested or for any loss or damage arising from the bankruptcy, insolvency or tortious act of any person with whom any moneys, securities or effects are deposited, or any other loss, damage or misfortune which happens in the execution of his or her
duties, unless the same happens through his or her own negligence, default, breach of duty or breach of trust. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into deeds
of indemnity with each of our directors and officers. These agreements will require us to indemnify these individuals to the fullest extent permitted under our constitution and the Singapore Companies Act against liabilities that may arise by reason
of their service to us as a director or officer of the company (as the case may be), and to advance expenses incurred in connection with any proceeding against them by reason of their status as a director, officer, agent or employee of the company
in accordance with the terms of the deeds. These indemnification rights shall not be exclusive of any other right which an indemnified person may have or thereafter acquire under any applicable law, provision of our constitution, agreement, vote of
shareholders or disinterested directors or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to maintain standard policies of insurance that provide coverage
(1)&nbsp;to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2)&nbsp;to us with respect to indemnification payments that we may make to such directors and officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplements, summarizes the
material terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer pursuant to this prospectus, we will describe the
particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus supplement may differ from
the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will
issue any such senior debt securities under a senior indenture that we will enter into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture, which we will enter into
with a trustee to be named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part. We use the term &#147;indentures&#148; to refer to either the senior
indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture Act of 1939, as in effect on the date of the indenture, or the Trust Indenture Act. We use the term &#147;debenture trustee&#148; to
refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all the provisions of the indenture applicable to a particular
series of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that debt securities may be issued from time to time in one or more series and may be denominated and payable in
foreign currencies or units based on or relating to foreign currencies. Neither indenture limits the amount of debt securities that may be issued thereunder, and each indenture provides that the specific terms of any series of debt securities shall
be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture, if any, relating to such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in each prospectus supplement the following terms relating to a series of debt securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title or designation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount and any limit on the amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or units based on or relating to currencies in which debt securities of such series are denominated
and the currency or units in which principal or interest or both will or may be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will issue the series of debt securities in global form, the terms of any global securities and who
the depositary will be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date and the date or dates on which principal will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest
will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the subordination of any series of subordinated debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where payments will be payable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt
securities pursuant to any optional redemption provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on which, and the price at which, we are obligated, pursuant to any mandatory sinking fund
provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the indenture will restrict our ability to pay dividends or will require us to maintain any asset ratios
or reserves; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be restricted from incurring any additional indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to a series of debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable
upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the U.S. federal income tax considerations and other special considerations applicable to any of these debt securities
in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable
for our ordinary shares or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of ordinary shares or
our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale; No
Protection in the Event of a Change of Control or Highly Leveraged Transaction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures do not contain any covenant that
restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or
the debt securities, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not
contain any provisions that may afford holders of the debt securities protection in the event we have a change of control or in the event of a highly leveraged transaction (whether or not such transaction results in a change of control), which could
adversely affect holders of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default Under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are events of default under the indentures with respect to any series of debt securities that we may issue: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay interest when due and our failure continues for 90 days and the time for payment has not been
extended or deferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal, or premium, if any, when due and the time for payment has not been extended or
delayed; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant set forth in the debt securities of such series or the
applicable indentures, other than a covenant specifically relating to and for the benefit of holders of another series of debt securities, and our failure continues for 90 days after we receive written notice from the debenture trustee or holders of
not less than a majority in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur as to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or
reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under any bank credit agreements we may have in existence from
time to time. In addition, the occurrence of certain events of default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the
holders of not less than a majority in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the debenture trustee if given by the holders), declare to be due and payable immediately the
principal (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and premium, if any, and accrued and unpaid interest, if any, on all debt
securities of that series. Before a judgment or decree for payment of the money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding debt securities of that series (or,
at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events of default,
other than the non-payment of accelerated principal, premium, if any, and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect
of principal, premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions
relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an event of default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be
under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable
indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the debenture trustee, or
exercising any trust or power conferred on the debenture trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might
involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder
of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder previously has given written notice to the debenture trustee of a continuing event of default with
respect to that series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least a majority in aggregate principal amount of the outstanding debt securities of that
series have made written request, and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in
aggregate principal amount of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at
such meeting) other conflicting directions within 60 days after the notice, request and offer. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not
apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable
indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debenture trustee and we may change the applicable indenture without the consent of any holders with respect to specific matters,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fix any ambiguity, defect or inconsistency in the indenture; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to change anything that does not materially adversely affect the interests of any holder of debt securities of
any series issued pursuant to such indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indentures, the rights of holders of a series of
debt securities may be changed by us and the debenture trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series (or, at a meeting of holders of such series
at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) that is affected. However, the debenture trustee and we may make the following changes only with the
consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or any premium
payable upon the redemption of any debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount of discount securities payable upon acceleration of maturity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment or
waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the
outstanding debt securities of any series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may on behalf of the
holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt
securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series or in respect of
a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt security of the series affected; provided, however, that the holders of a majority in principal amount of the outstanding debt
securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged with respect to a series, we must deposit with the trustee money or government obligations
sufficient to pay all the principal of, the premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form,
Exchange, and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we
otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry
securities that will be deposited with, or on behalf of, DTC or another depositary named by us and identified in a prospectus supplement with respect to that series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange or in the applicable indenture, we will make no
service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or
rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Debenture Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes to
perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use
in the conduct of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered
reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check which we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate
the corporate trust office of the debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt
securities which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination of Subordinated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to
certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of senior indebtedness we may incur. It also does not limit us from issuing any other secured or unsecured
debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_10"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to
purchase our ordinary shares and/or debt securities in one or more series together with other securities or separately, as described in the applicable prospectus supplement. Warrants for the purchase of ordinary shares and/or debt securities will be
in registered form only. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the warrant agreements and the prospectus supplement relating to the
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to
the warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the price at which we will issue, the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, amount and terms of the securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our ordinary shares and the number of ordinary shares to be received upon
exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our debt securities, the amount of debt securities to be received upon
exercise, and a description of that series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in definitive or global form or in any combination of these forms, although,
in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents,
transfer agents, registrars or other agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and the ordinary shares and/or debt securities will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants may be sold separately or with other securities as parts of units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_11"></A>DESCRIPTION OF RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue rights to our
shareholders to purchase our ordinary shares or the other securities described in this prospectus. We may offer rights separately or together with one or more additional rights, debt securities, ordinary shares or warrants, or any combination of
those securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. The
rights agent will act solely as our agent in connection with the certificates relating to the rights of the series of certificates and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates
or beneficial owners of rights. The following description sets forth certain general terms and provisions of the rights to which any prospectus supplement may relate. The particular terms of the rights to which any prospectus supplement may relate
and the extent, if any, to which the general provisions may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular terms of the rights, rights agreement or rights certificates
described in a prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus supplement. We encourage you to read the applicable rights agreement and
rights certificate for additional information before you decide whether to purchase any of our rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide in a prospectus
supplement the following terms of the rights being issued: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date of determining the shareholders entitled to the rights distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of our ordinary shares or other securities purchasable upon exercise of the rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of rights issued; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the rights are transferrable and the date, if any, on and after which the rights may be separately
transferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the rights will commence, and the date on which the right to exercise the
rights will expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the method by which holders of rights will be entitled to exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conditions to the completion of the offering, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the withdrawal, termination and cancellation rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether there are any backstop or standby purchaser or purchasers and the terms of their commitment, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether shareholders are entitled to oversubscription rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax considerations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange
and exercise of the rights, as applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each right will entitle the holder of rights to purchase for cash the
principal amount of our ordinary shares or other securities at the exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may exercise rights as described in the applicable prospectus supplement. Upon receipt of
payment and the rights certificate properly completed and duly executed at the corporate trust office of the rights agent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the ordinary shares or other securities, as applicable, purchasable upon exercise of the rights.
If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than shareholders, to or through agents, underwriters or dealers or through a combination of such methods,
including pursuant to standby arrangements, as described in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights agent for any rights we offer will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_12"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information that we include in any applicable prospectus supplements summarizes the
material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any
series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes the terms of the series of
units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all
the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we may offer under this
prospectus, as well as any related free writing prospectuses and the complete unit agreement and any supplemental agreements that contain the terms of the units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of
our ordinary shares, one or more debt securities, warrants, or rights for the purchase of our ordinary shares and/or debt securities in one or more series, in any combination. Each unit will be issued so that the holder of the unit is also the
holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities included
in the unit may not be held or transferred separately, at any time or at any time before a specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of units being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement that differ from those described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those set forth in any prospectus supplement
or as described under &#147;Description of Share Capital,&#148; &#147;Description of Debt Securities,&#148; &#147;Description of Warrants&#148; and &#147;Description of Rights&#148; will apply to each unit, as applicable, and to any ordinary shares,
debt security, warrant or right included in each unit, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unit Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in
such amounts and in such numerous distinct series as we determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency
or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit,
including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate
legal action its rights as holder under any security included in the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_13"></A>COMPARISON OF SHAREHOLDER RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of Singapore. The following discussion summarizes material differences between the rights of holders of our
ordinary shares and the rights of holders of the common stock of a typical corporation incorporated under the laws of the state of Delaware which result from differences in governing documents and the laws of Singapore and Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete statement of the rights of holders of our ordinary shares under applicable law in Singapore
and our constitution or the rights of holders of the common stock of a typical corporation under applicable Delaware law and a typical certificate of incorporation and bylaws. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A typical certificate of incorporation and bylaws provides that the number of directors on the board of directors will be fixed from time to time by a vote of the majority of the authorized directors. Under Delaware law, a board of
directors can be divided into classes and cumulative voting in the election of directors is only permitted if expressly authorized in a corporation&#146;s certificate of incorporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The constitution of companies will typically state the minimum and maximum number of directors as well as provide that the number of directors may be increased or reduced by shareholders via ordinary resolution passed at a
general meeting, provided that the number of directors following such increase or reduction is within the maximum (if any) and minimum number of directors provided in our constitution and the Singapore Companies Act, respectively.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Limitation on Personal Liability of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A typical certificate of incorporation provides for the elimination of personal monetary liability of directors for breach of fiduciary duties as directors to the fullest extent permissible under the laws of Delaware, except for
liability (i) for any breach of a director&#146;s loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the
Delaware General Corporation Law (relating to the liability of directors for unlawful payment of a dividend or an unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit. A
typical certificate of incorporation also provides that if the Delaware General Corporation Law is amended so as to allow further elimination of, or limitations on, director liability, then the liability of directors will be eliminated or limited to
the fullest extent permitted by the Delaware General Corporation Law as so amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pursuant to the Singapore Companies Act, any provision (whether in the constitution, a contract with the company or otherwise) exempting or indemnifying a director against any liability which by law would otherwise attach to him
or her in respect of any negligence, default, breach of duty or breach of trust of which such director may be guilty in relation to the company is void. However, a company is not prohibited from (a) purchasing and maintaining for any such director
insurance against any such liability, or (b) indemnifying such director against any liability incurred by him or her to a person other than the company except when the indemnity is against any liability (i) of the director to pay a fine in criminal
proceedings, (ii) of the director to pay a penalty in respect of non-compliance with any regulatory requirements, (iii) incurred by the director in defending criminal proceedings in which he or she is convicted, (iv) incurred by the director in
defending civil proceedings brought by the company or a related company in which judgment is given against him or her, or (v) incurred by the director in connection with an application for relief under Section 76A(13) or Section 391 of the Singapore
Companies Act in which the court refuses to grant him or her relief. Nevertheless, a director can be</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">released by the shareholders of a company for breaches of duty to a company except in the case of fraud, illegality, insolvency of the
company and oppression or disregard of minority interests.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to the Singapore
Companies Act and every other Singapore statute for the time being in force and affecting the Company, we may indemnify our directors against costs, charges, fees, and other expenses that may be incurred by any of them in defending any proceedings
(whether civil or criminal) relating to anything done or omitted or alleged to be done or omitted by such person acting in his or her capacity as a director of our company, in which judgment is given in his or her favor, or in which he or she is
acquitted or in which the courts have granted relief pursuant to the provisions of the Singapore Companies Act, provided that such indemnity shall not extend to any liability which by law would otherwise attach to him or her in respect of any
negligence, default, breach of duty or breach of trust of which he may be guilty in relation to our company, or which would otherwise result in such indemnity being voided under applicable Singapore laws.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interested Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in specified corporate
transactions (such as mergers, stock and asset sales, and loans) with an &#147;interested stockholder&#148; for three years following the time that the stockholder becomes an interested stockholder. Subject to specified exceptions, an
&#147;interested stockholder&#148; is a person or group that owns 15% or more of the corporation&#146;s outstanding voting stock (including any rights to acquire stock pursuant to an option, warrant, agreement, arrangement or understanding, or upon
the exercise of conversion or exchange rights, and stock with respect to which the person has voting rights only), or is an affiliate or associate of the corporation and was the owner of 15% or more of the voting stock at any time within the
previous three years.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may elect to &#147;opt out&#148; of,
and not be governed by, Section&nbsp;203 through a provision in either its original certificate of incorporation, or an amendment to its original certificate or bylaws that was approved by majority stockholder vote. With a limited exception, this
amendment would not become effective until 12 months following its adoption.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">There are no comparable provisions under the Singapore Companies Act with respect to public companies which are not listed on the Singapore Exchange Securities Trading
Limited.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Removal of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A typical certificate of incorporation and bylaws provide that, subject to the rights of holders of any preferred stock, directors may be removed at any time by the affirmative vote of the holders of at least a majority, or in some
instances a supermajority, of the voting power of all of the then outstanding shares entitled to vote generally in the election of directors, voting together as a single class. A certificate of incorporation could also provide that such a right is
only exercisable when a director is being removed for cause (removal of a director only for cause is the default rule in the case of a classified board).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the Singapore Companies Act, directors of a public company may be removed before expiration of their term of office, despite anything in its constitution or in any agreement between the public company and such directors, by
ordinary resolution (i.e., a resolution which is passed by a simple majority of those shareholders present and voting in person or by proxy). Notice of the intention to move such a resolution has to be given to the company not less than 28 days
before the meeting at which it is moved. The company must then give notice of such resolution to its shareholders not less than 14 days before the meeting. Where any director removed in this manner was appointed to represent the interests of any
particular class of shareholders or debenture holders, the resolution to remove the director does not take effect until the director&#146;s successor has been appointed.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Filling Vacancies on the Board of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A typical certificate of incorporation and bylaws provide that, subject to the rights of the holders of any preferred stock, any vacancy, whether arising through death, resignation, retirement, disqualification, removal, an increase
in the number of directors or any other reason, may be filled by a majority vote of the remaining directors, even if such directors remaining in office constitute less than a quorum, or by the sole remaining director. Any newly elected director
usually holds office for the remainder of the full term expiring at the annual meeting of stockholders at which the term of the class of directors to which the newly elected director has been elected expires.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The constitution of a Singapore company typically provides that the directors have the power to appoint any person to be a director, either to fill a vacancy or as an addition to the existing directors, but so that the total number
of directors shall not at any time exceed the maximum number (if any) fixed by or in accordance with the constitution. Any director so appointed shall hold office until the next following annual general meeting, where such director will then be
eligible for re-election. Our constitution provides that the directors may appoint any person to be a director either to fill a casual vacancy or as an additional director but so that the total number of Directors shall not at any time exceed the
maximum number fixed by or in accordance with the constitution.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Amendment of Governing Documents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, amendments to a corporation&#146;s certificate of incorporation require the approval of stockholders holding a majority of the outstanding shares entitled to vote on the amendment. If a
class vote on the amendment is required by the Delaware General Corporation Law, a majority of the outstanding stock of the class is required, unless a greater proportion is specified in the certificate of incorporation or by other provisions of the
Delaware General Corporation Law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our constitution may be altered by special resolution (i.e., a resolution passed by at least a three-fourths majority of the shareholders
entitled to vote, present in person or by proxy at a meeting for which not less than 21 days&#146; written notice is given). The board of directors has no right to amend the constitution.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Singapore Companies Act, an entrenching provision may be included in the
constitution with which a company is formed and may at any time be</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, the board of directors may amend bylaws if so authorized in the charter. The stockholders of a Delaware corporation also have the power to amend bylaws.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">inserted into the constitution of a company only if all the shareholders of the company agree. An entrenching provision is a provision of the constitution of a company to the effect that other specified provisions of the
constitution may not be altered in the manner provided by the Singapore Companies Act or may not be so altered except (i) by a resolution passed by a specified majority greater than 75% (the minimum majority required by the Singapore Companies Act
for a special resolution) or (ii) where other specified conditions are met. The Singapore Companies Act provides that such entrenching provision may be removed or altered only if all the members of the company agree.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Meetings of Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual and Special Meetings</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Typical bylaws provide that annual meetings of stockholders are to be held on a date and at a time fixed by the board of directors. Under the Delaware General
Corporation Law, a special meeting of stockholders may be called by the board of directors or by any other person authorized to do so in the certificate of incorporation or the bylaws.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual General Meetings</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All companies are required to hold an annual general meeting after the end of each financial year within either 4 months (in the case of a public company that
is listed on an exchange in Singapore approved by the Monetary Authority of Singapore) or 6 months (in the case of any other company).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Extraordinary General Meetings</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Any general meeting other than the annual general meeting is called an &#147;extraordinary general meeting.&#148; Despite anything in the constitution,
directors of a company must to convene an extraordinary general meeting if required to do so by requisition (i.e. written notice, requiring that a meeting be called, given to the directors) by shareholder(s) holding not less than 10% of the total
number of paid-up shares as at the date of the deposit of the requisition carrying the right of voting at general meetings of the company. In addition, the constitution usually also provides that general meetings may be convened in accordance with
the Singapore Companies Act by the directors.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quorum Requirements</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, a corporation&#146;s certificate of incorporation or bylaws can specify the number of shares which constitute the
quorum required to conduct business at a meeting, provided that in no event shall a quorum consist of less than one-third of the shares entitled to vote at a meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quorum Requirements</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our constitution provides that any two shareholders present in person or by proxy or by attorney or, in the case of a corporation, by a representative and
entitled to vote thereat; in each case representing in aggregate not less than a majority of the total voting rights of all shareholders having the right to vote at a general meeting, shall constitute a quorum. In the event a quorum is not present,
the meeting if not convened</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the requisition of shareholders may be adjourned for one week. When reconvened, the quorum for the meeting will be the same and if at such
adjourned meeting a quorum is not present, the meeting will be dissolved.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholders&#146; Rights at Meetings</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act provides that every member has, despite any provision in the constitution, a right to attend any general meeting of the company and
to speak on any resolution before the meeting. The company&#146;s constitution may provide that a member shall not be entitled to vote unless all calls or other sums personally payable by the member in respect of shares in the company have been
paid.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public companies may issue non-voting shares and shares that confer special,
limited and conditional voting rights, such that the holder of a share may vote on a resolution before a general meeting if, in accordance with the provisions of Section 64A of the Singapore Companies Act, the share confers on the holder a right to
vote on the resolution.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Circulation of Shareholders&#146; Resolutions</I></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Singapore Companies Act, (a) any number of shareholders representing not less
than 5% of the total voting rights of all the shareholders having at the date of requisition a right to vote at a meeting to which the requisition relates or (b) not less than 100 shareholders holding shares on which there has been paid up an
average sum, per shareholder, of not less than S$500, may requisition the company to give to shareholders notice of any resolution which may properly be moved and is intended to be moved at the next annual general meeting, and circulate to
shareholders any statement of not more than 1,000 words with respect to the matter referred to in any proposed resolution or the business to be dealt with at that meeting.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Indemnification of Officers, Directors and Employees</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, subject to specified limitations in the case of derivative suits brought by a corporation&#146;s stockholders in its name, a corporation may indemnify any person who is made a party to any
third-party action, suit or proceeding on account of being a director, officer, employee or agent of the corporation (or was serving at the request of the</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Section 172 of the Singapore Companies Act, any provision exempting or indemnifying the officers of a company (including directors) against liability, which by law would otherwise attach to them in connection with any
negligence, default, breach of duty or breach of trust in relation to the company is void.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporation in such capacity for another corporation, partnership, joint venture, trust or other enterprise) against expenses, including
attorney&#146;s fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with the action, suit or proceeding through, among other things, a majority vote of a quorum consisting of directors
who were not parties to the suit or proceeding, if the person:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the
best interests of the corporation or, in some circumstances, at least not opposed to its best interests; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;in a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delaware corporate law permits indemnification by a corporation under similar
circumstances for expenses (including attorneys&#146; fees) actually and reasonably incurred by such persons in connection with the defense or settlement of a derivative action or suit, except that no indemnification may be made in respect of any
claim, issue or matter as to which the person is adjudged to be liable to the corporation unless the Delaware Court of Chancery or the court in which the action or suit was brought determines upon application that the person is fairly and reasonably
entitled to indemnity for the expenses which the court deems to be proper.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To the
extent a director, officer, employee or agent is successful in the defense of such an action, suit or proceeding, the corporation is required by Delaware corporate law to indemnify such person for reasonable expenses incurred thereby. Expenses
(including attorneys&#146; fees) incurred by such persons in defending any action, suit or proceeding may be paid in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of that person to
repay the amount if it is ultimately determined that that person is not entitled to be so indemnified.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Singapore Companies Act allows a company to:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;purchase and maintain for any
officer insurance against any liability which by law would otherwise attach to such officer in connection with any negligence, default, breach of duty or breach of trust in relation to the company;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;indemnify such officer
against any liability incurred by him or her to a person other than the company except when the indemnity is against any liability (i) of the officer to pay a fine in criminal proceedings, (ii) of the officer to pay a penalty in respect of
non-compliance with any regulatory requirements, (iii) incurred by the officer in defending criminal proceedings in which he or she is convicted, (iv) incurred by the officer in defending civil proceedings brought by the company or a related company
in which judgment is given against him or her, or (v) incurred by the officer in connection with an application for relief under Section 76A(13) or Section 391 of the Singapore Companies Act in which the court refuses to grant him or her relief.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In cases where a director is sued by the company, the Singapore Companies Act gives the
court the power to relieve directors either wholly or partially from their liability for their negligence, default, breach of duty or breach of trust. In order for relief to be obtained, it must be shown that (i) the director acted reasonably and
honestly; and (ii) it is fair, having regard to all the circumstances of the case including those connected with such director&#146;s appointment, to excuse the director. However, Singapore case law has indicated that such relief will not be granted
to a director who has benefited as a result of his or her breach of trust.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our
constitution provides that subject to the provisions of the Singapore Companies Act and every other applicable statute for the time being in force concerning companies and affecting the company, the directors and officers are entitled to be
indemnified against costs, charges, fees and other expenses that may be incurred by such person in defending any proceedings, whether civil or criminal, which relates to anything done or omitted or
alleged</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">to be done or omitted by such person as a director, officer or employee of the company and in which judgment is given in his or her favor or in which such person is acquitted or in which the courts have granted relief pursuant to
the provisions of the Singapore Companies Act, provided that such indemnity shall not extend to any liability which by law would otherwise attach to him or her in respect of any negligence, default, breach of duty or breach of trust of which he or
she may be guilty in relation to the company, or which would otherwise result in such indemnity being voided under applicable Singapore laws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder Approval of Issuances of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under Delaware law, the board of directors has the authority to issue, from time to time, capital stock in its sole discretion, as long the number the shares to be issued, together with those shares that are already issued and
outstanding and those shares reserved to be issued, do not exceed the authorized capital for the corporation as previously approved by the stockholders and set forth in the corporation&#146;s certificate of incorporation. Under the foregoing
circumstances, no additional stockholder approval is required for the issuance of capital stock. Under Delaware law, stockholder approval is required (i) for any amendment to the corporation&#146;s certificate of incorporation to increase the
authorized capital and (ii) for the issuance of stock in a direct merger transaction where the number of shares exceeds 20% of the corporation&#146;s shares outstanding prior to the transaction, regardless of whether there is sufficient authorized
capital.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 161 of the Singapore Companies Act provides that despite anything in the company&#146;s constitution, the directors must not exercise any power to issue shares without prior approval of Company&#146;s shareholders in a
general meeting. The affirmative vote of shareholders holding at least a majority of the ordinary shares held by the shareholders present in person or represented by proxy at the annual general meeting and entitled to vote is required for this
authorization. Once this shareholders&#146; approval is obtained, unless previously revoked or varied by the company in general meeting, it continues in force until the conclusion of the next annual general meeting or the expiration of the period
within which the next annual general meeting after that date is required by law to be held, whichever is earlier; but any approval may be revoked or varied by the company in general meeting. Notwithstanding this general authorization to allot and
issue our ordinary shares, Wave will be required to seek shareholder approval with respect to future issuances of ordinary shares, where required under The Nasdaq Stock Market rules, such as if we were to propose an issuance of ordinary shares that
would result in a change in control of Wave or in connection with a transaction involving the issuance of ordinary shares representing 20% or more of our outstanding ordinary shares.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder Approval of Business Combinations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under the Delaware General Corporation Law, completion of a merger, consolidation, or the sale, lease or exchange of substantially
all of a corporation&#146;s assets or dissolution requires approval by the board of directors and by a majority (unless the certificate of incorporation requires a higher percentage) of outstanding stock of the corporation entitled to vote.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law also requires a special vote of stockholders in
connection with a business combination with an &#147;interested stockholder&#148; as defined in section 203 of the Delaware General Corporation Law. See &#147;&#151;Interested Shareholders&#148; above.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act and the Insolvency, Restructuring and Dissolution Act 2018 mandates that specified corporate actions require
approval by the shareholders in a general meeting, notably:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;despite anything in the company&#146;s constitution, directors must not carry into effect any
proposals for disposing of the whole or substantially the whole of the company&#146;s undertaking or property unless those proposals have been approved by shareholders in a general meeting;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the company may by special
resolution resolve that it be wound up voluntarily;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;subject to the constitution of each amalgamating company, an amalgamation proposal must be
approved by the shareholders of each amalgamating company via special resolution at a general meeting;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a compromise or arrangement proposed between a company and its shareholders, or any class of them,
must, among other things, be approved by a majority in number representing three-fourths in value of the shareholders or class of shareholders present and voting either in person or by proxy at the meeting ordered by the court; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;despite anything in the
company&#146;s constitution, the directors must not, without the prior approval of shareholders, issue shares, including shares being issued in connection with corporate actions.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholder Action Without A Meeting</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, unless otherwise provided in a corporation&#146;s certificate of incorporation, any action that may be taken at a meeting of stockholders may be taken without a meeting, without prior
notice and without a vote if the holders of outstanding stock, having not less than the minimum number of votes that would be necessary to authorize such action, consent in writing. It is not uncommon for a corporation&#146;s certificate of
incorporation to prohibit such action.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">There are no equivalent provisions under the Singapore Companies Act in respect of public companies which are listed on a securities exchange, like our company.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholder Suits</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself
or herself and other similarly situated stockholders where the requirements for maintaining a class action under the Delaware General Corporation Law have been met. A person may institute and maintain such a suit only if such person was a
stockholder at the time of the transaction which is the subject of the suit or his or her shares thereafter devolved upon him or her by operation of law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Standing</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Only registered shareholders of our company reflected in our register of members are recognized under Singapore law as shareholders of our company. As a
result, only registered shareholders have legal standing to institute shareholder actions against us or otherwise seek to enforce their rights as shareholders. Holders of book-entry interests in our shares will be required to exchange their
book-entry interests for certificated shares and to be registered as shareholders in our shareholder register in order to institute or enforce any legal proceedings or claims against us, our directors or our executive officers relating to
shareholder rights. A holder of book-entry interests may become a registered shareholder of our company by exchanging its interest in our shares for certificated shares and being registered in our shareholder register.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Additionally, under Delaware case law, the plaintiff generally must be a stockholder not only at the time of the transaction which is the subject of the suit, but also through the duration of the derivative suit. The Delaware
General Corporation Law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff, unless such demand would be
futile.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Personal remedies in cases of oppression or injustice</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder may apply to the court for an order under Section 216 of the Singapore Companies Act to remedy situations where (i) the company&#146;s affairs
are being conducted or the powers of the company&#146;s directors are being exercised in a manner oppressive to, or in disregard of the interests of one or more of the shareholders or holders of debentures of the company, including the applicant; or
(ii) the company has done an act, or threatens to do an act, or the shareholders or holders of debentures have passed some resolution, which unfairly discriminates against, or is otherwise prejudicial to, one or more of the company&#146;s
shareholders or holders of debentures, including the applicant.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Singapore courts
have wide discretion as to the relief they may grant under such application, including, inter alia, directing or prohibiting any act or cancelling or varying any transaction or resolution, providing that the company be wound up, or authorizing civil
proceedings to be brought in the name of or on behalf of the company by such person or persons and on such terms as the court directs.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative actions and arbitrations</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act has a provision which provides a mechanism enabling shareholders to apply to the court for leave to bring a derivative action or
commence an arbitration on behalf of the company.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative actions are also allowed as a common law action.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applications are generally made by shareholders of the company, but courts are given the discretion to allow such persons as they deem proper to apply (e.g.,
beneficial owner of shares).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">It should be noted that this provision of the Singapore
Companies Act is primarily used by minority shareholders to bring an action or arbitration in the name and on behalf of the company or intervene in an action or arbitration to which the company is a party for the purpose of prosecuting, defending or
discontinuing the action or arbitration on behalf of the company. Prior to commencing a derivative action or arbitration, the court must be satisfied that (i) 14 days&#146; notice has been given to the directors of the company of the party&#146;s
intention to commence such action or arbitration if the directors of the company do not bring, diligently prosecute or defend or discontinue the action, (ii) the party is acting in good faith and (iii) it appears to be prima facie in the interests
of the company that the action be brought, prosecuted, defended or discontinued.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class actions</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The concept of class action suits in the United States, which allows individual shareholders to bring an action seeking to represent the class or classes of
shareholders, does not exist in the same manner in Singapore. In Singapore, it is possible as a matter of procedure for a number of shareholders to begin proceedings on behalf of themselves and other shareholders who have the same interest in the
proceedings whom they represent. These shareholders are known as &#147;representative plaintiffs.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Distributions and Dividends; Repurchases and Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Delaware General Corporation Law permits a corporation to declare and pay dividends out of statutory surplus or, if there is no surplus, out of net profits for the fiscal year in which the dividend is declared and/or for the
preceding fiscal year as long as the amount of capital of the corporation following the declaration and payment of the dividend is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes
having a preference upon the distribution of assets.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act provides that no dividend is payable to the shareholders of any company except out of profits.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act does not provide a definition on when profits are deemed to
be available for the purpose of paying dividends and this is accordingly governed by case law.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our constitution provides that no dividend can be paid otherwise than out of profits.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, any corporation may
purchase or redeem its own shares, except that generally it may not purchase or redeem these shares if the capital of the corporation is impaired at the time or would become impaired as a result of the redemption. A corporation may, however,
purchase or redeem out of capital shares that are entitled upon any distribution of its assets to a preference over another class or series of its shares if the shares are to be retired and the capital reduced.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of a company&#146;s own shares</I></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act generally prohibits a company from acquiring its own shares
or purporting to acquire the shares of its holding company or ultimate holding company, whether directly or indirectly, in any way, subject to certain exceptions. Any contract or transaction made or entered into in contravention of the
aforementioned prohibition by which a company acquires or purports to acquire its own shares or shares in its holding company or ultimate holding company is void. However, provided that it is expressly permitted to do so by its constitution and
subject to the special conditions of each permitted acquisition contained in the Singapore Companies Act, a company may:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;redeem redeemable preferred shares on such terms and in such manner as is provided by its
constitution. Preferred shares may be redeemed out of capital only if all the directors make a solvency statement in relation to such redemption in accordance with the Singapore Companies Act, and the company lodges a copy of the statement with the
Registrar of Companies;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;whether listed on an exchange in Singapore approved by the Monetary Authority of Singapore or any
securities exchange outside Singapore, or not, make an off-market purchase of its own shares in accordance with an equal access scheme authorized in advance at a general meeting;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;make a selective off-market
purchase of its own shares in accordance with an agreement authorized in advance at a general meeting by a special resolution where persons whose shares are to be acquired and their associated persons have abstained from voting; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;whether listed on an exchange
in Singapore approved by the Monetary Authority of Singapore or any securities exchange outside Singapore, or not, make an acquisition of its own shares under a contingent purchase contract which has been authorized in advance at a general meeting
by a special resolution.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A company may also purchase its own shares by an order of a Singapore
court.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The total number
of ordinary shares, stocks in any class and non-redeemable preferred shares that may be acquired by a company in a relevant period must not exceed 20% (or such other prescribed percentage) of the total number of ordinary shares, stocks in any class
or non-redeemable preferred shares (as the case may be) as of the date of the resolution to acquire the shares. Where, however, a company has reduced its share capital by a special resolution or a Singapore court made an order to such effect, the
total number of ordinary shares, stocks in any class or non-redeemable preferred shares shall be taken to be the total number of ordinary shares, stocks in any class or non-redeemable preferred shares (as the case may be) as altered by the special
resolution or the order of the court. Payment, including any expenses (including brokerage or commission) incurred directly in the acquisition by the company of its own shares, may be made out of the company&#146;s profits or capital, provided that
the company is solvent.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial assistance for the acquisition of
shares</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A public company or a company whose holding company or ultimate holding
company is a public company must not give financial assistance to any person whether directly or indirectly for the purpose of or in connection with:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the acquisition or proposed acquisition of shares in the company or units of such shares; or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the acquisition or proposed
acquisition of shares in its holding company or ultimate holding company, or units of such shares.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assistance may take the form of a loan, the giving of a guarantee, the provision of security, the release of an obligation, the release of a debt or
otherwise.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">However, it should be noted that a company may provide financial
assistance for the acquisition of its shares or shares in its holding company or ultimate holding company if it complies with the requirements</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(including approval by special resolution) set out in the Singapore Companies Act.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our constitution provides that subject to the provisions of the Singapore Companies Act,
we may purchase or otherwise acquire our own shares upon such terms and subject to such conditions as we may deem fit. We may deal with any such shares which is so purchased or acquired by us in such manner as may be permitted under the Singapore
Companies Act (including, without limitation, hold such shares as treasury shares).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Transactions with Officers or Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, some contracts or transactions in which one or more of a corporation&#146;s directors has an interest are not void or voidable because of such interest provided that some conditions, such
as obtaining the required approval and fulfilling the requirements of good faith and full disclosure, are met. Under the Delaware General Corporation Law, either (a) the stockholders or the board of directors of a corporation must approve in good
faith any such contract or transaction after full disclosure of the material facts or (b) the contract or transaction must have been &#147;fair&#148; as to the corporation at the time it was approved. If board approval is sought, the contract or
transaction must be approved in good faith by a majority of disinterested directors after full disclosure of material facts, even though less than a majority of a quorum.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Singapore Companies Act, directors and the chief executive officer of the company are not prohibited from dealing with the company,
but where they have an interest, whether directly or indirectly, in a transaction with the company, that interest must be disclosed to the board of directors. In particular, every director or chief executive officer who is in any way, whether
directly or indirectly, interested in a transaction or proposed transaction with the company must, as soon as is practicable after the relevant facts have come to such director&#146;s or, as the case may be, the chief executive officer&#146;s
knowledge, declare the nature of such interest at a meeting of the directors or send a written notice to the company detailing the nature, character and extent of the interest.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a director or chief executive officer who holds any office or possesses any
property which directly or indirectly might create interests in conflict with such director&#146;s or, as the case may be, the chief executive officer&#146;s duties as director or chief executive officer is required to declare the fact and the
nature, character and extent of the conflict at a meeting of directors or send a written notice to the company detailing the nature, character and extent of the conflict.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act extends the scope of this statutory duty of a director and chief executive officer to disclose any interests by pronouncing that an
interest of a member of a director&#146;s or, as the case may be, the chief executive officer&#146;s family (including spouse, son, adopted son,&nbsp;step-son,&nbsp;daughter, adopted daughter and step-daughter) will be treated as an interest of the
director or chief executive officer (as the case may be).</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A director or chief executive officer is not deemed to be interested
or to have been at any time interested in any transaction or proposed transaction where the interest of the director or chief executive officer (as the case may be) consists only of being a member or creditor of a corporation which is interested in
the transaction or proposed transaction with the company if the interest may properly be regarded as immaterial. Where the transaction or the proposed transaction relates to any loan to the company, no disclosure need be made where the director or
chief executive officer (as the case may be) has only guaranteed the repayment of such loan, unless the constitution provides otherwise.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, where any transaction or proposed transaction has been or will be made with or for the benefit of a related corporation (i.e., the holding company,
subsidiary or subsidiary of a common holding company), the director or chief executive officer is not deemed to be interested or to have been at any time interested in such transaction or proposed transaction by virtue of only being a director or
chief executive officer (as the case may be) of the related corporation, unless the constitution provides otherwise.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to specified exceptions, the Singapore Companies Act prohibits a company (other than an exempt private company) from, among others, (i)&nbsp;making a
loan or a quasi-loan to its directors or to directors of a related corporation, or giving a guarantee or security in connection with such a loan or quasi-loan, (ii)&nbsp;entering into a credit transaction as creditor for the benefit of its directors
or the directors of a related corporation, or giving a guarantee or any security in connection with such a credit transaction, (iii)&nbsp;arranging an assignment to or assumption by us of any rights, obligations or liabilities under a transaction
which, if it had been entered into by us, would have been a restricted transaction, and (iv)&nbsp;taking part in an arrangement under which another person enters into a transaction which, if entered into by us, would have been a restricted
transaction and such person obtains a benefit from us or our related corporation pursuant thereto. Companies are also prohibited from entering into any of these transactions with the spouse or children (whether adopted or natural or step-children)
of its directors.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to specified exceptions, the Singapore Companies Act prohibits
a company (other than an exempt private company) from making a loan or a quasi-loan to another company or a limited liability partnership or entering into any guarantee or providing any security in connection with a loan or a quasi-loan made to
another company or a limited liability partnership by a person other than the first-mentioned company, entering into a credit transaction as a creditor for the benefit of another company or a limited liability partnership, or entering into any
guarantee or provide any security in connection with a credit transaction entered into by any person for the benefit of another company or a limited liability partnership if a director or directors of the first-mentioned company is or together are
interested in 20% or more of the total voting power in the other company or the limited liability partnership (as the case may be).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such prohibition also applies to a loan, quasi-loan, credit transaction made by a company (other than an exempt private company), a credit transaction made by
a company (other than an exempt private company) for the benefit of another company or limited liability partnership and a guarantee or security provided by a company (other than an exempt private company) in connection with a loan or quasi-loan
made by a person other than the first-mentioned company to another company or a limited liability partnership where such other company or limited liability partnership is incorporated or formed (as the case may be) outside Singapore, if a director
or directors of the first-mentioned company (a) is or together are interested in 20% or more of the total voting power in the other company or limited liability partnership or (b) in a case where the other company does not have a share capital,
exercises or together exercise control over the other company whether by reason of having the power to appoint directors or otherwise.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Singapore Companies Act also provides that an interest of a member of a director&#146;s family (including spouse, son, adopted son, step-son, daughter,
adopted daughter and step-daughter) will be treated as an interest of the director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Dissenters&#146; Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, a stockholder of a corporation participating in some types of major corporate transactions may, under varying</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">There are no equivalent provisions in Singapore under the Singapore Companies Act.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Singapore</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">circumstances, be entitled to appraisal rights pursuant to which the stockholder may receive cash in the amount of the fair market value of his or her shares in lieu of the consideration he or she would otherwise receive in the
transaction.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cumulative Voting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, a corporation may adopt in its bylaws that its directors shall be elected by cumulative voting. When directors are elected by cumulative voting, a stockholder has the number of votes equal
to the number of shares held by such stockholder times the number of directors nominated for election. The stockholder may cast all of such votes for one director or among the directors in any proportion.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">There are no equivalent provisions in Singapore under the Singapore Companies Act.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_14"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block
trades or a combination of these methods. We may sell the securities (1)&nbsp;through underwriters or dealers, (2)&nbsp;through agents or (3)&nbsp;directly to one or more purchasers, or through a combination of such methods. We may distribute the
securities from time to time in one or more transactions at: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fixed price or prices, which may be changed from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prices related to the prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase the securities being offered by this prospectus and may also engage in &#147;at the market&#148;
offerings as defined in Rule 415 of the Securities Act. We may also designate agents to solicit offers to purchase the securities from time to time. We will name in a prospectus supplement any underwriter or agent involved in the offer or sale of
the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell the securities to the
dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we utilize an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with
the underwriter at the time of sale, and we will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or
the purchasers of the securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and the underwriter may
compensate those dealers in the form of discounts, concessions or commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to underwritten public offerings, negotiated
transactions and block trades, we will provide in the applicable prospectus supplement information regarding any compensation we pay to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions
or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and
commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil
liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so, indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit
offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the
aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and
savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any
conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares sold pursuant to the registration statement of which this prospectus is a part will be authorized
for quotation and trading on The Nasdaq Global Market. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Global Market or any securities market or other securities
exchange of the securities covered by the prospectus supplement. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, certain persons participating in the offering may engage in transactions that
stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than we sold to them. In these
circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In addition, these persons may stabilize or maintain the price of the securities by
bidding for or purchasing the applicable security in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if the securities sold by them are repurchased in
connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be
discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, Inc., or FINRA, the maximum
consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of
their business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_15"></A>ENFORCEMENT OF CIVIL LIABILITIES UNDER UNITED STATES SECURITIES
LAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Republic of Singapore, and certain of our officers and directors are residents outside
the United States. Moreover, a majority of our consolidated assets are located outside the United States. Although we are incorporated outside the United States, we have agreed to accept service of process in the United States through our agent
designated for that purpose. Nevertheless, since a majority of the consolidated assets owned by us are located outside the United States any judgment obtained in the United States against us may not be enforceable within the United States. There is
no treaty between the United States and Singapore providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters and a final judgment for the payment of money rendered by any federal or state court in the
United States based on civil liability, whether or not predicated solely upon the federal securities laws, would, therefore, not be automatically enforceable in Singapore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty as to whether judgments of courts in the United States based upon the civil liability provisions of the federal
securities laws of the United States would be recognized or enforceable in Singapore. In making a determination as to enforceability of a judgment of the courts of the United States, and subject to the Singapore courts having jurisdiction over the
judgment debtor, the Singapore courts would have regard to whether the judgment was final and conclusive and on the merits of the case, given by a court of law of competent jurisdiction, and was expressed to be for a fixed sum of money. In general,
an <I>in personam</I> foreign judgment that is final and conclusive (that is, in general, a judgment that makes a final determination of rights between the parties and cannot be re-opened or altered by the court that delivered it, or be overridden
by another body not being an appellate or supervisory body, although it may be subject to an appeal), given by a competent court of law having jurisdiction over the parties subject to such judgment, and for a fixed and ascertainable sum of money,
may be enforceable as a debt in the Singapore courts under common law unless procured by fraud, or the proceedings in which such judgments were obtained were not conducted in accordance with principles of natural justice, or the enforcement thereof
would be contrary to fundamental public policy, or if the judgment would conflict with earlier judgment(s) from Singapore or earlier foreign judgment(s) recognized in Singapore, or if the judgment would amount to the direct or indirect enforcement
of foreign penal, revenue or other public laws (save where any such component of the judgment can be duly severed from the rest of the judgment sought to be enforced). Civil liability provisions of the federal and state securities law of the United
States permit the award of punitive damages against us, our directors and officers. Singapore courts would not recognize or enforce judgments against us, our directors and officers to the extent that doing so would amount to the direct or indirect
enforcement of foreign penal, revenue or other public laws. It is uncertain as to whether a judgment of the courts of the United States under civil liability provisions of the federal securities law of the United States would be regarded by the
Singapore courts as being pursuant to foreign, penal, revenue or other public laws. Such a determination has yet to be made by a Singapore court in a reported decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, holders of book-entry interests in our shares will be required to exchange such interests for certificated shares and to be
registered as shareholders in our shareholder register in order to have standing to bring a shareholder suit and, if successful, to enforce a foreign judgment against us, our directors or our executive officers in the Singapore courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of book-entry interests in our shares may become a registered shareholder of our company by exchanging such holder&#146;s interest in
our shares for certificated shares and being registered in our shareholder register. The administrative process of becoming a registered shareholder could result in delays prejudicial to any legal proceeding or enforcement action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_16"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered pursuant to this prospectus and certain other matters of Singapore law will be passed upon for us by
WongPartnership LLP. Selected legal matters as to U.S. law in connection with the offering of the debt securities offered pursuant to this prospectus will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston,
Massachusetts. Additional legal matters may be passed upon for us, or any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_17"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Wave Life Sciences Ltd. as of December&nbsp;31, 2021 and 2020 for the years then ended have been
incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_18"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, and file annual, quarterly and current reports, proxy statements and other
information with the SEC. SEC filings are available at the SEC&#146;s website at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is only part of a
registration statement on Form S-3 that we have filed with the SEC under the Securities Act of 1933, as amended, and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with the
registration statement that are excluded from this prospectus, and you should refer to the applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may obtain a copy of the
registration statement, including the exhibits and schedules, from the SEC&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at
http://www.wavelifesciences.com, through which you can access our SEC filings. The information set forth on our website is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="cov872484_19"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file later with the SEC will automatically
update and supersede this information. We filed a registration statement on Form S-3 under the Securities Act with the SEC with respect to the securities we may offer pursuant to this prospectus. This prospectus omits certain information contained
in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this
prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any
part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained from the SEC&#146;s website at http://www.sec.gov. The documents we are incorporating by reference are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001631574/000156459022008414/wve-10k_20211231.htm">Form
 10-K</A> for the year ended December&nbsp;31, 2021 that we filed with the SEC on March&nbsp;3, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our ordinary shares contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1631574/000119312515371452/d57859d8a12b.htm">Form
 8-A</A> that we filed with the SEC on November&nbsp;9, 2015, including any amendment or report filed for the purpose of updating such description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Exchange Act after the date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of
filing such reports and other documents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC file number for each of the documents listed above is 001-37627. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies
or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, all reports and other documents filed by us pursuant to the Exchange Act after the date of the registration statement of which
this prospectus is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request, orally or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be
provided to you at no cost, by contacting: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wave Life Sciences Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">c/o 733 Concord Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge,
MA 02138, USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ATTN: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents on our website, http://www.wavelifesciences.com. The information contained on, or that can be accessed
through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide
you with information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in
which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>23,125,001 Ordinary Shares </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g872484g05g05.jpg" ALT="LOGO" STYLE="width:1.5625in;height:0.5625in;">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom" ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Leerink Partners</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Book-Runners </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Truist Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Mizuho</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September 25, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g872484g05g05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g872484g05g05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[14Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %D< @   @  ' )0  AR<C8Q,S(W-!P"!0! 36EC<F]S;V9T(%=O<F0@
M+2!0<F]J96-T(%=E8B!0<F5L:6UI;F%R>2!0<F]S=7!P(%-E<'0N(#(P,C0@
M(%!&5P X0DE-!"4      !",? %0E@D_+;?U.X]2'])G.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  8     $  0!@     0 !.$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              -@   )8
M   & &< ,  U &< ,  U     0                         !
M      "6    -@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    -@    !29VAT;&]N9P   )8    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   #8
M4F=H=&QO;F<   "6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    #.$))300,      JC     0   '$    I   !5   -G0
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M?]=N^U6N8E#$",<"/5,W(_U5F:9C"<AN!Z?[S%WU]S^EY%.5E6ORJ[; +Z=
M!6"/6LJ8![?3W_HU9_QC=7^L72NHXF1TSJ#Z,#.I(8&!CF^K6=Q+7.8_^=JL
MK?\ V%S'U@Z';C]#Z/UE[7;>H"QEP)EK0\^M@;?^/QO4_P# UOAQ^LO^*]P^
MGG=".DP)^S#VNY]WJ]-L_P"W4_+[9G&<8CA!X"/VL?*8YPPB,Y2E,^LF1XOF
M_1>R^IG6G];^KF)FW.W9(::<HZ3ZM1].QS@T-:WU=OK?]<7,?XR?K9U+IV?B
M]-Z5E'$<RLY&78P-)]QV8]?O:_;]"VU__6U0_P 4W66TYN;TJU\4Y+!ET28
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M_7%UG6?JMTOK%K<C(WU7M 8;J7!KG-!W!EFYKVOV_F>WV*[TOIN#TS#9AX+
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M_]D .$))300A      !7     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M #( ,  R #$    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'P   'X!,@ "    %    )T!.P "    "0   +&':0 $     0   +P   #H
M    8     $   !@     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S
M*0 R,#(T.C Y.C(T(#(R.C(Y.C4X ')R-C$S,C<T      .@ 0 #     ?__
M  "@ @ $     0   ):@ P $     0   #8         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%.17AI9@  34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    ?
M?@$R  (    4    G0$[  (    )    L8=I  0    !    O    .@   !@
M     0   &     !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P
M,C0Z,#DZ,C0@,C(Z,CDZ-3@ <G(V,3,R-S0      Z !  ,    !__\  * "
M  0    !    EJ #  0    !    -@         & 0,  P    $ !@   1H
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M 0$               4&!P@" P0!"?_$ %$0  $# P,! P@$" D+ P4   $
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M8VD\D?34&1^0_P"2]_&)I3^F8/U'_)4<^E+E@$5CP3R>B\-VNG\]?]P^2E_
M_P BYLO)^,72G]-0?J/^2/QBZ4_IJ#]1_P E1KZ6N?\ /'_L7GTO<_YX_P#8
ME_!7V'-EY?QBZ4_IJ#]1_P E[^,72G]-0?J/^2HQ],7/^>/_ &+PWBY_SQ_[
M$?PH_8U-EYSVC:3:,F]08_,?\DN6F]6^[0F6W53)XPT/W-!'!Z'D+Y].O-R+
M2#5O(^Q6U\G6::HL#C42&3-)!U]X*JRZRA%R&I62)==6V.U3F&X7&."4 $M<
MUQX/3H%G2:HLU73RST]?')%$W<]P:[@8SGI[E&?;OIYS+9->(9(V>G%%C!W>
M*UU%GFLW9Y//%,P2U=K,H<P'(/=9R?O5"A%^&-MHF"VU]-<J-E50RB:G?G:\
M @'!P>OO"U6R[4-S$IH*ALPB?L?@$8=[.57/0_:%<+-I.CHYYJF66-S\O;MP
M<O<?WIQ=@5=<Y#<#65CI6RUX< 1T!'1)XZ%S)X0A"K)G!?K>RZVBIHI-^R9H
M!V$ ]0?'X*C':/:7V;7%[C<UP@;5O9&YS@2<'QPK[*LOE0Z8CHJ:EN<$;#+5
MUSR\LBP[U2>3XKLU)\94RK(O9 K<2>F.O1:G/?#,R3 RUVX9]Q64<@</1&T(
MJ>6-&.OBMATT5%M?)KO\-;HF&DD>T51GF=L:QPXR/'HIB50?)LOKZ#64%#+(
M[S<0S/P9,-R0/!6]C<'L:X=' %8>S#C,NQOJCU"$+G+ 58/*CU'OOD5H@,;H
M*B@B>XEAW9$SSP>G\D>"LY-,R%H,CVM!./2.%\_M6W^HU'=XJJK?*][(1$#(
M_>< N/7[2NK5Q\W97D?H28F2M!VM&WXK8R*-PR2=_L6,&[<[+CCP"W @'U5M
M0BDBAFHM,9^I&[=ZV4H:7O#[#?A7?5A[6%OIM+AR/<N%SL'(7-.-Q+E7DBFJ
M&?0W3M6RMLE#,QP)=!&XX!'):#XI140>3OJ22_V"K$\CV^:/BA:V23=D;/#V
M=%+ZP\L.$FCH@^2L$(0JR1R7:OAMEOEK*I^R&/&YVTG&2!T'/BJ']H=<;IKG
M4,L>UT/TC4/8X C(,CL=5:SRA+X;9V=7B&!Q94N9"]KVR;7#Z]@X^XJG.]TD
MLD\CB]\YWN)Y.3SD_>M+1Q^9,JR,\#'2,( 6ET4CYHX6-R^1VUHSU/1=!)B;
MQS\$KZ%MYNVL['3$99+701N);N #I .5H9*C'LJB6>\F^PFAT'05DP>VJ<9F
M.;N!;CO#[/A[5*U=.V"G?(\X:T9)PN/2]G98;-%;XBPLC+B"QNT<DGI]J1>T
MBY^8:<KMA+9#"2UP=@CE8E?+DI$\L_BQN3(5[3;DZLU7<(V[#"U['-(!!/H!
M(4-1$V,ASOV%)M1625=SGGGD<\O Y<[/@ O&2 1N<1D#P7I=7%\<.T?/-_\
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M-&I3<Z"Z054P#HC3QQM?-N)X<. ?@N/<QW&_HG!TR<4(7CW-8TN>X-:.I)P
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M[!W99X8PJA>4II]]!K85%-!(:-E%%ND#,-!+G#G'Q"QM7+^S3]GIW"HD5#U
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M:D99-,2TCI'M?<:2JA8&L#@3L Y]GK*1J.JAK(N\II62LSC<PY&56#R@K_\
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M\JIC&P<GJKH]D.F1IK3\\!9"'2S]\.Z<XCEC1X_!54[-M/2ZGO=721QRO=%
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M\"O6'ZP"/D%8O;R_VK72LKCY+;]CVKG3]F=3<:E\[WLK7,W;6YQAGOQXJO\
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M=EPD+6[VD$&*,>'VKEV<BC%DDKZ)GI86T]/'$P -8, #HMB$+%.GP"B#RC[
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M=&M_R%>3I%/V>JU9N9G*\C'#5UAH(6U%656/'L=U/1:7N\TM?2R3]Y- YFS
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M+3W-RCC8XT\+!L>'<M!S_:N/9RJ46D6079(J$(6<= (0A  A"$ "$(0 (0A
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M2VCA$32 " 2>!TZI-KT"LZT(0HC!"$( $(0@ 0A" !"$( $(0@ 0A" !"$(
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M<A.PH$(0D!Q55M@J79EWYR3P?:N9M@HVR]X#+NZ>M_@E9"=L5'C&AC&M'0#
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H0DTFGZ.E&(C+USR[_!*D;!'&UC>C1@+)"=A0(0A( 0A" !"$( __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g872484g08n08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g872484g08n08.jpg
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MJ+#;9*6DG=3OW,R.=EKN<QXS.W(@<?*J8\PI9'_:2MUI?1 V^XO9-51;H_\
MI'OUW..>>8S/(0M4VJ,>_MABDU2ZCH*ZDN-,VIM]5!54[B0V6"0/8<CD<B-B
MLN5SH+7 V:YUM+1PN=J!]1*V-I=PY9N(V[#V+SX;L%MPU:(K99*44M#$7.9$
M'N?D7',[7$GA/*HB^UU_D\MO_:;/_*E7"BF*JLK4SA&*5Y\5X>@JX*6:^VN.
MIG#711.JXPYX=M:0,]N?%RK*U,\-- ^>IECAAC&L^21P:UHY23P+EO27H[PS
M:-"5GQ#0TSH+Q)%2O?,9WN,YD8"X9$D<9.P#@6*THX@NMPT7:-Z&NJ964]9
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M']J>14W2H;/4D?V(P2&Y^[8YQ_S N-NG-5@W5.$/;]F>QU#;!<\677-USO\
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MN#FZI: &@<)VK6+KIOQ+A_$E#%BG"'FNT5;LV;H]V[:F8!=G]TD9@EN06/\
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M/5EYQ3>JJVNI()VT$C]9L>LP$M8XG)HVY;!GEQJ3,<:.+%BW#%+9*J%U+!1
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MLT'+E"/8UXR>T.'O&:JB  &@!H  X@B(@(B("(B B(@(B("(B B(@(B("(B
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M6VRY7Y]YBBR%/)+!N<D;>:7:QUAP99[1V9;NU451V]V:(F)[M-^U#_DFK/\
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MGW_(OHZ_T$'_ *9JVVUZ/:? N'+ECFANMSKKXRS2R@U+FN9K&+,'@SV9#CX
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MPR.CUA*!GD2,^#W++X-OCKW'5/?0MI#$6C8<];//W#D6B8? .DH@C,>5S_\
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M4U6G[V1 [5SKIIFB:HHF/Q>OI[EVF_%NN_%<_.,(B?;Y8-E1$7E?9$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 "($0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0>VD_J?S1*3^I_-$'EF_K7_ (JQ
M7S?UK_Q5B H9P+24];BO<:N%DT1;(2QXS&:F9>:"@HX)=T@I*>.3G,C /: N
M]J[ITU1N^?UG0^IN6Z\>U,XX;^W^D58AMU3@[$,5;;B13/<71$\&7'&[_P"N
M!;E>KK!><!UU73'8Z+)S3PL=F,P5L]13PU,>I40QRLSSU9&APS_ KYQT%)'$
M^*.EIV12??8V, ._$9;5JJ_%66:H[PXV_LZJS-RFW5_97$]MIG9I>BR&.HP[
M<(9FA\4DQ:YIX""P+1,3V>2R7>:E?F8_O1//]IAX/#\E.5-304K"VFABA:3F
M1&P-!/Y*VIHZ:J+34TT,Q;P&1@=EVK5'59;DU8=I<+_V-%WIJ+.;^ZGYM*Q'
M<O(='5OB8[*6JIXHA_FZH+OTV?FL%AC"EWJ[8RMH;CY$R?\ LM>]I< 2 3E^
M:E&:AI)F1LFI8)&1C)C71@AHY!R+[11LBC:R)C6,:,@UHR 'X*1U&6G"F.\R
MZU_947KT5W:L8B(B(CM^J&:BGJ\)8JII*J02O:X2F1N?MM)(=P\?"%,\;VR,
M:]A#FN ((XPOC4T5+5.#JFF@F<!D#)&'$=J^S&M8QK&-#6M&0 &0 6+U[5B,
M8[P[]!T,]'-<4SC3,XQ&S5])G_-.?_2,_P!I:C@O%])8K5)2U,%1(]TIDSCR
MRR( XS[E*D\$51&8ZB)DL9VEKVAP["O+YHMO1]'\%O@M6[U,6\E48N74]#>K
MZF.ILUQ$X8=XQ8W#.**7$$T\=+#/&8FAQ,F6W/\  J-*:X16K',];4->Z**J
MF)# ,SF7#C_%3'34=+2EQIJ:&$NV$QQAN?8OF^UV][W/?0TKG..9)A:23R\"
M6[U%$U81VE.IZ"_U%%O-7&:F<<</IV1SB?&AO5$;=:J29HG(#R[:]PSX !FM
MDP1:'8=L5355S2)Y!NLC!M+6M!('X\/:MGIZ.FICG3T\,1__  V!O^"^KVM>
MTM> YKAD01F"%*[T9<E$80W8Z"N+WJ+]>:O#".V$0A/&5WI[S?!5TC9&Q"-K
M<I  <QGR$J6,.WREOM+)-1ME:R-VH=T: <\L^(E>CS1;>CZ/X+?!>BFIH*5I
M;3010M)S(C8&@G\E;MZBNF*8CV9Z+H;_ $]ZN[77$YO?LCS2_P#?M?X2?_"M
MUPK_ ,V[7_JT?^R%[:FCIJK5\IIX9M7@W1@=E^&:^L;&1L:R-K6,:,@UHR '
MN6*KN:W%&SO9Z.;?57.HQ[51';\L$<Z3;[2U$#[3&V7RJ"=KG$M&KEJG@.?O
M'$OOHROE*VDALY;+Y4YSW@ZHU<N'AS]W(MVFMM#-(Z2:CII)'<+GQ-)/YY*L
M%OHJ>0204=/%(.!S(FM(_,!;UJ-/3P__ ->>.AOQU?J<\;88?+_:-+W_ )4X
M?]8@_P &K,Z3K#Y32BZTS/Z: 93 #[S.7\O\/P6Z/H:1]0)WTL#IP0=T,8+L
MQP;>%?=S6O:6O <TC(@C,$)ZC":9CY01]EQ51>HKG'/,S'X(NT1_\K5W^@'^
MT%Y\96VLL.)?.U*PF!\HG8_+,-?GF6N_//\ (J4J:BI:5Q=34T$+B,B8XPTD
M?DOL]C7L+7M#FG801F"M>I_[DUQ':7.G['__ !:;%57]U,XQ,;HRO&)[#>+9
M4/J*!S+FZ$L8YS [5=D<LG9\&?N7VT/@Z]U.1RRBV]Y;MYAM&OK^;*+6Y=P;
MX+(111PL#(F-8P<#6C(!2J_3DFBF/=JS]G7O44]1>JB9IQ]HPQ_->B(O*^R(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B $0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@]M)_4_FB4G]3^:(/+-_6
MO_%6+Z2L<979-/#R*W4=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M1
M7:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=
MS7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.
MYKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V
M(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[
M$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M1
M7:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=
MS7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.
MYKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V
M(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[
M$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M1
M7:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=
MS7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.
MYKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V
M(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[
M$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M1
M7:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=
MS7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.
MYKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V
M(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[
M$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M1
M7:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=
MS7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.
MYKNQ-1W-=V(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V
M(+45VH[FN[$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[
M$U'<UW8@M17:CN:[L34=S7=B"U%=J.YKNQ-1W-=V(+45VH[FN[$U'<UW8@M"
M*[4=S7=B:CN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:C
MN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:CN:[L06HKM1
MW-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:CN:[L06HKM1W-=V)J.YKN
MQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:CN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW
M8FH[FN[$%J*[4=S7=B:CN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J
M*[4=S7=B:CN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:C
MN:[L06HKM1W-=V)J.YKNQ!:BNU'<UW8FH[FN[$%J*[4=S7=B:CN:[L0>ND_J
M?S1*4$1;01M1!]41$!%X,05TMMLE=74\ J)::%THB+M77U1F1GD>(+7,!8XB
MQ/A^ON=13MH_(WN$C!)K^R&AVMGD/?V*X)C\FY(HZT<Z2O2Z\SV^6WMHWLA,
MK'";7ULB 1P#ES7IMN/9KECZMPY16Z-T=-N@=4F8_P!@;?9U>=D.%,),T-\1
M:)H]Q^[%-UN%MK+>*"KI6ZVINNOK9.U7<0RR.7:J8MQ[)9\74&'[?;VUM34Z
M@<XRZFH7NR X#Q;?P3"3-&&+?$4:8QTE5=BQ6^QT5D-?*&L+-24ASRYN>0:&
ME>O"^-;_ '6^TM%7X1K+?32EVO4R:^JS)I(SS8!M( X>-,),T>R0$1:OI QC
M2X/M<=3/$ZHJ)G%D,#7:NL1PDGB V=H4]UF<&T(HDATJW.WU=$<3X=?0T-7[
M4<S2[,-Y<B-N68V;"MPQ[C6CPE:8*I\9JIJDY4\3'9!^S,N)X@,QVA7"4S0V
MM%$L.E6Y6^MHQBG#SZ"BJ]L<S2[,-Y<B-N68S&PK?L6XGM^&;,;C7/+V.(;$
MR/:Z5QV@#\MN:8215$LXBBZVX_Q3<G05-)@^7S;*YN4I<XG5)^\-@S&6W8%*
M*3&!$XB(BBB(B B(@(B("(B B(@+!XKQ99,*48J;]<8:1CON,.U[_P#-:-I_
M(+&:4\:T^!L+37*1K9:MYW*E@)_K)"./W#A/9QKF%]+'70>F6DRMJJCRYQ-%
M01.U9JP \.?!'".#,?E[_19L9XS5>W[L558=H2[</M'8>BF+:*TW.I8#EKOU
M(P?P&9/;DLIA[3]A&Z3-AKA6VM[CEKU$8='G_G-)R_$@* 7:1Y*4[G8\-X<M
MU,-C6^0MGD(_ZTDF9<??L68M^([7>K=Y3C7!-,VTNE%.;Q:*<TKXI",]N7L/
M.6W+]"O5/341'^/EB*YW=>4=5!6TL531S1ST\K=9DL3@YKAR@C85]ES18ZNX
MZ(+E05U'<'7K1[=G#5F9MW//CR_LO'_BR(V$;.E*>:.H@CF@>V2*1H>Q[3F'
M-(S!"\5RWD]N\.E,XKT1%R:$113I;TO4F#9'VRU1QUU[R!>UQ.YTX(S&MEPG
M@]D<NT\NZ**KDY:6:JHIC&4K(N';[I"Q5?)B^OOE;JDYB.&0Q,'_ '6Y!8 7
M"L_O=1\1WBO9'03AWJ>>>ICY0_0%%^?_ )PK/[W4?$=XJHN%9_>ZCXCO%:]!
M/+PSZO\ !W^BX!%PK/[W4?$=XJOG"L_O=1\1WBIZ">7A/6?@[]1<!BOK/[W4
M?$/BJ^7UG][J/B'Q5]!/+PGK?_U=]HN!17UF7_&ZCXA\545]9_>ZCXA\4]!/
M+PGKO_U=\HN!Q7UG][J/B'Q5PKZS^]U'Q#XIZ">7A/71Q=[(N"17UF7_ !NH
M^(?%7>7UG][J/B'Q3T$\O">OCCY=Z(N#!7UG][J/B'Q517UG][J/B'Q3X?/+
MPGQ"./EWDBX-\OJ_[U4?$/BKA7U?]ZJ/B'Q3X?/+PGQ&./EW@BX0\OJ_[U4?
M$/BJBOJ_[U/\0^*?#YY>$^)1Q\N[D7"0KJO^]3_$/BJBNJ_[U/\ $/BGP^>7
MA/BD<?+NQ%PIY?5_WJ?XA\545U7E_P :G^(?%7X?/+PGQ6./G^'=2+A?RZK_
M +U/\0^*"NJ_[U/\0^*?#YY>$^*QP\_P[H1<,>75?]ZG^(?%7"NJ_P"]3_$/
MBGP^>7A/BT<//\.Y47#7EU7_ 'J?XA\5=Y=5_P!ZG^(?%/AT\O"?%XX>?X=Q
MHN'?+JO^]3_$/BJBNJ\O^-3_ !"GPZ>7A/C$<//\.X47#XKJO^]3_$/BJBNJ
M_P"]3_$/BGPZ>7@^,1P\_P .WT7$0KJO^]3_ !"JBNJ_[U/\0I\.GEX3XS'#
MS_#MQ%Q+Y;5?WF?XA05M5_>9_B%7X=/+PGQJ.'G^';2+B?RVJ_O,_P 0JHK:
MK+_C,_Q"GPZ>7A/C<<//\.UT7%7EM5_>9_B%5%;5?WF?XA3X=/+PGQN.'G^'
M:B+BSRVJ_O,_Q"JBMJO[S/\ $*?#9Y>$^.1P\_P[21<7^6U7]YG^(4\MJO[S
M/\0I\-GEX3X]'W?G^':"+C$5M5_>9_B%/+:K^\S?$*?#9Y>$^/1]WY_AV<BX
MS\LJO[S-WRJBMJLO^,S?$*?#9Y>#X_'W?G^'9:+C7RRJ_O,W?*N\LJO[S-WR
MGPV>7A/C\?=^?X=D(N-Q657]YF[Y5PK*G^\S=\I\-GEX/Z@C[OS_  [&1<="
MLJ?[S-WRJBLJ?[S-WRGPV>7@_J"/N_/\.Q$7'@K*G^\3=\JOEE3M_P"$3=\I
M\-GEX3^H8^[\_P .PD7'OEE3_>)N^4\LJ?[S-WRK\-GEX9_J*/N_/\.PD7'O
MEE3_ 'F;OE5%94_WB;OE/AD\O"?U)'W?G^'8*+C[RRI_O$W?*N%94_WB;OE/
MAD\O#/\ 4L?=^?X=?HN0A65/]XF[Y5165/\ >)N^4^&3R\']2Q]WY_AUXBY%
M%74_WB;OE7"KJ?[Q-WRGPV>7A?ZDC[OS_#KA%R3Y74_WB;OE5%74_P!XF[Y3
MX;/+PG]2Q]WY_AUJBY+\KJ/[Q-WRJBKJ/[Q-WRGPV>7@_J6/N_/\.LT7)OE=
M3_>)N^545=1_>)N^4^&SR\)_4T?=>?X=8HN3Q5U&W_A$W?*J*NH_O$W?*?#)
MY>$_J>/NO/\ #J]%RCY74?WB;OE5\KJ/[Q+WRGPR>7A/ZHC[KS_#JU%RF*NH
M_O$O?*J*JH_CR]\I\,GEX3^J8^Z\_P .JT7*HJZC^/+WRJBJJ/X\O?*?#)Y>
M#^J8^Z\_PZI1<L"JJ/X\O?*N%54?QY>^4^&SR\']4Q]UY_AU*BY<%549?U\O
M?*N%54?QY>^4^&SR\']4Q]UY_AU"BY?\JJ/X\O?*KY54?QY>^4^&SR\)_55/
MW7G^'3Z+F$54_P#'E[Y7MM]^NM \.I+C51Y?V=T);V'8I/V;/RJ*?^JJ,?[K
M4X?G_$.D44;X+TBBMGCHKZ(XIGD-CJ&C)KCR.'$??P?@I(7ANV:[4Y:H?HNC
MZVSUMO4LSC^\?F(B+D]8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MDTL=%AUL<CV-(E)#7$9D"/(_J5NF_<KR1'SQ\.-SH;%G5JJB9BF*9PQPGO\
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M1V"EDB96EIF$DKI-;5SR^]_G%$0E]FB^VJW:.<4T]PN5'23"9\FK/,UA+3$
M",SMV@A>/[-]/35>C72#35U8*&EFC$4M4>"%KHG@O/N&>:E.+05@2.[/KO-<
MCM9Q<*=T[C"TGD;R>XG)9[#FC7#.'K+=;3;J&04%S;J544D[W:XR(RSSS&PG
M@17.M+;<;:+,/5E53TN&[UAM\@DDG(BJ&2!V30>$/(.S9M [5G=*=YI+]]F[
M#U?;[;':X'W,-\DB_JXW#=P[4_ZI.9 XL\N)2*S[/V!&U(D-'6NC#L]Q-6[4
M_#E_5;CB' 6'K]AFDP_74 ;::5[9(8('F(,+00/N^YQ[4$0:4<,>>_LZX6N4
M#-:KL]OI9P0-NY.B:V0?[+O^ZM0AO$FF/'6 [3*'OI;?1L?7ZPV%[=LQ_!P8
MP?\ >74E-9*"GP['8V0ZUL92BC$3R79Q!NIJD\)V;%K^"-&N&<%5U168?HI(
M:F>/<GODF=(=7,'(9G9M [$$'?:1DK&Z8<,MDEI8:1D$)IWUS2:9CMU=K.>,
MCLV-UO< O9C' ^*;O=[+?L08FP72R4DD8IYJ:1\1D]L%H'L>T<^#+E4\8QP?
M8\84#:3$-!'5QL)=&[,M?&>5KAD1_@>-:99]!&![7<8:QE'5SR0O$D;9JEQ:
MUP.8.0RSV\J"4D1$01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!A\3
MXFLV%Z%M9B"X0T-.YVHUTF>;G99Y #,D[.):_A_2O@J_W&.@ME^@?5R.U8XY
M8WQ:YX@TO: 3[N%9O%6$K-BME%'?Z,5D-)*9HXGN(:79$9N X>'@.Q<RZ>+%
M8Y](EDL& +?3PWG^KJ643=1C7DC4!#=@<T!Q)X@1GP(L.J;U=J"QVZ6ON]9#
M1T<7WY9G:K1R#WD\BU6PZ6,$WVYQV^VWZ!]7([4C9)&^+7/$&E[0"3R<*B+[
M7594E^%;1NKMQ>))I.1[_9:"?PS=VKX_:8P58\,X1P[66*WT]#/#4"E,D#0U
MTC=0N!<1M<X%G"=NTH.C;W>+?8K;+7WBLAHZ.+[TLSM4#D'O/N&U:MA_2O@J
M_P!S9;[9?H'U<CM6-DD;XM<\C2]H!/NX5 WV@KW67O#FC>GGE=JUM RLFY'2
MO:P:Q_#-W>*RGVG,&6/#.&\.UE@M\%!/%/Y,7P-#'/&H7 N(X7 MX3MVH8.@
ML4XJLF%::&HQ#<(Z&&9^YQN>UQUG99Y; >)?2Y8DM%LL#;W7U\,%J<QDC:A^
M8:6ORU<APG/,;.%<_?:/KI;IHEP)<*@YS5;8IWGE<Z ./ZE:I27A^EW%.%<)
M35OFVP4%+%&&.=DZ=\<8#R.(O.1#<^ 9GA)!&#JW#6(;7B:WFNL=6*NCURS=
M6L<UI(X<M8#/\EE5Y+3;:2T6VFM]M@93T=.P1Q1,&QK1_P#7"O6B"(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B(//<*N*@H*FLJ26P4\;I7D#/)K02?
M\%J5%?<67.ABN5NLEN%%,T20PSU9$SV':#L;JC,9'+-;;<6TS[?4MKS&*-T;
MFS;H<FZA&1S/$,LUI/HK=K)0.?AO%<T5%"POCIZV-DT0:!GJZ_"UJL).+)XA
MQ+<+99+141VM@N%PJHZ3R6:;(1O?GPN V[1PK[6VMQ5)70LN%GMT-(3_ $DD
M=87N:/<-49K4<0W&;$^#<%UE1KT<]9=J=KG0'5<PYO;K,)SRX,QP\2V^VX7D
MHJV&H=B&^U(C.>Y3U#7,?[B-49JI'=C_ $DO]9>[O1V>T451#;I6Q.=-5&-S
MR6AVP:I"]MLQ6*_"UTN@HWP5=N$S*BED=GJ2Q-)+=8<(X-JU2DBQ$[$.-I,-
M55'&]E2P[E/"7.D=N8RR=GD/S!7MP^^A=HOOIHWS&K=!5/KQ/LE%26.U]<<6
MW@]V28)$R^S<9WRELE/>[G8:?S/)&R5\E-5ZTD;'99.+"T9\(V K(XDQ'=:"
M[6JFME%05,%S.I3RRU#V'6#=8ZP#3D,N#A6!LEAQ!B#!EIH+A<*"FLDM+#K-
MIHG&>2,-!#2YQR!.S,@++XPC;%BC!$<;0UC*J1K0.("(IV7O@NQEC*;#EVH:
M<T J*9\1GJI&O.M#&'M:YP&6W+6S68O5\\@J['%#&R:.Y5.XZ^M]T:A<'#EX
M%A[S!%5:2;=3U#!)#+:JACV.X'-+V@A:I!/+;[_A[#%<]SI[9<P:9[N&6F=&
M_4/Y?=/X!(@Q;WC?$4V'Z&F-#1BMKZF7<X:?6U=;)I<X_D!^JR>'[I%>K)17
M&#9'4Q-DRSSU21M'Y',?DM(N-PN%9I&EJ;;9Y;K36>#R8!D[(PR>3(N.;CM.
MKDW8O1HMJ*BCGO-AKJ1]#)33FJIZ=[VN+(922&@MV$ Y]J8=B)[LM28M\KQC
M'9([?5P,-/),Z:IB=%K%K@/8!X1M.U;2M-K_ /*S:O\ LN;_ ,QJW)25AK^*
M[U46Y]OH+5'%+=;A+N<#902QC6[7R. (.0'OX2%[,175MBP]67*IU7FFB+LA
M[(>_@ '#EF<AQ\*PD@#]+,(EVB.S.=%GSC, XCWY9+PZ2:FIJ[I9++043Z]^
MZBOJ:=DC6%T49&0)=LR+B.Q,$Q9W!6();_05+JVE%'7TD[J>HI];6U'#(C;R
M$$?JO%CW%LN&A2LHJ'RZHD;)/)'KZNI#&,W/_4+"62OKZ+22]]RM,MKI[Y!J
M!CYF2!T\0X<VG9FPY;>$KX0UUPN.,+_<J2P2W:A:SS5$]M1'&T-;ME'M';FX
M\(Y%<#'LWFXUU?+:::KP[34]:^;5>!-*8V[F6DZP(!V_=V>]:M1XHQ55WFXV
MR&Q6WRJ@$9FSK7!OMC-N1U=NQ>C1-53ML,]FN$;X:ZTS&G=&]P<X1GVF9D;.
M Y;.17X9_P I>,_\RB_\HH>ZZXXBOD5[H;116NBEKY:'RN825):QA#M4M!#3
MGMR7WM^*:J*[T]KQ):C;*BJS%-,R830S.']D.R&J[W$+X5'^5ZD_[&?_ .<%
M\-)$L=;68=M-*]K[FZY0U#6-.;HXV9ESSR#)!F*Z]5=MQ51T5<R$VNX QTT[
M&D.9,!GJ/S)!UAP$ <GO6PK4-*  L%)(W_C$=QI70\NONH&S\B5MZBP(B**(
MB(-%TKX9K;Q;J*ZV#5&(+-*:FC!X)1_;B/N<!^F7&OOHWON'\28?8RU45/1R
MTS=RJ;:8PU],_+5+2W+@X1GQC\PMS6DXNT=6V^W$7:@J:JRWYHV7"@=J/=[G
MC@>/UXL\EUIJB8RU,S'SAL-\P_;;W0/I*^F:6..NU[/8DC?GF'L<-K7 [<QQ
MK2Y\,8TI<J:AO5%6TH;J,GJWRQ3-;N<K!K:N8>[^D!S]G,L;L5C;;I5MXW*F
MOF&[K&-@EK::2&0_B&;%;+@_'6(!N6*,7PT-"[9)362$QEXY-U=[0_5:IC+_
M ,HP/T:G?::KO-]J,,6B[27?$->W<KM<69BFME*2->*-N9 +M4 C,DY9'W3?
M9[=36BU4ENH6;G2TL388V\C6C(?FO#A3#%IPK;&T%CHV4\.>;W<+Y'<YSCM)
M696;ES-VCV(C 1$7)IH^FG#DF)]'MRI*6(RUD.K4T[1PE[#F0/>6ZP_-<5+]
M#5SQIET,5$U;47W!\(D$IUZBWL&1#N-T?+GPEO9GGD/=T=^*/[*GFOVYJ_NA
MSV$"^M33S4E0^"JADAGC.J^.1I:YIY"#M"^07U(>.5RJ%15",2J%54"JC,JA
M55 JHRJ.!5"H.!5",JA7!6A7!&9!P*Y6C@5R,*A5"H%4*LRJJA450C,JJH5%
M4(S*H50J!5"K$JJHX%15' C*Y5"HJA5F17!6JX(RJJA450JDKE4<"HJC@1D"
MN"M"N",KAP*H5!P*H1%R!$"K*Y92Q7ZZ6)\K[16RTCY0&O,9^\!P+%JHX%)B
M)C"4BJ:9QIG"7MI+E64ER;<*6IDBK6O,@F:<G:QX3^>97JNN(+K=ZF&IN5=-
M/40;(Y7')S-N>PC;PK%*H4RQCC@9ZL,,>S;8M(N+(H!"V^5)8!EFX-<[O$9_
MJL?;L57RWU]16TETJHZJH(,TFOK&0C@UL]AR]ZP85P2+=$?*"J_=G"9JGM^+
M8;WC'$%[IC3W.ZU$].>&/8QKOQ#0,_S7PL.*+U8621VBXSTT<AUG,:06D\N1
MS&?O6&0)ITX9<.SG-ZYFSYIQWQ9?TANWGIUW%PG;<G?>J&NU7'9EELXL@-B]
M]WQQB.[T;J6ONT\E.X9.8T-8'#D.J!G^:UL*JNG3[X>R:UR(F(JGO[]V5M5_
MNEII:BGMU=-3P5']:QAV/V9;?R7QL]UKK/5>56RI?35&J6;HSAR/"/T7A51P
M*Y8[]O=G4JC#O[>WX/57UE1<*R6JK9GS5$IUGR/.9<5E8\5WR.CIJ1ESG%/3
M%IAC)!#"W[N7X+!!54FFF>TPD7*Z9F8F>[WW>[U]YJ6U%UJY:J9K P/D.9#<
MR<OU*]%#B&[45KFMU+7S1T,NL'P@^R[6&1[0L2%4)EIPPP34KQS8SC+W6BZ5
MMHJ_*K;4R4U1JENNSAR/"%\Z^LJ+A62U5;*Z:HE.;Y'<+BO.$"N$8XLS55AE
MQ[,K67VYUUMI[?5ULLM%3ZNY0N/LLR&0R_ ;%[;-C&_V:F\FMMSGBIQP1G)[
M6_@' Y?DM?"KRJ9*9C"8[+%ZY35FBJ<?S>RZW2MNU6ZIN55+4SD9:\CL\AR#
MD'N"^UXOMSO+8&W2MEJ6P9[F)#]W/+/+L"QJ+66.W;V<YN5SCWGO[_C^;)7.
M^W.Z4L%/<*V6H@@_JF/.QFS+9^2QP5%4*Q$1VARKJJKG&J<996R8ANUC+O--
M?/3!QS<UIS:3REIV+T7C%5\O4.XW.YU$\/''F&M/X@9 K!*X*:=..;#NL7[D
M4Y(JG#;'LRE;?;G7V^"AK*V6:DI\MRB<=C,AD,ORV*MSOESNM/!!<:V6HB@_
MJVO.QNS+9V+&!5"9*8^3,W:YQQJGO^+*76^7.[QPLN59+4L@SW,//W<\L\NP
M*ZX7RY7*D@IJZLEGIX,MR8\[&Y#+9^2Q85X4BBF/DLW:YQQJGO[]_=DKM>[E
M=VPMN=9+4MASW,//W<\L\NP+(6W&6(+=3-IZ.ZU#(6C)K'9/#1R#6!R6O*H4
MFW3,83'98OW::IKBJ<=\9Q9>#$=W@NK[G'<*@5SQDZ4NS+AR'/81L&Q>PXTQ
M$ZH?.;O5;HX!I(( R]PX M>0)-NB?>((ZB]3VBN=_>63M-\N5H?,^VUDM,Z;
M+="P_>RSRS[2L?GF<RK5<%J(B)QAQFNJ8BF9[0R%GO-QL[Y76RKEIG2 !Y8?
MO9<"\<CW2R/DD<7/<2YQ/&2OF.-7#@5B(B<69KJFF*9GM#WVB[U]HE?);*J2
MF>\:KBP\(Y%XY'NDD<]Y+GN)<2>,E6!52(CW9JKJFF*9GM#8;?C+$%!2-IJ6
MZ3-A:,FM< [5'("02%C35OKKFRHND\LVO(TRR.<2XMSV_HO"%<%(HICO$8-5
M7[E<1375,Q'RF>R7Z*\86I9H)W8KO%3! X/92RF0MS&T ^P,P#ELS6DXOQ1)
M=\4^=: R4XA#64[C]X 9[3[\R5JP5P7&CIJ:*LWN]?4?:=V]1IX13&./;'W_
M %F7LN-PJ[G5&HKYWSSD!I>_AR' LC;L4WJWT7D='<9XJ<<#!D=7\"=H_)80
M*X+K-%,QA,=GBIOW*:IKIJF)GYX]V3KKY<[A11TE;6S3T\9#FL><P" 0#V$I
M77BX7"FAIJVKDF@ARW-CCL;D,MGY+'#@5P2**8]H)O7*L<:I[_BR%=>;A7TD
M--65<DU/#EN;''8W(9#+\E6MO%PKJ2&EJZN26GARW.-QV-R&0R_)8]52**8^
M3-5ZY..-4]_Q5' JA4' JM!)R ))X@MN .!3-H?M+J.QS5TK=5]8\:F?,;F
M?S)=^BU3!> :NY31U5VC?34 R<&.V/E]V7"![S^7*IFAC9#$R.)C61L :UK1
MD !P !?+Z_J:9ITZ9_-^N_Z=^RKE%SU5Z,-OU^:Y$1?)?LA$1 1$0$1$!$1
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M&EHS.7(2LIZ04'/?W"GI!0<]_<*#6,7Z*,.8II+5#</+HGVR!M-334\^J]K
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M)N,7\)G="O1!9N,7\)G=";C%_"9W0KT06;C%_"9W0FXQ?PF=T*]$%&M:T9-
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M)9&AKVTLX#'9; =5P(S]X3$P:'<*ZCGLEDM>&Z.JCH*NXR055#),87AS&YF
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M_P!BFA$1?GW]+$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6)Q/B*UX8M$USOE6REHXL@YQ!)))R
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M$1?)?LQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M:9-%U\%DP;#ARE=>*.R0"GFI<\B]V;27ZN>T.R(.6T;%A<;X/QEBNOPW64F
MJ6QTE(\@T]++%K :S27/'LY<&P<.PY\2ZE1%Q0=IHP;?[]I1P?=+1;9*F@HG
M0FHF:]H$>4^L<P2#P;=BG%$1!$1 1$0$1$!$1 1$0$1$!$1 1$0%XKW+60V:
MOEM4+)[@R"1U-$_[KY0TZK3M&PG(<(7M1!!L>B_&>-G"?27BB2&C<=;S7;2
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M"PLA:&M)<"&EQ=MV9YC:L;A+%VD\XXNV!?/%!4W0%[165;,VP:NTO9DW;F.
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M351OCD#69:N8&0S&0XROA?,(Z0\<T#[;BJZ6.UVF5S72PV^%\CWZIS&UW!M
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M.'(J*RTD,KFUAF:Z1SR\N#2&O/./%Q+6;W@S&6 ]*UPQ7@JU1WBAN!D<^ .
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M><FMA!/8M=M< N%94R3D %I.WE/ N=%,8S,^SU7[E>6FBB>\MAM59Y;1B5P
M?F0X#B*^5T-P#X_( "W(ZW!P_FL5AF<PUDM,_9K\ ]X5^*R1)39$C8[_ '*Y
M,*\&=?-TV>?>-NS/P:^XQ[K_ %FJ-;\<MJ^B^-'_ ,4@_P QO^"^RXR]U/M
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M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0 B!$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MUE*W,-8XG/5=JO!SY#DF+L>5=LQI;\.VFC@JIZC4$CI'$:A<?=R#:5IV,O\
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MP'BSJU>/E)/!?1N!,5]6[O\ */\ !=KHKZ^K9SGH*9^;BMN!<5=6[O\ */\
M!7MP-BKJY=_E'^"[117XA5LS/V=1/_)QBW ^*>KMV^4?X+Z-P1BCJ[=OE'^"
M[*1/B%6S$_9=$_\ *7'#<$XHZO7;Y5_@KVX*Q/U>NORK_!=B(GQ"K9B?LBB?
M^4N/VX+Q-U?NORK_  5XP7B;J_=/E7^"Z]17XC5LQ/V+;G_E+D48,Q+T!=/E
M7^"KZ&XEZ NGRK_!=<HGQ&OC#/P.WSER/Z&XEZ NGRK_  51@W$O0%T^5?X+
MK=$^(U[)\"M\Y<E-P=B3H&Z?+/\ !7#!V).@;G\L_P %UFB?$:MCX%;YRY.&
M#\1] W/Y9_@KA@_$?05S^6?X+J]%/B%6R_ [?.7*(PAB/H*Y_+/\%<,(8BZ"
MN?RS_!=6(GQ"K8^!V^<N5?1'$705R^6?X*OHCB+H.Y?+/\%U2BGKZMCX%;YR
MY8&$<1=!W+Y9_@JC"6(>@[E\L_P74R)Z^K8^!6^<N6QA+$/0ER^6?X*X83Q#
MT)<OEW^"ZB1/7U;'P*WSER^,)X@Z$N/R[_!7#"F(.A+C\N_P73R*>NJV/@5O
MG+F(84O_ $+<?EW^"N&%;_T+<?EW>"Z;1/75;'P.WRES,,*W_H6X_+N\%<,+
M7[H:X?+N\%TNBGK:MCX';Y2YJ&%K]T-</EW>"N&%[[T-</EW>"Z31/6U;+\#
MM\I<VC"]]Z'N'R[O!7C#%]Z'N'P'>"Z/13UE6Q\$M\I<XC#%\Z'K_@.\%<,,
MWSHBO^ [P71B*>KJV/@EOE+G48:OG1%?\!W@KAAJ]]$5_P !W@NB$3U=6Q\$
MM\I<\C#5[Z(K_@.\%48;O?1-=\!W@NA44]5.Q\$M\I<^##=ZZ)KO@.\%<,.7
MKHFN^ [P70*)ZJ=CX);Y2@ 8<O/15=\!W@KAAV\]%5WP'>"GU%/4SL?!+?*4
M"##MYZ*K?@N\%48>O'1=;\%W@IZ1/4SL?!+?*4#C#UXZ+K?@N\%<,/WCHNM^
M"[P4[(IZB=CX';Y2A:APC>JMX#:%\3>-TWL =NU2#A7"%/9GBHJ'BHK,MCLL
MFL_ <OO6T(L57:JNSU=-]EV;%6;WG\1$1<GT1$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M/ SYJ2IMDDM(YVMJ.:=7/E:\9C;E[UXKSYUQAB%M=2V:ICS#&EH!<T9<9<0
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M-CMLC"Q\;7$%V?"2[AS]Z\&!:BONE%->[A-((Z]VO2TIV-@A&QOXN<-I/O6
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MB?\ 2(0@4O[RDO3K/E3]:^])H5C;(#5WI[X^2*GU2?S+C_@IZBWN?%>EB/\
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MM3;IV2P-.V+_ /W;\N?J51IUQ?\ ^[?ES]2BD*\*QT]KC#K3:HV2J-.F+O\
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M4]/:XPU'1V.$)*&F3%!_N'P#]2J-,>)__P @^ ?J4;-5XX5G0M\6XZ.QPA)
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M9Q:*=T;G-;J:@'([ASS60Q/>IJK%T]H=/>*>@HX&22>:X'/EED?F1K.:"6M
M'NS/X+8;]AQUUP:+$*D1.W.%F[%F8_HW-=P9\>KR\:^=ZP[627L7FQ7!E#<#
M$()FRQ;I%.P',:PS!!'*"F*X2P%JN=TBL6+8W/NAIJ.E=-05=? Z*8YQN)!)
M UBUS>'WK*X*M]UGHK3=[G?JJI,M*QYI0QK(B',&6>S,NVYYY\*]D=GN]59[
MO2WFZPU$M= Z!@AI]SC@S:X9@9DN^]GM/$LO9*(VVS4%"9-T-+3QP:X&6MJM
M SRXN!3$B&)Q_>I[%A>JK*,9U1<R&(ENMJN>X-SRX\L\\N-:@VLKJ&KM\]KJ
M,5UTYJ(V545=1R;C)&XY/(!: PCA&7(I Q%9Z>_6:IMU67MBF ]MAR<QP.8<
M/>" 5AJ2U8J;)!%58AI'TL3VESV464TK0?NDEQ S&PD!()B<6*Q7?J_!EY?4
MS/?7VNY LIX7R .IZ@#8 3_]V[CY/\?K>I[S8L+T%/)<#+>KK714SJDC-D#I
M3MU&\&JT @=JRM1A2&Y7:OK;[(RN9-$::G@+-5M/$?O9;3F\GA=LX!DO.<)3
MU&%66:ONCYI::5LE%6"/*2+4.<9=MR<1P9[,QVJ]C"7@KX:W"-TLDT=XN%PH
MZ^L90U$-;()/:>#JO8<AJY$;1P+YTU+<<08KQ-2RWZXT=!1S1-CBI'-8[-T8
M/WR"0.'8.59.GPY=JZZT%7B6YTU5%;W[K!!30&-KI,L@]Y).T9G(#(+*6:RF
MW7J]UYG$@N,L<@9JY;GJL#<L\]O!FF)@U"DNN(#@&]LHY9JRZVZNEH6S-8'2
MOC8\ N X"X-)[%Z<&5MMJ;S&R@Q->)ZEK"9;?<B=9VSA <T$$';[*S%'ARNH
M+==HK==13U59<9:]DVX!P8'N!U"TG:-F6>Q646'KE4W^ANV(*^EGEH&R-IXZ
M2G,0S>,BYQ+B3LXM@3L82V.X3^2T%34 9F*)TF7+D"?]RU[1E3"#!5ME<=:>
ML8:N:0\+WR'6)/:!^2V::-LT+XI!FQ[2UPY05J.CFH=1T4V&ZUVK<+2XQ@'9
MNL!.<<@Y1D0/<0I\E^:W17_R'<?^TZK_ &UCZ")EOQUBJAH&B.BEM[*J6)FQ
MK)CF,P.(D;5Z;;A3$-K9506W$=-3TL]1)4 &@#WM+W9G:79?HLU8\,P6FAKF
M-J)JFNKLW5-9/M?([+(<' !Q <"J1"-[#4U>%;%:*ZV0.F;?*%E,V-HS#:P#
M*)Q]Q!R/^:M@P':F63'=VH(W:YBMU/KR'AD>2XN<?Q<2?S6YX9M/F;#]OMKY
M!.:6(1[IJY:Q''EMR7PHK&:;%MQO1J YM7!'"(M3+5U,]N>>W//D3$B&(T3#
M/"D@/!Y;4_\ FN7PPI$RWZ1,3V^@:&4+HH*ET3/NQRN!SR'%K#:J6K">(K32
MRTENQ)304KY9)1_P />W7<7':79<?(MAPW8:;#]+4%L\M14U#]VJJN=V;Y7<
MI/$!Q#B0AB*)OD.E*OAAV17"VMJY&C@W2.34S_-KAV+<%IN%'^?,577$4?\
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MMDIP[7SU<AELUW ';Q;$$H:,<6LQO@RAO;8/)Y)=9DL0.88]I(.1Y-F8]Q6
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M_P!-UWPF*H^S[:A_TW7?"8KZRUNZ1U5N/FYW"N"Z']7^U]-UOPF*HT 6L?\
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M9M>.0A>E$&DT>BG U)5-J(,,T&ZM.8UVE[0?\UQ(_1;LT!H :  -@ 1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6#M&$K%9[S
M67:V6R"GN-9K;O.S/6DUG:SL]O&1FLXB B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@@/&6F3%5EQ5=+90X=IZBFI9W11RNBE)>T'
MAS!R6&W^<9=5J;X,WBNAIOZU_P"*L7HB[;B/\&,L[N?-_G&75:F^#-XIO\XR
MZK4WP9O%=!HKK6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&B:UO@99W<^;_.,NJU-
M\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-_G&75:F^#-XIO\XRZK4WP9O%=!HFM;
MX&6=W/F_SC+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,
MNJU-\&;Q70:)K6^!EG=SYO\ .,NJU-\&;Q3?YQEU6IO@S>*Z#1-:WP,L[N?-
M_G&75:F^#-XIO\XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^<9=5J;X,W
MBN@T36M\#+.[GS?YQEU6IO@S>*;_ #C+JM3?!F\5T&$36M\#+.[GS?YQEU6I
MO@S>*;_.,NJU-\&;Q70:)K6^!EG=SYO\XRZK4WP9O%-_G&75:F^#-XKH-$UK
M? RSNY\W^<9=5J;X,WBF_P XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^
M<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,NJU-\&;Q70:)K6^!EG=SY
MO\XRZK4WP9O%-_G&75:F^#-XKH-$UK? RSNY\W^<9=5J;X,WBF_SC+JM3?!F
M\5T&B:UO@99W<^;_ #C+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6I
MO@S>*;_.,NJU-\&;Q70:)K6^!EG=SYO\XRZK4WP9O%-_G&75:F^#-XKH-$UK
M? RSNY\W^<9=5J;X,WBF_P XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^
M<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,NJU-\&;Q70:)K6^!EG=SY
MO\XRZK4WP9O%-_G&75:F^#-XKH-$UK? RSNY\W^<9=5J;X,WBF_SC+JM3?!F
M\5T&B:UO@99W<^;_ #C+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[GS?YQEU6I
MO@S>*;_.,NJU-\&;Q70:)K6^!EG=SYO\XRZK4WP9O%-_G&75:F^#-XKH-$UK
M? RSNY\W^<9=5J;X,WBF_P XRZK4WP9O%=!HFM;X&6=W/F_SC+JM3?!F\4W^
M<9=5J;X,WBN@T36M\#+.[GS?YQEU6IO@S>*;_.,NJU-\&;Q70:)K6^!EG=SY
MO\XRZK4WP9O%-_G&75:F^#-XKH-$UK? RSNY\W^<9=5J;X,WBF_SC+JM3?!F
M\5T&B:UO@99W<^;_ #C+JM3?!F\4W^<9=5J;X,WBN@T36M\#+.[!Z*\37#%F
M$X[I=J)E%5.F?&8F-<T9 [#D[:BVFD_J?S1>>J8F<8:AY9OZU_XJQ7S?UK_Q
M5BBB(H^TNXPJL,4%%':Y&,KJF0G-S0[*-HV[#RDCL*W11-RK+ D%%%>B/'=P
MQ#=*RWWN6-\VYB6 M8&<!R<-G#P@_D5N6D*Z55EPA<;A0/:RIA#"QSFAP&;V
M@[#[BM56:J:\D^YBV)%H.B#$MRQ+::^>[2LDDBG#&%K W(:H/$M]/ 5FNB:*
MIID511!HQQS?+_BY]!<JB)],(I'ZK8FM.8(RVA2^K<MS;G+) BAC2%CO$5JQ
MM4VJT3Q"(&)L3#"UQ)<T'+,^\JOG/2K_ ''_ /Q1>*Z1TU6$3,Q&*8IF1:'C
MR_WBPX H;@QS8;J[<63ZS X!Q:=<9<'"%[=%E\KL0X6%==)&R5!F>S-K T9#
M++8%SFU,49_DK;T6-Q)5RT.'KI5TQ#9X*:25A(S <UI(V?DH4L6-\?7Y\S+1
MN=4Z$ O#8(QJ@\'#^"U;LU7(FJ)]DQ3ZBC7!==CZ;$-.S$=+N=L(?NCMSC&1
MU3J[0<^')24L5T9)PQQ41?&KJ(J2EFJ9W:L,+#(]W(T#,G]%"XQ[B[%MVFI<
M(4T<$,8UA[+"X-SRS<Y^P?@/U6K=JJYC,>T)BFY%#7G[2-8*J!UZI65%&^1K
M'2&)CVM!.69,>67YK,Z8L6W;#,MJ;:)HXQ4-D,FM&'9ZI;EP_B5KT]4U13$Q
M.)BDQ%"='?-)];20U5+2B2"9@DC>(HLG-(S!X5O-IN.(8, W.NO[!#=X(II&
M L;D UN;3D-G"E5B:?G!BW-%&.A[%]WQ-5W..[S1R-@8QS-6,-R))SX/P4G+
MG<MS;JRRHB@JZX]Q<_&%?:+1+%(YM5+#!%N+,R&N.0S/N"R,5STIF1FO0^SF
M,_Z*+@[5VGIJH]YCZIBF1%J^D#%]/A&TMG?'NU7,2R"'/+6(X2?<-G:%&=KQ
M!I)Q,Q]99VAM*"0-2.)C,^0%^T]I6*+%5=.;VC\3%.B**,.8IQE5LO5JN%&U
MMXIJ3=J<F(-<YVL!P?=(V\(6 O>+-(MCI6U-UC930.>(P]T,9S<03EL_ K4=
M-5,X8Q]3%.R*#;1B;23=Z%E9;8&STSR0V1L,0!R.1X?>MBQY=\;6BDIZ^@;$
MR@BHXG5;W-C);,3D[83GPD<&Q)Z>8G+C'U,4H(H8P%BK&^)+E!)&Z":VQ5$;
M:MP9&PM83MX=O!GP+ZXXQQB#"^./))9HWVHNCF:TPMS=$?O#/ASS#A^2>FJS
M9,8Q,4Q(O)6U\%):Y[A(\&FBA,Q<.-H&?^"C+15B[$6*<0U(K9XO-U/&7O:V
M)HVDY-;GP\I_)<Z;4U4S5\H5+"*!JC'V,:K%-9:K1)%-(VHECAB$+,R&EW&?
M<%F:.Y:4'5< J*+*$R-#SN47W<]O'R+K/351[S'U3%,"(M:Q]BF+"=C-:^+=
MIY'[E#%GD'.R)VGD "\]-,U3A"ME10E:[WI+Q+3><+2(HZ-Q(9JLB:TY'(Y:
M^9*V;1_B#%<^(I;1BND;%JT[IF2&+5+B'-&PM.J1[7$NU73S3$SC'9,4CHH1
MQIB['6&Z]WECH(*6>604QU(WZS&G9P9D;".%;=HQN6++J368A;$;9- 'TSV"
M,%SB1Q-.?!GPI5T\TTY\8P,4@(H@LF.;Y5Z4'V2:HB-O%9/#J")H.JW7RV\/
M]D*7UBY;FW,1*B*)-+6-[WAO$=/1VJ>..!]*V4AT37'6+GCA/N 7C9==*CVA
MS:(%I&8.Y1>*Z1TU4TQ5C$8IBF=%H]UO%\M>B^6YUVK#?(HP7ZS&D F0#@&S
M[I6BX&TJ7*;$$%/B*>%]%/\ T>N(PS<W'@<2.+B/XY\2E/3UU1-5/R,4Y(HT
MTQ8MNV&9+4+1-'&*@2&36C#\]75RX?Q*VX7V*@P=!>KJ_)HI(YI2T;7.<T;
M.4DY#\5B;566*MU9U%!4>.\:XLN4L.%Z=L$3-NI&QCM4<6N]^S/L68L6)<<6
MO$MMMN**5KZ>LF$0E?&W9GS7L]G/W%=9Z:J/>8QV^:8I=11#I%Q)C7#EPJ:F
M(PQ69TPBIWED;B<VYY9?>XCPKW:,;YC&_5<%;<]Q?8WAX,C6QM.L-@V#VN'W
M+,]/,49\8P,4H(H0TA:0\067&%QM]!4Q,IH2P,:Z%KB,V-)VGWDJ0\'XJ9B+
M"#[C$6MK88W-G8/[$@;GGER'A'_R4JL5TTQ7/M)BVQ%%VA_&-XQ-<;C%=YHY
M&0Q->P-C#<B3EQ)I'TF26:X.M-ABCFKF$-EE>"YK''^RT#A=_AP;5?3UY\D>
MYBE%%"\,NE>2#RMH.J1K")S( [+_ #3M_+A6Z:,\272_TE?'?:5E/6T4K8G
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M$0$1$!$1 1$0$1$!$1 1$08+'-FJ\085N%JM]>^W5-4UK&U3,\XQK DC(@\
M(X1PKFW2]HKI]'6&J:_VO$ER?<A4LB.ZO#2\D$YL+<B",L^$KI+'&**+!V&:
MR]W)LKZ>G ]B(9N>YQ#6@?B2-JY-JL=VS2!C-ESTD5M1362D/_!K71QN>",^
M NV99[-9W"> 9#@+":+S>;G=/LPRW2Y22-N4MN:Y\H]ESLI  _9QD '\U"F
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M;6XWT:2T<\=/@>2.9\;FL?[/LN(V'[W*KDKB[55,3WP]DQC+@VG07_D1Q?\
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MA'O)Y$'8$\\5/&9*B5D48V%SW!H[2JPS1SQ"2"1DD9X',<"#^86FX*MU9?\
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M1W>IJ@!/"V6-^X^T3P-VC:2-JVC1Q@.T8!LSZ"SB5[I7;I/43$%\KN 9Y
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MVT=-209Y[G3Q-C;V  **-->CG$&D'$-CCIZBB@P_1[9M>5PE+G.&N0T-(V-
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M9)W:CHLO=[Q!A..NQ-0^0W$S/88=P?#DT'8=5Q)1;<B\]4XSC#4=A$111$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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,1$!$1 1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g872484g11g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g872484g11g11.jpg
M_]C_X  02D9)1@ ! 0$ @ "   #_[27V4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R-C$S,C<T' (% $!-:6-R;W-O
M9G0@5V]R9" M(%!R;VIE8W0@5V5B(%!R96QI;6EN87)Y(%!R;W-U<' @4V5P
M="X@,C R-" @4$97 #A"24T$)0      $(5A[-_]8%!-I7 F93 8.-@X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 8             IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ "      0 ! (     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  $E   !F     8 9P Q #$ 9P Q #$    !
M  $              9@   $E                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   $E     %)G:'1L;VYG   !F     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !)0    !29VAT;&]N9P   9@    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     ,X0DE-! P     &U@    !    H    ',
M  '@  #7H   &SP &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( ', H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"
MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _
M /2*ZW9;GW7/>VMKW,JJ8YS!#'&MUEAK+76/L>S_ (OT]GLWHOV*CQL_[=L_
M\FE@_P P?^,M_P#/EBL)TB02 :K31CA&)B"0"2+-^+7^Q4>-G_;MG_DTOL5'
MC9_V[9_Y-6$-]S&.AQ@ 2YW8>'^<AQ2[G[5W!']T?8C^Q4>-G_;MG_DTOL5'
MC9_V[9_Y-8C.IY&']8K*<RQPISVA^)4]P@.9Z>/=0QF[VV;V^K7L_I/KV?GU
MJW=U6]C-SG,9[MS)$;F$_HP0Z?I)2F8UZB;%J&.)_1 ^CH?8J/&S_MVS_P F
ME]BH\;/^W;/_ ":EBW_:*&V["S=^:?+N/Y/[J,EQR[G[5<$?W1]C7^Q4>-G_
M &[9_P"30PVS$R*FML<_'O)9LL)<YCPUUC7,L?N?L=Z;M];_ /K:N*KF?SN)
M_P ?_P"B[D02=";T*)1 H@4;&VG5BYK\K)L8Y[F8]!#"QCBQSWEK;27V,A_I
ML997LV._?]1*RC&KLJK/JDW$M:199 (:ZSW?I/Y"GB_S^9_QP_\ /5"P_K-T
M_*OZCBW56-:R:F>F7.!>6V.L>W8T?1;6G1WHRX!5K)FH\0Q^[(RX:ZUQ</\
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M\Q\RMQ_)'^Z%CPJ-]ILM+66"6.G86B?: YK?TD?G;GL>KZH9F.Z+'U"'ES7
MG6)(#GMYV;?T>[_BTTKGELXU.LZL_,+B19#R-@<VO9OPC6VSZ-U?ZO\ S'ZQ
M_IOTJTLSTGU,;?Z;<IK-UP#'/ !:W]X#T_<[]U4<VC]H]?M!>TV]/JK%#S+P
M^\_K8O<QHV/IJ?L;53ZC/\,CUY[GX=.7O!KLK9=MF9W>^W;Z;',W.G\^S]'9
M_P "CGLQQ[Z#7]WU1C0_YJW$!QY#8U/RZW^E^]_B_P#H[?Z/GY;LNO&)G&-<
M5M#0  T>TCZ+VL_P?O6\N8Z#66]4+Y>X%KX@D@;C[_6W?F[J_2;L_P )4NG4
M>/9DENI5<S^=Q/\ C_\ T7<K2JYG\[B?\?\ ^B[E)'?Z%CEM]1_TE\7^?S/^
M.'_GJA<_]:Z>F_;\7)RLL4.J-1=5 W.8U[[&NKG\[<'-V^]=!B_S^9_QP_\
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M3V^L?^DK%_G\S_CA_P">:%95;%_G\S_CA_YZH5E*6_T'Y*AM]9?])2A9:VN
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M%SR2  !JYSOW4>3GEGB_6Q$91/!<3&49\/7]7Q15EX!+TG?6C8X?\9F@Y?\
M,_VV?]6U$8]EC&V5N#V/ <US3((.K7-*'E_S/]MG_5M5H;CS8Y?*?(O_U/3<
M'^8/_&V_^?+%5Z[DOQ\,/V%U>X>H\"0T#W;G#]W<K6#_ #!_XVW_ ,^6)9K+
M;*FUUB6O>UMT1/ID_I-L_P#3_P"#_F_TB>?G/FMQFH1-7H-'G>GY6/E]<QCZ
MKFVM:\L8V"'PUVCR[>YOM>ZQ6<)D=5K<3.(,C*9B,$$MN]WVAUCOSFNC+]%O
M^!_PGJ^I5Z2Z;@9F#DV6T=+IQW9#SZUK7[SM+M_Z,66^VOW?S+/28S_1_HZZ
M[-7'Z7BT9=N8!NNM<7!QX;N#&O%;/H,W^DWU;-OJ6_X11P%&9H S-^G^7^,S
MY3C,@<=U0XN,?/.M9U^AP_H,<;%RG.R6Y;]]-EA-39,Q_6;MVM_X-!L;EM:X
M,K][)E[R"1(VM>7#_"?O^W8M1- /;GE.!6"5/"8N%BMZC?E,J;ZI.1Z42XTN
MI?7B=SZ5C[VW?SMM?J>E^K>IZ"EFU$-.^8DP_7@>W>_=_GOW+H3TIOV[+;CU
M -NK:^ZRP&'W%SRR'1[_ $:"ZKV_X/T:O\'^CS\CI/4LBU]#*Q2\@DVQ-3C&
MWW/<-W^8I1(7?U9,$P ;THG\W3^K-F*_I3&XP+?3<YMK'.+HLG=9J[\U^[U?
M9[/TBNY7\[B_\=_Z+N2Z=ALP<*G%K$"INNI,N/OL=+OWK'.<EE?SN)_QW_HN
MY1W<B?-@RFR3WD/^DK%_G\S_ (X?^>J%95;%_G\S_CA_YZH5E"6_T'Y(AM]9
M?])S[>A=.LM?8&V4FTEUS:;'U->X\O>RIS&[W;O=8W](A6?5W"W[\-]G3R6A
MCVXI:QC@)^E2]EE/J:[?7]/U]G^$6JDCQR[E0A$7Z1KOHX'5/JUT^[ ?C.WF
MS(#JQF.)=>PV MW"SZ3J?W\3^C_F++P^B=3Z9=;FXU&)D69 :Y^.QME&T,:V
MO9BVDYV[U65[[F65U_I/\(NR<T.:6NU!Y5.YPQK:YW;'.#1M$F#/M@?FL53F
M>+AHR_5&HS!.P98 &5T./>W!Q.J8U5Q=U:J_$Q[FFIQRJP_'(?#&U?:L?U\/
MT_S7>M;3ZBU+>C=#QV[LB?L]>HQ[;'NI&V7#;CO<66;/S*MKV?Z-BUT&S$Q;
M6O9;4U[; 6O#A,AVCFF5+RV+[OCX($BSQ2K0<7]5;E(R2N0!K06.C7Z9U*S/
M-K_LUE%#2!39:US'6"7MW>C<RJROZ#;&?3_175_X7U::K&7_ #/]MG_5M5?I
MG37=/-K&Y%EN.XCT*K'.?Z;07NV^I<^U[OYST_S&>C53[/4]2VVQE_S/]MG_
M %;5*-QYK9?*?(O_U?3<'^8/_&V_^?+%857I[AZ5E?Y]=UH>WN-SW6L_SZK*
M[/[:+EG(;BW.Q0'9 K<:6N$M+X/IAPW5>W?_ ,+7_P 8C+YCYK<?R1\@E27%
M9=7U^R:!94QV/DD-<X5VUM!<RO+^C78^ZMNZW[$]E/Z.NY_Z/+M]+U;*BV4_
M7KULD5ESJ,K[0,8N?4UU MRJ:ZM_TOZ-TRNW+Q'[+GUVWV8]U=FRI!<]@DN:
MR;_K@[IF#75B#[591:SJ WL#A<&>G5;3>RZIK66V_IO8W?\ S7\S^D0&V?7K
M&]5M..R]I&397ZSFO.\FXXE.[UZO2J;MQ?2W>K_.7>OZ22GI,W#;F,K8ZQ]?
MIV-M!K,$EO#72';F+"ZCTW,QK2W#=U&\NJ]V0+P0TC]'54YABZ_V69%__&>G
M_IO4JC99]<['C'MH9Z;7M'K40S>UF7M?;8[[7ZF+NZ<RJZNBO[5ZWJWUW>G_
M #+ 6]5^NV-]D9D8M1LR+:P?2K+_ *8Q?6I<VO)M]*O']3/WYGJ?]IZ?T/H^
MI8G1D0D&FWB8&;=:*;G=1QVGU"ZYV3N^B6;&^VO9^D=;;]#_ +C_ .%I]-:3
M,,X9QV&^[)WY!?NO=O</T5C=K(:S:SV[]BT54RGM.5B4@S9O=86]PQK+&.L_
MJ^I;6S^VCQ$GZ%;DEI]8_P#298O\_F?\</\ SU0K*J8SFMS,RHF'N>VT-\6&
MNNH/_P"W*;&K-ZKD_6MG47U]+Q*WX8I]MMA8?TI,R&^O39[?H/8[_MQ-EO\
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M %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ #( ,  R #$    ! #A"24T$(@     !1DU- "H    (  @!
M$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    'P   'X!,@ "    %    )T!.P "    "0   +&':0 $
M 0   +P   #H    @     $   "      4%D;V)E(%!H;W1O<VAO<" R,BXP
M("A7:6YD;W=S*0 R,#(T.C Y.C(T(#(R.C0X.C0T ')R-C$S,C<T      .@
M 0 #     ?__  "@ @ $     0   9B@ P $     0   24         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
M  (!  0    !   !1@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0%.17AI9@  34T *@    @ " $2  ,
M   !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q
M  (    ?    ?@$R  (    4    G0$[  (    )    L8=I  0    !
MO    .@   "      0   (     !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I
M;F1O=W,I #(P,C0Z,#DZ,C0@,C(Z-#@Z-#0 <G(V,3,R-S0      Z !  ,
M   !__\  * "  0    !   !F* #  0    !   !)0         & 0,  P
M  $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$
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M-3="4J&SP=+P8B3A-&-T@B9#1*+Q)2=D@\)%H__$ !L! 0 " P$!
M       #! $"!08'_\0 /1$  @$# 04%!0<$ @(# 0$   $" P01$@4A,5%Q
M%#(S05(3<I&AL14B-%-AP=$&-8&R(T+A\"0EHD-B_]H # ,!  (1 Q$ /P#]
M4HB( L51504S<U$T<0ZWN 55U;K2EM#NQ*4MGKWD-$1VFXR#@YQCB J[16'4
M6HG\_=:NJH87[Q&)&R-'0>GR?S5N%J].NH]*^ISJNT%J=*WCKDN.."ZO@7"I
MUC9*=Y8:^F<X=#9F>]:[=<V=W"9I_P#>WWK7I>3^UQ8,[(JA_2Y\0R5*,TE9
M&#=;:7V865V9<<LB_P#LI;UI7Q-3MXM'C1]MOO3MXM'C1]MOO6[VJ63YMI?9
MA.U2R?-E)[,+.JUY,SIVCSC\S2[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83
MM4LGS92>S"QFUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+
M)\V4GLPLYM>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-
ME)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4GL
MPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"9M
M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:
M=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIVES
MC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./S-
M/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WF
MT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX
M?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MO
MO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].W
MFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;1X
MX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]M
MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];
MG:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JE
MD^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YL
MI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F
M$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83M4
MLGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-
ME)[,)FUY,:=I<X_,T^WFT>.'VV^]?.WFT>.'VV^];O:I9/FRD]F$[5+)\V4G
MLPL9M>3&G:7./S-+MYM'CA]MOO3MYL_3,T#K,C/>MWM4LGS92>S"\R:1LCV%
MOP;2C_\ J"SFUY,QIVESA\SU1:KLU6X-CN%*''H,S<_>IF&:*9NU#(R1O6TY
M5-K>3V@DVG43VTDAX.BB&1_-0$])J32DG/Q2U-?1_O"24, Z2<9/0W^:U=*E
M/PI;^3':[JWWW%/*YQW_ "XG5$5;TEJRCU!!WCFLJ6@;<0#CLY)QO(\BLBKS
MA*G+3);SHT:].O!5*;RF$1%H2A$1 $6.HGCIXC)*[98.G"YQ<M85]\JWT6F8
M3(T$ SQR[!&1N.'8Z<J:E1E5>XJW-Y3ML*;WO@EQ?^"^UUWM]"UQJJRGBV=Q
M#Y .G'25#2:XLC/BU<+_ $96'^Z@+?H6MK7":]W&HD+N^=#( \9/1G/05/4N
MAK+".^HZ>3RF(*:,;>.Z;;?Z%/VM_5WP@HK]>/R/G;S:/&C[;?>G;S:/&C[;
M?>MT:3L@'ZMI?9A?>U2R?-M+[,)FUY,SIVCSC\S1[>;1XT?;;[U][>;1XX?;
M;[UN]JED^;*3V87SM4LGS92>S"9M>3&G:/./S-/MYM'CA]MOO3MYM'CA]MOO
M6YVJ63YLI/9A.U2R?-E)[,+.;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=
MJED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63
MYLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD
M]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83
MM4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R
M?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4
MGLPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"
M9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY
M,:=I<X_,T^WFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIV
MESC\S3[>;1XX?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./
MS-/MYM'CA]MOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^
MWFT>.'VV^].WFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1
MXX?;;[T[>;1XX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]
MMOO3MYM'CA]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^]
M.WFT>.'VV^];G:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;
M1XX?;;[UN=JED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA
M]MOO6YVJ63YLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^].WFT>.'VV^
M];G:I9/FRD]F$[5+)\V4GLPF;7DQIVESC\S3[>;1XX?;;[T[>;1XX?;;[UN=
MJED^;*3V83M4LGS92>S"9M>3&G:7./S-/MYM'CA]MOO3MYM'CA]MOO6YVJ63
MYLI/9A.U2R?-E)[,)FUY,:=I<X_,T^WFT>.'VV^]?.WFT>-'VV^];O:I9/FR
MD]F$[4[)\VTOLPF;7DS&G:7.'S--FN;*XG:JHF#K=*P?W4A0ZEM%:<07"E<>
MH3-/]UIU.BK),S9%!3,\HB"AZOD\IVL)MM4ZD?G_ .5&!_=8:MI;EE&=6T*:
MRXQETW?4O;'->W:8X.;U@KZN5Q72_P"D:AL=T9+5T)(S/-,.]'$G9&3TKH=B
MO%+>*)E122!^6@N !&"1G&\**K0E3^\MZYEBVOH5WH?W9KBGQ_\ /^"11$4!
M="J/*!J0V>WN@H\OKY1F(- =P<,Y&<\,JTU<S:>EFF?\6-A<?J"YIIRF=J+6
ME7<*G\Y3T<[A&#T-<UW2,>16K6$<NI/A'YG.VA6DDJ%)XE/=GES?P);1&DQ
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M0SLVQWCB <-'O5DB>)(F/'!P!'UK6,E+@9P>D1%L8"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"@M:_J*3TVJ=4#K;]12>FU24>^B"Y\*70B>2,8T?3^F_\
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MS^17:W5T5= )(B> )R,*S">I$3C@VD1%N:A$1 $1$ 1$0!$1 $1$ 1$0!$1
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MQR@/J*)??Z)EY-L<7]E9:W&SNWC(W^8J60!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$7QSVM!)( " ^HJU=]:6FV&5L[Y-N/CLLS_?RKF.L^5%]>WL>QX
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MRU^4?P;G]%WX7+8T'X+V_P"@9]RF?X1=2I'^YOW/W+ B(J)V B(@"(B (B(
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M,E?<X2;A-(YP>X%IV#LN QG''I5^6CW'06?,(B+!D(B(#3O'ZLJ/1_NOSA5
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M\SSFU:4:TM$&M?/A_@\25\S+A&ZZDO$O?!\AVCO*_0.D;4RFIS'"P9 /YP
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M3FEB#8)22 1AA7 FEEGTZQ:4H9?(JDGZ"7KV"NZ?DY$&PW#''G(\_97"W[;
M8Y8WL<[=APQQ78_R?J@T;ZBCDW.J) YOF#"?[*QL]8J,I?U<O_C1?ZG5-65[
MJ"WA[*9D^V[9(<<8W'?_ "7(+O6W>2H+8J+9HZDX+Q,-P'D72>4IU=%04-10
MQ-E;#5-DE9LEQ+ '$X _NJ)<FW#5-+<KD*1]+#0-#Z>+FG1N?M;B"-X.-GH/
M2NR?/#JNDH>8L-(WI,;''S[(4C6@FDE &3LJN<FTE:_3;?A%@9(U^RP!I'>!
MC<9ST\5:>*P#E=YAECK)'2,V6;1.<CK633]IEN=8QVS^8:0XG=O (R,*W:IM
M$ES:V&+88PC>=X.<YZ IBW445#3-BA&X=)XK;)@PU-$R*TR4].QK1L@  8Z5
M^?[G;JVBJIC/"6M+R1WP/2>HK]"7<EMMG+3@X_NN"LU#40U<S9HXI(P]W%I)
MX^4KL[(<TIZ5D\E_4\:,G355M<<%8NCVD@D#>M"FMM;7S-;20;>7?Q ?>5:+
MA<Z$WAE9)!+S#7 A@:WH !W9PM"\ZMEG:8:"GAA@V@ XQ[+^.[>#U*_5<VN'
MD>>MJ%*"RYYZ'Z(T;324E@@AF;LO#G9&<_O%3:@-"/=)IJG<\DG:?O/I%3Z\
MO+O,^F4NXCE<&BJBX7NJDK8S'&87!CN]=WV=W2I#3%INM)25]FK*8LIG!D<<
MYD:2X;R3L@[N(71  #D 95?U!J>CLU1#%/%-)+*7!HC:T\,=9'6K?::M;[F,
M_P#@Y:V=;6K]JWCCE\\^3*+3Z6K+;/4PRV]E3'),Z1KI'-X9P-V5*WZQ766W
M4+:"-\4<4A=) Q[0W9ZN/2K)8M1Q7>H=&**JAV03M31!H./+D]:G.>AW#G(]
M^X#:&]8G=5<K5Q0H[.MW3:IMX?\ .3EUCTW<!JBCJI:3FX6,>'.#FG>0?*MA
MMENMCNU6^CI34Q3TSH0\R-;O<0>OR+I)E@8<.DB:?*X!>G&/9VG%N.LK#NYM
MY:_0VCLNC&.(MIYSG=QQCD<_TS9[E!;[V:JG,<M5S98W;:<X)SP/E7RDT_<!
MI.>D=">>=6NE#=IOQ2./%7]LT!.&R1;^@."]"2(G9#V9Z@0M>TS3S_DW6SJ6
M$FV\)KX[R@U]BKG:&HZ". F=@E#F[3=V7$CIQTJ*U5:I*"BM-4[)E@HXXG1[
ML9X'>NJ/=&QN9'-:W_D<+0N=LI;O!L3.<6;M\9'GZBI*5W*$LOAEOXD=QLNG
M4@U'CA)?XX'-(KJ;YK:B>(PWFI(7'!SP<.M=<4/:-.4-JD+Z</<\],F">.>I
M3"BN*RJ826Y$]A;5*"DZKRY/(5*UK#*]Y+&9 /'(Z@KJM.[0\]03-8UI>1NR
M/*H$7SE<4<DD@CA9M3=6<+HNF['':X=IP!G<,.<0,\=V]8].6-M"))IL.E<X
MN'2 "/*%/HS""B+SJ"AM,C&5<P8YS@T9:X\<]0\BEG.#1EQ '65QS7$OPC=\
MQOS$ W>#TC*LVENJ\]+X'-VI>RLZ.N"RSJ,%]M\P;L5 )=P[QWN5;UKJMM-"
M::WNVYGM!R"6D#)!Z%SL0.8P 32C'4]8*MDL<7.L=MD;N_)*Z5/9L8SRWD\_
M<;>KU*3C&.'S1A+))I72S$F5^,DG)6G60NFF$/[N/N6_05'/QDO8YCNDD8'%
M9I:9LK2X'OANW%=5S3Q^AYKV+:;7F1LE)WN:5Q;L[^]&%I5\AG;% '$R$8/G
M4\"R(AD7?9.#TK1NM$S;!9M;;LGS*.3CG>2PHK'WCJG)S:Z:Q6X&67\_,<[V
M;\$-Z1Y0KT"",C@N/V'1U=5&![[BP1MV9,"=P.[&[@NJ0OBH:(-EF:1&#DEP
MSQ7G+J*]H\/)[[9<Y*EIE#1%<-YN(JC'K6D-Q=3R->V,9&V0 -QZ]I6UCVO;
MM,<'-ZP<J&=*5/O(O4;FG7S[-YP?41%&3A$1 $1$!2KUX81>E%]X5U5*O7AA
M%Z47WA756*W=CT*5IWZG4J_*/X-S^B[\+EL:#\%[?] S[EK\H_@W/Z+OPN6Q
MH/P7M_T#/N4S_"+J5(_W-^Y^Y8$1%1.P$1$ 1$0!$1 $1$ 1$0!$1 $1$ 7B
M;]#)Z)7M:5WYP4P=%^Z<NW]&"@(VB[-;6'FP_L<D= QA;&HW2"W_ )O/QAG'
MUK-:ZZ.>#9:,2- R,8'2MV6-LS-F09"U8*/%70MM?8[(<R$$%VUUGJ4?C'QO
M4I>_T,=#-M19V20-^.I>+7:GUPYW]T;N/D6N=YD6BCFIZYCY6.:"6XR/*I^]
MW.*T6RJN%0 8X=G(+L9RX-X_6M"[4=4PLJ&']&X.P';MRY_RJZB?/:(:+ ;S
M@/.  C.'-(Z5);T_:54GP(ZM3V<&SD%<^NUKJN6:HVR&M+&Y />AQQPQ_$NC
MZ?Y-@P,J8M[FG((C/6?*J-I73EUU#7N?:G"(@%IV9.;X$>\+J5DT5JBU3,=4
M53C$#G'91/7T?6NO=U=/W(U,)>1R;6BY+VE2&ILDFZ4JGQ$N<[O6X V/)YUQ
M*\66Z-K)"^BF.0.^QY%WTVR[C)$IQ]*56-94YM-"^:IR78/#?P:2N74HTZ\'
MKJ;EO.SL?:M;9=PW:V^^>%OZGKD\I*BCLM)+4,="T,&2X>3"F[;30W*K?)*0
M6AI !ZP50-":KGK[S':9PWL.;:(<T.V@&M)'$XXCJ5]NM.^RSMDIR3&0/C'K
MW]&.I<ZE.+CB)V=JVM:WN).MQEOW&I6PNM=T#V B(N/\A_W4Q'74\[ X2-&&
M[QGI415RSWMS0UK&@9X;N/\ ^%D98MAF'R2-)_A</<MF<PT*FLC=<F\TT-;M
M-WYSU*=WEC'#@6@Y416V)T<)?"YQ(!.]P]RQ4%TYD<S5'XG>[@3P6&;'N\4
MJ'A^V& $$[L]:T7QU,,#VT\Y=&..&C<L]&Z2X51?*XMB X-.,X*PW:![9&LI
MGN ?G<3A:IF4:%#60T[W<\P/D)(SM85TTC:YJ^YQ5DL3F4\9#FY&0>(.]5>D
MMC8B'S=\_C@X(5TT]J44?-TU0QC8N +&G/$GK6]-K5O,2X%^: UH W ;@BQT
M\S*B%LD9RUP!&?*LBN%<(B( B(@"(B (B( B(@"(B (B( H'6WZBD]-JGE Z
MV_44GIM4E'Q$07/A2Z$7R3>"%/Z;_P 15R5-Y)O!"G]-_P"(JY+:OXDNI'8?
MAJ?1!<WU!^T2T?2R_P!,+I"YOJ#]HEH^EE_IA2V???1_0@VIX*]Z/^R.CQ_H
MV^8+ZOD?Z-OF"^JH=%< B(AD+Q4,YR"5G\32/Y+VAX%#*W%#BTQ1PU\LU6UL
MI<0<$$</K6#5T%%!3PF&E#2UH:"''@K)7$&H=U95;UF?^EB\P5.45A[BY.YK
M3::DRFW"QVFZ.#GP,AFSD.+G'?P'2MVKM[M'5=ENM*"^F9 3*]HP,N&R,DY_
MB6%H[]F.&T,KHM1:(K_HYMOER&R1Q .;@.&"';B0>I:VD4FV;7-[7K4U3J/*
M18Z=[:FD8X[VR,!/UA>F01,AYIK (\8PN<\F5[EI9JBQW-SG3L<Z5CCEQV<M
M:!DG^2Z%65D-''MSNV6J\EG@4#.UH:T-:, ;E]7)ZG5-[=K,TU)'3.H3&7 N
M+MKXY _>QPPNJP;7-#G,;7D6</&6L&TU&+Q%YZ'M$18-33O'ZLJ/-_=?FRIW
M5<^__P"8[[U^E;F\1T,SR 0!P/G7#ZJ2V76HEB>'Q2!Y_1,#>!_[KM[(J:%/
M<>1_J>@JSIK4D]_'S*;=<8: >]WJ$J2!LAIZ1]ZNE?8V2W=M%'([8R 7%PSO
M /4L-4VS6%Q:3+-4M=C9E8'MSG!Z%?JU=V[D>>M[*I!9GN29WC0/@S38_B?^
M(JPJ%T=4"JL$$K6,8"YW>L&!\8J:7EY=YGTNEW%T"Y9RE!PU):.8:73&279
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M>3BOM%4OHI74]<2&XV@]W>CR!<9RU[XE_$<X7%&V:6 '(:#Y7 *.N5PIJ?\
M-\V''AN9E;E73UEPCV:".01']YK=H'_<%2>E]*LHRZ>NQ+,3D;BTCAY5F,&P
MY8('3^FJJL+JMV(XI!WH:[' XX8\BFJ/23Q4N-3+)S63C9D&<='0KDBE4$::
MF:%NM5-0?H6DGK<!G[EOHBWQ@P$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %
M ZV_44GIM4\H'6WZBD]-JDH^(B"Y\*70B^2;P0I_3?\ B*N2IO)-X(4_IO\
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MEN)_>A:5;%@H*2*AI(J: 8CC;LMSU+.JM2>N;ES+]"G[.G&#\DD$1%H2A$1
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M=.G=O_7?\\GQNE:#X"AMCVA\<0<&.(X;1))QGRK!9]*-MM4V05KY(V@AL98
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M7O>T/AB,8!!/$YZU/(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MN3GXHRK[HQKVV&(2-+7;3MQ\ZEC24YAYHP1&+CL%@V?4LD<;(F[,;&L;U-&
MHIUG..G]<EFWLE0GK3\DO@>D1% 7@B(@"(B I5Z\,(O2B^\*ZJE7KPPB]*+[
MPKJK%;NQZ%*T[]3J57E*.SIBH/\ Q?\ @<MC0!SI6W'K@9]RUN4WP7J?1?\
M@<MCD^\$[;_Z=GW*5_A%U*T?[D_=_<L:(BI'6"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (BAM4ZDM^FK>:RZ3B&(=)8YW2!^Z">)" F459TMK6T:DIY
M9;;5"5L8<78C>W : 3\8#K"B*7E4TS4WIMKBN#35EP:&<S+Q(R-^SC^: OJ+
M7?60,@9,]^(W@.!P>!X++#*R9@?$[::>G&$![14W5_*+8=*U3:>[5K89' D
MQ2.X''[K2K#8+S17VWBLMLW/0%VSM;+F[]W00#TH"11$0!$1 $1$ 1$0!$1
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M9Z/,@-I%1=.<J.F[]=!04%>V2H<YK6M$,HR7' WEH"O2 (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B I-[/_Q?$/\ E%]X5V5'OGAC%Z47WA7A
M6*W=CT*5KWZG4JG*9X+U/HO_  .6QR>^"EM^@9]RU^4QI=I:JQT,>?\ ['+-
MR=O#M*6X#BV!@/J4K_"+J5E_<G[O[EE1$5(ZP1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 %J7*XTEN@=+6U$4+!_&\-SZSY%MK\N?E!ZKJZZ_P 5NII'1TK8F%S
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MKGIJBN5?;HIJYKW.$A<X$%LAV3N..@(#/RMTVBZRIH:G4CKHU\\1?'V-)$T
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M>#BKDORO^30QK-=3!HQLNG ^R%^J%@!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MV4T@DIZ"EC>.#F1 %5SN@V[Y)6?9;_DG=!MWR2L^RW_).SU?2.W6_K1<@,#
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M $N]ZO2)VZOZV/LBR_*7P*+W-[;_ *7>].YO;?\ 2[WJ](G;J_K8^R++\I?
MHO<WMO\ I=[T[F]M_P!+O>KTB=NK^MC[(LORE\"B]S>V_P"EWO3N;VW_ $N]
MZO2)VZOZV/LBR_*7P*+W-[;_ *7>].YO;?\ 2[WJ](G;J_K8^R++\I? HO<W
MMO\ I=[T[F]M_P!+O>KTB=NK^MC[(LORE\"B]S>V_P"EWO3N;VW_ $N]ZO2)
MVZOZV/LBR_*7P*+W-[;_ *7>].YO;?\ 2[WJ](G;J_K8^R++\I? HO<WMO\
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M%':CH#<K-5TK'\V^2,M:_&=DGIPJ/R:WJLI[M7:?NLKIGPRN93O< W\VS=N
M'#=UK90;3:-7))X9TI$1:FP1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 %$:KM9N]CJJ-DLD3Y&@!S'[)&\'C]2EUXG.(G'8V_^/6LQ>EIHUDE*+3.
M5\E^J9:>Y56G;H7<Y"Z1S)' [VAS6COB=Y^I=77(.4NWS2PQ7&CM4M-415#
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M_0,^Y:_*/X-S^B[\+EL:#\%[?] S[E,_PBZE2/\ <W[G[E@1$5$[ 1$0!$1
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MH/2!@.STE= I.2.PTD+8Z9HCQQ+8QOW^=3&E^4+3VH6?]'6,A<#L[$[V,=N
M/#:/6K,*VE+PP5,&T=V.<&5@$;8-,6JQM::&DB9,!WTH&"XXP3]:FD!!&0<A
M$ 1$0!5_77Z@D^D:K J_KK]02?2-4M#Q(]2M=^!/HS7Y-O!:#TW_ (BK0JOR
M;>"T'IO_ !%6A*_B2ZFMC^&I]%] N;Z@_:):/I9?Z872%S?4'[1+1]++_3"F
ML^^^C^A!M3P5[T?]D='C_1M\P7U?(_T;?,%]50Z*X!$1#(1$0!$1 $1$ 1$0
M!$1 $1$ 1$0'QS@UI+C@!:53<H8@0UP+NK!6M>97EPCC!('QL?4H<,<20,E^
M=P*@J5</")(PR9HHY:R?;8"2,'.0I:*"=K #*_=T;EEH(.QZ8!V 1G)6-]:U
M\IB@[YX."<9"JN/FS9/R1OP AF'<5Z<=EI)Z%HQ.GAB([TG.>M:;*Q]94O@<
M-D,.#NQQ_P#PK/MHQC^IHH-LVHY!.Z0\X>]<1C"]OJ3 QSG': &=ZTZVA:(?
MS3G YZ2LEN@V:9O.$D[^G/2J+JU-6YDNB.,FF*8W*9TLNZ/.X>1>0V2UDG>^
M+RG_ 'J4Q@ 8:,!8W%O!Y;OZU7J2R]_$VC+&[R*Y<JQM6-S ".D+<L##S3G9
MW9(QZE(U,,+87.<  .K"KL%:ZFJ78QS9<0-WE5:IN>\FA]Z.$3SMSO*JM?&;
M%;D\""?YE6?:$C!(T\5@E8R0Y>W)\RIU%Y$M*6EY9@ #8<,6A*]D9)GW9X'B
MMUT6R<@G'G49>*62=K3'T KGU<M/!8A@SU4\+827.SD8 P5H68U44DDL4CHV
MOQAK2,;EAMM/F0MJ-O(&1U*0?EK2&='!<^52I2?M(O>3Z5ITLL=ANW9CG0R'
M,C21T[\!32Y70U53;+J:D,+F=]N#2>*Z3;[A3UT0?!(T_P#'(R-^."]OL7:2
MN:6BH_OHY%Y;.C+*X&VB(NX4@B(@"(B (B( B(@"(B (B( B(@"(B I5Z\,(
MO2B^\*ZJE7KPPB]*+[PKJK%;NQZ%*T[]3J5?E'\&Y_1=^%RV-!^"]O\ H&?<
MM?E'\&Y_1=^%RV-!^"]O^@9]RF?X1=2I'^YOW/W+ B(J)V B(@"(B (B("KZ
MVTXR[4[:N!H%?2[4D+@,G:P,8WXZ%CT)?G5T,MOK6F*MHR("'.R9"T8+L8W;
MQP5JEW1NQQPN<1L=;]?L? ?T[9I'CH))/4K%->TBXOR*]5^SDI+S.DHB*N6
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MT2T?2R_TPIK/OOH_H0;4\%>]'_9'1X_T;?,%]7R/]&WS!?54.BN 1$0R$1$
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M/S:[5VO*J,0,DJ 3NVA7N!_$I"FY']27.F^$JET[ZJ7\YEU0PG?WW$G/$K]
M6B>)ID$S80=V,M ZUOSUK(FYV';/1C@MY7VE9A$Q[%O<?F!\VM]&50CEDJ7Q
MQD'9?7$C^+@'>56NT\NAA8R"[4T#'M&'._./.0/KZ5V.GE;7U1<YC"QI! +1
ME1MXT5IVZRNEKJ0[6=Y$A;TYZ%4=W1J^+##_ $)'3<-Q Q:LT]<98Y;=6O$F
MT.\;"YH)]76K/0UO9<(V,'<%R/4')!3&5\MHJ8H-D9:U\SR20/>J;+:=7:>J
MG.IGOE9$<-V('NR.'2/*JKL;:X\&IOY,F5:<%B<<G?+Q1[PZ)H#\C.,#=O2@
MHXXX]N4 R>4 KD]HY7KI#*&7FEJ3&!C/8[6=(Z3CRJZVCE#L-VD#6RLIY3TS
M3, _%Y%R;K95Q3;E-97Z;RU3NHR6'N+!<*@1,V6@%W$-/#"G- 1;,+S*2Z39
MX'?COBJ_'-2U4FU25=-.\\.;D#ON5RTS0.I6%S@07#&\'K6-@0FKSN[ES,WL
MX^PPF3R(B^B' "(B (B( B(@!. 2> 5>J-8V6"[_  9+5.%9M!FQS3B,D9&_
M&.E5'E?O50VHH;%12"*:H?&]SG 8V'%[".OJ6M=.3&TT&C*J2I+C<H87.-1S
M[PW.3@[_ "80'5V.#V-<W@1D+ZN=\A];4U>FJQE6_;['JS!&['%K6,QY_.NB
M( B(@"(B (B("E7KPPB]*+[PKJJ5>O#"+THOO"NJL5N['H4K3OU.I5^4?P;G
M]%WX7+8T'X+V_P"@9]RU^4?P;G]%WX7+8T'X+V_Z!GW*9_A%U*D?[F_<_<L"
M(BHG8"(B (B( JUJG3OPG^>ADYN1K0,!N<@$GK\JLJ$9!!Z5E-IY1M&3B\HX
M'<I/^I:WBYA[[R+&RIC,S6N[YP'!=DJ].T;J6J:QAVY68R<;OY+BFIK-/;+E
M-%O<Z1[G,V23WN3Y%>I2]IN1<C=0S]XVVUI$8!;@DXQE>I)Q' 7$[+>E0\4P
MAE,4^YW5TK6KZQ["]C2"P]:CKU%3IO>=.WMJDZB6DD/A!LN=G=T96)M2TOP7
M]^WIQQ4/!4!D;W'CO6Q9J:>YU#6TS=HR$ G?N7F5F<\1/62HPIP>O@CM_)]?
MS<Z".F=#LF "/:V\YV6MWXPK=(X@8 4/I"UMM=DIHRT<XYC7//EV0#T>12[7
M9=C&Y=F&4ED^=W+A*K)TUN(76M(ZOTM54[:QU$Y^Q^?:S;+</!X=.<8^M43D
MSHC26^>(Q"ZOYUYYUYYLXW;L'_=ZN7*-:OAG25;1B5\7.<WWS'[)&)&GC]2Y
M3R77."WS362&28R%QDVY3D;RUOQO^RNTJ].-%TY2WM\"A5M*M62K0BW&/']#
ML].W%-OM[6''Q.<!_FN8\KE+1/BAEN#FVZF#H\N#3+EV7= W_P#X74:2GE92
M!KY(R0.(=D+E6O:RTW2\166]R3[!:V4&F+<Y#G ;S]?0MK:C&LW&:RO,AJ7-
M2U<)T7B6=SPCI6AY:*;3E,ZUU'9-&2_8EV"S:[XYW'>-^5/!0^G+5!8+=%:Z
M(R&GAR6F0Y=WQ+CO '25,!4VHIXCP\B]-N3U2XL^.&6D=8PM"BM<5-5S5)PZ
M60YSC!'$?W4@BP:A$1 %\< X$$9!W+ZB P&D@((,3<'BHVHBAIZ9S=P&<MW=
M*F5K55.Q[,NSNWK*9O"6&05)325D8-22,\,[U).M>S &TTG-G<3AO'^:] 8#
M-C"D6?$;GJ67)F\IM<"%-#521&%X(W8V\CI\F5'UU*\TKH..QAN>O!5K53NE
M5/35DN&!T9<3\4GI6T<O@;4ZF_>4[E<,53IB&3:VC2U G<S'$-8_I4'I&XQW
M>W43J6RQM;$SOYA-OWYP<$#J5HO].+]35%&]CF1RQEF<;.,@CCOZURG3E7+I
M/6$]F?+&ZC,O-AP=M$!K2>.X=/4NE;1UTW!<5O.==YI554_Z/B=8NH[#MTLE
M1 &AT9:UVUG&0<#<J;R1:?KH:JJN,\SG4-0QH:T@8.R2#TYXCJ6YJ*I?JZ-M
MHHI6MV<2EVULG R.(S_%U*QZ+LS=)V9M#)*^5[6D$[>V-[B[C@=:U=10MW!2
MRV]YM9V\^TRJSBTL;L\OX%=42TM4]DKCV*22!T#?N6M5RPFX1F@B#<EO XSZ
MU(WJ6G?#M%LG1T>588YXJ^MC[':&M86DDC'2JRX9.NLYPR.O3JN:(M+"U@W.
M[X'I6VT#L=NP-W!9YR(JUS)M\;G'AO6"HGAIN\<=QX8621&I4ED#"\@-'2H1
MT3KC.2>\C&[K5@E#)8\\6E:<K0T;+0 /(MXLW*W6Q1T52',.WLD$C&%L12MJ
M&%[./2U2,\<;@\8RYPQO5;J&26^L,F<L<2<<5LF;HV'.YPN;C&!E6/DYU"RV
MW62GJ9SS#W <#WH =T *K.JV/J"0"T.;C>,*?TCH6LNM::N1[64F0[<\M<00
M?(L5<:=YI6:T/4=TB>V2-KV'+7 .!ZP5Z6*CA%/2PP@DB-C69)SP&%E7/.0$
M1$ 1$0!5_77Z@D^D:K J_KK]02?2-4M#Q(]2M=^!/HS7Y-O!:#TW_B*M"J_)
MMX+0>F_\15H2OXDNIK8_AJ?1?0+F^H/VB6CZ67^F%TA<WU!^T2T?2R_TPIK/
MOOH_H0;4\%>]'_9'1X_T;?,%]7R/]&WS!?54.BN 1$0R$1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 4!J$.#P>@G ]2GUI72D;54[LYVF@D8Z\*&O!S@T
MC:#PRM6^)\E2!"\L=OX+9N;9@^..=Q+"X;RLEEA<RIDVA\1Q'\EXO+W&MB:?
MB[3?[KBRW1P^)<3S(]_ ['L:]DFR?1_[K8-..8YF2,.(X$E;L'Z!GF6)\S02
M #ZE'4RN#,*4F\$52T#Z-Y>'9:?W<866<"3>\[+>KBMETC=_'<LU)2BIRZ3(
M:#T;E4C0=Q-0BB5U-*U2(6XT(E@<Z&(->T$C!\BK99(9VPU/3D8.]=2$;0,;
M(]2B[S9HJ^(EHV91\4C<./F5JXV(_9MTWO-:5[AX:W',KUHFU5<):*2($[\[
M/D/E52=R).K87SVNJ$$@&6AL(\W$O'E78:>W53Y!&\,W'.=_!6JEA$$+6  8
M6NQK>ZC)^T;45\_B9N:E/3]U;S\N.T#RAZ8>Z>B=/+$TX#A-"SCN_C/4I&R<
MM=ZLCA'J&V/D:/WWU@/3G@UAZ%^EG-:\8<T.'41E1%XTU:[K2O@J:2(-<""6
M1M!WC''"]+&G"+U);SGN3:PV4;2_+9IF\#9JIQ1R8^+L2R='6&!=$M5UH[M3
M<_;YN>BR1M;);O'G 7)M7<AEKK:5QLTU5%4DY[^9K6\=_!G4KSR9Z6DTII\4
M-1*9)1(YV><VQ@XZ<#J6Q@M3W.:-S=KZU@-;&U^S+WOK*VEBFYDM(D+!]80'
MJ.:.3XCL_4O:K5SN=!2LD:TU#I&C=L8(SA0]5J6XMM,E1;X&F:-P8P2QNP1Y
M0"LX,%QNMSI+52FIN$W-0C.7;)=P!/  ] *Y=J'EVT];I'QVXBO>TD8_.1=/
MEC4E;;>Z_P! ^74TSH&2!S,1/V!U?O9Z,K+8^3725%4MGI)Y*AY.0))8W@[C
MT;*8,G)'4NM.4>^,OE!2RTT-/AC *B-V=EVV.):1N>.A= ?9-?7:$4%RDJ(*
M27+)I#-$_O3_ ,0[>NMTM-!2Q".GB9&P#@QH'W+,L A]*V*GT_:VTE,&[\.D
M<&XVG;(!.,GCA3"(@"(B (B( B(@*5>O#"+THOO"NJI5Z\,(O2B^\*ZJQ6[L
M>A2M._4ZE7Y1_!N?T7?A<MC0?@O;_H&?<M?E'\&Y_1=^%RV-!^"]O^@9]RF?
MX1=2I'^YOW/W+ B(J)V B(@"(B (B(#X_P"*=^/*N>QO%UUX&M;MQTS98GN!
MX$$J6UQJ 44<=MI7'LZL+H8\9!#L#&\<.*V-%6$6JC=/.725E5B61TF'%KB-
MX!X\5/!NG%OF5IXJSTI\.)RGEDL)MEY^%**-SF2%D98,[@&Y)R2>I<W97S3U
M#N:B+G9WM!X+]<5]MH[@PLK::"=O5+&'XZ.D*'I-%V.FJ))F6VB+GG.#31[M
MWF7+KVTJKX[CV6SMOT[6CHJPU/G^A^?-*62MO]V;2.A?!$1ESRW:'$#R=:[[
MHO1U'IF%PA[^5X&T[OAG!.-Q)ZU.TMJM](_;I:"DA?PVHX6M/\@MQ26]K&@M
MW$H;3VQ.]^[!:8<CSD[6"-R8Z O2\O!(W<59.,:U?!'44[H)V[43\;0R1P.5
MQOE9LUGT7:Z>X6FVF.IDJ TR\^\[MESN#B1Q:%VO8)W%<HO^J+=J6X26&Y4T
M3FM;ML)@+N^)+!Q!'2E-*4XZMQ:HRJ*G-Q6J*[RRTGU(NT<I36Z#YUU'SM2V
M'+B)0,G:/1LX4C8- VO4D\.H*J/$@:&<WM/\C\Y#@/WNI6S2NCK12V84TE#2
MRL+0/SD##TGR*U4]-#20B&EACAC'[L;0T=7 >96JM65.K+V,FHE&V5.=NI5(
M?\F7O\E%O<O@9QO&2%]7PC(XX7T<%5-PB(@"(B (B( A (P41 8F0,:\N \R
MRHB +R^-KVD.&05Z1 5W5%7:;3:YFUM3%2=D-,#'/<?C.:<?=_)<5=R8Q7*K
MK+E!6"J$S@^-S(R /_NWKLNN-(T^J:.&&HFEBYJ5LPV,<0'#I]);%EL3++:8
MJ>%SI#&P-[_&_P!7G5FUN9T6\>9'>485J*@F]_'I^AQ/DHMU/:-7U5-=HN:E
MYN1K7O<6[0VV@#&?(5V*LL)AFD[#:>;DP, $XW>4JD<H])424T5=1T<%-415
M+ Z6'#'.8-HG)&_ZET;1MT%XT[25NUGG=O?OZ'N'3YE+<0BHJK!8SQ7ZE>TO
MKB51T*TW)Q6[/I_\%>J:=D=.^*K80X'=DXR J]2T,\ !I7ENT<'O<[OK5YU?
M2"6D,D1Q*,# W9WJ&9+$ZG#VM8T$D# PH(RW9.U3EJ66:)IRZ'9J3MNQQQC'
MJ4->[3&^$2[7?@CH/4?*K'( 6YSG*U)VB1FR1EOE6ZDT3Q1#V\$V^/:ZCO\
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M3W2+#%*R49C<'#R+VH6V.<V7#22#@8^M32]#9W/::>MK!3J0T/ 1$5LC"(B
M(B("-J75SYBR NC8>#]D'"TW6.:I?M5M4)?)S>SN^HJ>1 15/I^W0$.;!WXZ
M=MWO4E'"R( ,;C'E7M$!6]>:7&J[.*$U IR'EP>6%W[I'#(ZUQ"NY.-::4K6
M3:;N4E4UA.!'0L\P^,3T$K])H@. :;Y:+I;'.MNI[;)-<&N.R72-B);N:.]:
MSK#E=(.51@E@[/M#J.GD=@S/J,AHZ3\50/*C:[?;=<6^ZSV^D[$?%% X\PTY
M>9'.)P!QP.*N>J8-/5VB*^KBIJ(0<P\L>(&AS>@D#&0=R M]#5PUU+'44SVO
MC>T.!:=V\96=<XY"ZF>HTU7\_))(R.L<R$R.)Q&&,P!G@/(NCH B(@"(B (B
M("E7KPPB]*+[PKJJ5>O#"+THOO"NJL5N['H4K3OU.I5^4?P;G]%WX7+8T'X+
MV_Z!GW+7Y1_!N?T7?A<MC0?@O;_H&?<IG^$74J1_N;]S]RP(B*B=@(B( B(@
M"^/.RQQZAE?4<,M(/ C" Y9IO8N6N+A73-+I&NB<W&[!QCH\RZDTY:#UA<QD
M>W2>MW&>-HH[C*R.-QWXV6C. -_3TKID$C)8621',;VAS3C&058K[\-<,%2T
M3BI1EQRSG&N]4WBBU'%:K/*(G/?&W+HFO'?#S9XE8K?JN^".[6ZI>7W.GD8R
M.9L(#6])W8ZO(HWE%H*ZKUQ#V 71/+X=F5C@"#NZ_*H]U=4Z:K;K3WE@DJZF
M1KF54CMIYQQ/>Y\R@+9.4NM;O%I.2JKI0:LUW8S9>::UK01N)&,;CDJ6T_<;
MT9&5-7?+=74F0964[6Y8-_QB!NRJK8;E0]H\_P *T\4\,EP<-J0$[&6CO@!T
MC>M.WTO/76.FTE<9JFDG<&U+=GF@&_N[G8SOVE@%GGU#J*_72J;IUYAHJ>1\
M#G/IQ(TO:3O#@#T%JM&BZJ]3PN;?0\R@$[1AYL'?NZ!T*C:>U _1$]?;+M"R
M,35,E2UY)<2#AH^+G^$J^Z0U&=00F9L3&18)#FD[R#CI0%B48;'0&M-7S3N?
M+=DNVSPSG@I-$,IM+"/$43(@0P8!7M$3B82QP"(B (B( B(@"(B (B( B(@"
M(B +Q-GFG8<&GK/ +VL=0&NA<'G#>DH@SG&K8JYEMJ737B@DB+W88W&1N.Y;
M?)<9(>3^C>QCL[,F!C_S7*I:ZJ*:XU[+/8JATU5S[991LEA#<D.WNP#O(76M
M/6QEJLU/0-:-B+:W>=Q/]UT*\M%%1:X[^&#DVT-=Y*JGNBL<<\7_ ."#JJET
M49>_B3DC"K=#!25D+F%[&/&3WS\+I,UOI9@1) PYZPHB;2U&VFF%,P,E<PAK
MFC?G&Y5(S2._&LD4%E2;=7.C#A)$'$=YOX>59GWB)\P86EK3TDCBI-FE*NGG
M?+/%SL6<Y>YN_P#FH&KHS72EM' V/8W]Z<<//YU*FI$U.IG@+W%SCH'@%\3=
MK.SOQPZ5@K:.&2F86,)=@=)6.*>:"H=1U#BX.P!DY\JDG-;&UH<<-PI%N)DR
M*^#X!3[#FG:P=^2JO<H^9J3'$0-YQTKIUFTO67$QS5&U%3N/0YIR <'=E6";
M0EJF,9?&W;8,%VQ\;RK1U4MQ%*O".XSZ!JI*BR-YV-[7![OC#'4K*L-)2PTD
M0CIXVQL'0U9E5;RR@WEY"(BP8"(B (B( J_KK]02?2-5@5?UU^H)/I&J6AXD
M>I6N_ GT9K\FW@M!Z;_Q%6A5?DV\%H/3?^(JT)7\274UL?PU/HOH%S?4'[1+
M1]++_3"Z0N;Z@_:):/I9?Z84UGWWT?T(-J>"O>C_ +(Z/'^C;Y@OJ^1_HV^8
M+ZJAT5P"(B&0B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#Q)&U
M_P 896A70&GC,E.UQ.=X SN4DO$SVLB<7\,*&M1C4BU(VC)ID'%,R=NVS<3Q
M:3O"^.&5ITS'OKY9(1BG.S@ [O*L]<7-A<6$@Y7DKB*RTN".E%;TD2-EV7M<
M\'/0I15C25QB=$:=SOSF>H])5G7IK!Q=!:2E<)JHTPB(KI $1$ 1$0!$1 $1
M$ 1$0$=?K/1WR@-)<(S)%G: #BW?@CH\Y7,9.1FE==FN;)$+8' \SMOVMG&\
M9\^5U]$!IVBVT]JH8Z6C861,:  7$\ !T^8+<1$ 1$0!$1 $1$!2KUX81>E%
M]X5U5*O7AA%Z47WA756*W=CT*5IWZG4J_*/X-S^B[\+EL:#\%[?] S[EK\H_
M@W/Z+OPN6QH/P7M_T#/N4S_"+J5(_P!S?N?N6!$143L!$1 $1$ 1$0&E<[73
M7)K&U+2=G.",9&5LTT+:>GBACSL1M#!GC@#"R(LY>,&,+.3PZ*-SMIS&EW61
MO7F2F@E.9(8WGK<T%946#)A[%I]C8YB+8SG9V!C*^QT\,1S'#&P];6@+*B Q
M24T$CMJ2&)YZW,!7J.*.(8BC8P=31A>T0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!0VKZVLH+#53VUC'U3&@L#VEP)VAQ \F5,HLIX>3$EE8.=\F6D7T#Y
M[Q==EUQJ7/=AIRP->6NX$9!SE=$1%O4J2J/,C2E2C2CIB$7QS@WB<(QS7C+3
MD*,D/I /%<_J;564-RD(:QT3V8&SDG)/F70$6T9:3:,G%Y1RN\Z?K>:=,QK"
MYP[WCGH\BE=/:0=+2B2O<=HX.&O/4.L*\]E0\_S/.-YWAL]*S+>5636#>563
M/,4;8V!K!@!>D11$01$0!$1 $1$ 1$0!5_77Z@D^D:K J_KK]02?2-4M#Q(]
M2M=^!/HS7Y-O!:#TW_B*M"J_)MX+0>F_\15H2OXDNIK8_AJ?1?0+F^H/VB6C
MZ67^F%TA<WU!^T2T?2R_TPIK/OOH_H0;4\%>]'_9'1X_T;?,%]7R/]&WS!?5
M4.BN 1$0R$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %BJ8N>B
M+3YUE18:RL,)X(5T)A9L ;AQ*KUYK2[:BBZ./G!5YD8U[2UXR#N54J;4V.X.
M+F8C<7'AY2O/;0LY4DYPWY+]O63>\@**&<SL?!AI:X'OLCI5YLU6^6+FYAW[
M,#(&Y:<%$\[HVEK>M2])3"!N_>[KPL;)I7"GJENB+J<)+=Q-A$1>C* 1%$OU
M':FO+#6Q;0XC?N6DIQAWG@RHN7!$LBUZ*MIZV,OII6R-&-X6PMDTUE&,8"(H
MNIO=/!=(Z%Y;SKV;8[[?C)'5Y%B4E%9DS*3? E$1%L8"(B (B( B(@"(B (B
M( B(@*3>_#"+SQ?>%=E2;WX81>>+[PKLK%;NQZ%*T[]3J5?E'\&Y_1=^%RV-
M!^"]O^@9]RU^4?P;G]%WX7+8T'X+V_Z!GW*9_A%U*D?[F_<_<L"(BHG8"(B
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M+I"YOJ#]HEH^EE_IA36???1_0@VIX*]Z/^R.CQ_HV^8+ZOD?Z-OF"^JH=%<
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M%]X5U5(OA_\ C"(?\HOO"NZL5N['H4K3OU.I5.4SP7J?1?\ @<MCD^\%+;]
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MG<6M#>8?Q/#?CRI7<I&F:*J=3U-;(V5I(($#SO'U("X(M>AK(:ZG$],XNC/
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M]614?E9KVTVGC"/TCI&. ST9*GMDY58I<RGM":IVTY/DR1Y-VENE*<'CMO\
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M&X\3E;W+SJ2HH(8-/TCP8V/+72#>"'LSN.?^2YI7VMERU3'VI4S6T^UG,.X
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M%6V"O-'(QKFF*JK6EQ)!)( Z,%1E7J;0E[MLCZ_3]OM];L.(;MND)/ ;]D=
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MK\_Z TWVSZTEM_/&(/F<W)<1P:X]'F7Z!Y,_V,U_T55^$KD'(,?_ -T1N_\
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M0+'X^3V3D[H%C\?)[)RD^U6T_)C[1WO3M5M/R8^T=[TS;\F--[ZH_!_R1G=
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8%%5KRJ;GN1;MK.G;[UOES?$(B*$MG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g872484g30t61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g872484g30t61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/*^8X8X0DE-! 0      %P< 5H  QLE1QP"   "<U\< E  "')R,CDT
M,38U' (% #M-:6-R;W-O9G0@5V]R9" M(%=A=F4@+2!&;W)M(%,M,R!A;F0@
M4V%L97,@4')O<W!E8W1U<R N9&]C>#A"24T$)0      $!"?W;B=WBXWDWFW
M6!;$,PTX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S\    &
M              %"   !EP    4 4P!4 #  ,  T     0
M           !              &7   !0@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !0@    !29VAT;&]N9P   9<    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   4(     4F=H=&QO;F<   &7     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    *.$))300,      YK     0
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M@:HI@ZG92WT?2_=_1>G4K&+!(CBH> EQ!BR98C2_K&G5Z?UVWTPSI6=E,SY
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MV>US
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 9P"" P$1  (1 0,1 ?_$ !X
M  $%  ,! 0             &!P@)"@,$!0$+_\0 /Q   04!  $$ 0(% 0,'
M#0  ! $" P4&!P@ "1$2$Q05"A8A(C$7&!F7&B,D05>QU24S-3@Y0E-887B!
MM=;_Q  < 0$  @,! 0$             !08#! <! @C_Q  V$0 " @$$ 0,"
M P8& @,    " P$$!0 &$1(3!Q0A(C$5(T$(%E%A<? D,C21P=%"4H'A\?_:
M  P# 0 "$0,1 #\ W\>FFF]Z9O/]/L?H=,)3'ZNPSU?!:RYBB"O[F_+ D,:+
M),%29+/ZS3&JQJ3R11UF=L))G#2L^L;&2S1;E"I[VTBN30K@XR7[AS$)2!0$
ME$&ZT^K7#F>L3++"XCM$\S/$3JW+,U:[7BHWDH8/PJ%K&$,EQ/4$*>TIXYF(
M%1<\3'Q\S&=[R(]Q?CG8]J%@IM/Y5^&6M7HUC2676"['LN9R=-6Y\N">GNI,
MC!LJ'YL#*N:J*OL-J>*2Q1+8/K"[ZJBG%U3NY8'8>6Q=0[XUML[LJ^P!P8L!
MQ=JRX[ S#51;FHZ( &^84W:N7$ORQ8*6]2JZX_G-XX[(V%TRL;@VV^+AK/(=
M\DA* 442MIU56ED1&OQDRI8QA",E(&Y(S%@GO*\J_*7@O&H>]<N\D>8>X]QL
M$K)T^P@CQ"Y?IV6MKBYN7F))#S@:23)5JT_[$$^?HU;:VL-L6DR5@HSAQ#8M
M>V]MYO,3A,E@,EL'*M"TVH4W/<8ZRI*5=9C\1(/=GY8<<1CV*42@F),I@C#,
M_<>XL+BXS&.SF/WOBUG65:&:GMLA68UCI*"BB$^U"5PE?>^MK(<<3XAC@&6A
M<'\J^?\ <P<O^FTU1A.EGA LW/CWO21J+K6(NF4YM@=5/R5FZGU/Y7R3!6 M
MH54$U5OFQ6657&.TR29G.\UMF_ACLR5=EW&@9^RSU$2?BKJ9<*P:-M?FK3$1
M!+-0N%BK!2IDE(=9O6$W3C\T-80M)HY(Q$;NW[Y C+4W"EC&*]HV4VN9F0:+
M322FU0\JQ#O,C++U6=6K1Z::/331Z::/331Z::/331Z::/337%//"-#*03-$
M./!&^:>>>1D4,,4;5?)+++(K61QL8BN>][D:UJ*YRHB*OKT1(I@1B2(IB!$8
MF9F9^(B(CYF9GXB(^9U\F8+ F,,06 R9F90(  Q,D1$4P(B,1,R4S$1$3,SQ
MJ+VA\O.1UW6L5Q;.V\&SVFMNX*DM] 5"90Y=DD<\KEN;D1#(76CVCOC'I@8R
M2(YW0K=34@<T9KK77V9FFX:]GK*"HT*2)<'N0)=BW/8 CVZ#Z%X8DXDK#) )
M&"\$/8)+CE>0]8MGU]WX/9&-NKS>;S%X*CRQS@=C\2,BPR]]=3#@FV4*,%4*
MXN:#)";Y8]# L3*;U4]=6TEMMIYL;EKG309?4[26H%4IF8Q((-GJ;=4>QGZ:
MF L;*H#**7[_ '2.:Q&;]&O=^3^WX]9ZJ(LO4B7HK0PNLOM$8(7\3/9I@#"$
M?CCF +YF/C6)[92HVPIKI".?$@1)I_R 2((F?Y24:SP:3W>^25VUVV?Z[IGZ
M*IG-AH;[GVI\>NF>/?6<774ED7:P5,&[PVVZN9=6H]B^OE_;+.KQM=/,+-,V
MTJH;&=6]LK^F&4=5JOQM:%-@":F[7S6.S6.ML: JEOM+E7&@I1+\@R8.M,""
MB)6P@B-<OL;ZI)>]=YLM61PIE5N-M8ZY7!<D<#%BK8O&P_)UGK*TCS$\$$3,
MZD=VWR!\%/=+X$)QK+=JY?GNH;!E81@,_P!6!GS70\CTHP>!U'29R>TGKAYM
M!+=RB9VYAR9FJK=15S6E+5SEL,'L88?#X3>7IUFYR]C#Y%^/J2T;SL:<6*-K
M'@4^9MCQ"R11"8*PF;05V56PMS!"5DN=C+Y3:V^,4.,3E**+UCI-)>0"47$7
M2B/$I$LD()I-D4.&L5@7J)JER7<614A@/;^]R7Q"['):\%LJ=W0:DF42O;E]
M?640^\SWX_U$GXJ?IT.6S/0*-(7P37%,%/HY,\;)#,; "8'&:/U.]OGT^W3B
M87G%N&BT1-GN:C'E1L3/2/SL;-JQ1=SR*6D-?W "4#)B4@7+4[0WUMW*>7"R
M'OU$8KBK;4GWJ8GM\+R7M*UZOUD9<H"L> Y&6 LQ@QG7?>;!L6/R^V]PWVU8
MICFV]/E++LC<>#4W;$,K[ FILZ&NV5&-<@&OC$LI:EU+T-H@U@"<X8VA-2N'
M(I]?:"CMV:6PO47@94VTO$^Z::2@# 6+<VFXDM#DE0WRT)(EF'*WAY"&:N;P
M(:M>WO\ ].19PY-5F8FHM+_K B4Q"KJ!:MW46DKPY$1%BCD#04+B9/<F[MXE
M]HK(7\+\U>I\1T#4^D'/^Z= L;^ .,5'@GN%CZOH;&ZDFLJ @V,:3GW6Q5KO
MU45I^*"SJEB&KV4P6Z<0V8S6SL9F4?>;^$H+012?4P@IQ2%H@5O )(<ABCAD
MC*N26V)*8QV<VGEU1&"WUEMO68Y$<?N#(LM+& Y6V1_&++;!$RL;( L;FEDK
MM#>!:B1"PJHG[!-F,Y?9G487H\=KK)-&9>YG0OAHM#CC\M;PR,R]=;1:@11A
M](^E)J:,;>A!N'CF+EV$,3):D^@M#%C9L(LU[N.E57VX(L(@GU[B[*9CW3%S
M6.2*M#X:\J)G!3 13F9ARN@J//%4J6:=K&Y46WIM-L5+1!7MXYM)\3[-+PNK
MX&Y-<D51RB@E<$R<D P5=KFA[K120AR6?*=W5/)&GFFA4G#VCP2(K0"OA!(_
M9]B<CIR!CI+5)AUF!B"K;%LAB$H! ?'G31!'"\G2:(&(B<#=7#!E3&$P?-37
M, !+A4P?5DL:OJ$AY"7*+R=N163L%E$R:R,A\F*=*CBPE(I/P9)G+#!I6.P=
MT"E#H)T,\(.0ND\B<MEK<6*WJ+VKRT>W)YUH-GH8!<I29_3M#&/!E*EU)=/^
M?.F02I&/?C_<6U),JXLTE\DYSZZ0K;>MVU%*&H=9FC&113KD5Q]BMW)9B U!
M?UL@0S)URB"2 -*W-;J'DA<AO7'8VPN+5>U7Q\98\)=REV$XVI1O^('))A9)
MM2&46@4"%Q<R%AC:P8\;W=TUW=BVN/FA<1'JLZZ%MJ71.D_>JYK&78'ZQ3J=
MZN(3ZV@:5U@XFO=\%P-!+=)$UHTRLB9IVX*!FK8[2D+$#X6<RAGC\;XCK\I/
MRJZ,CZ"\@=2GN/-C'*XP@E@Y&C(1:=2D_=HZQ<K^:7U)GR<193%=\M1/YJX2
MV2&(6<QWQ;^DL"#@JRVK+,^M3X-KZ^Q!)-%>Z)DT<1(["/L+)+'+$^-"?PM5
MLL3U<C'H[UC)#EBLV*8I;?E;&+,0.(*1D@*1X.!(2B9#MQ(S'WB8UE7>IO8]
M->U7LOK?#ZZ+"6.24@)B#5PSE1&!@0PWI$B8%S E$Z;_ %^SZ17T4!6(X];:
M;0DP?G2GO]?BLM7@.C/C'E#M;@6YTCVFR@K,>#^TUMP!(C8AC3Z^>1[8I&G2
MQC+)!?S2JM4"ZS8KTKUQC8E1$)I0:JG*Q9 K9YVH9',DM;1CF:[F<UN2MCUN
MP6S;>4R35^2*.0S.$Q%:O(V 6Q%R\JWE"&P5>66*_LZEZL<@*GV:IG,BA0J?
MR@U_]VHUW.>0U<DJ/=7<\J#-_KFB_+7?A_FS:Q5V9"*5/NR25F!MXD1?F)R.
M1'^I W[4I_Z2EE,TV!^&Y-R\;2D^)YF:- G7#&)XF(_%$3_[1,<QJOHI>JF9
M^<KF=L[-J$<%-7;=)^X\R*?B97^,YT*N)2[GD2*-M75\?(3S\Q&2\\L:/E^M
ML^4<-Y9T_OV[),FC,UYUW86U=HK<=C_W!P^IFAO2; '/E?JP3@:L"ES%&4+8
M!5[0((I'^K57V:_*TUYG/Y?$;;H" R%($+2^N@ICQ=J<36%9V0Z,4QS7V[($
MMK/*11SR^]ZNX_:N7M;0V'M7=7J)GV/.'YBQD+-VKDK:AF+1)RYADFV48QWE
M19K4ZU'$XYJ["*T5EB4ZJ3[MVWR![-I;ZMZ.?=(N;M"*:UQ%$AL&7H+4(Y:V
M80FH"+,KULHC6- >47*01(2U(VR_=ZM=V;;^ VW@JM9N,6C_ !:0L)R%KQE<
ML)-4.ABWL6MHIE?YO18@$!]4C/'.OR#OW?7J%O;)Y"KN6S<F<7;;0N8''>8,
M3CKB+$U&(;20YZ"M!8'VTML,<XFQXQ9R769M^&WBY9U@3.K55CC]KO[%D0.0
MFKM"43EN;TM^-95%WN[@VM:$9=[*C,&N**/$AFU$B20E$#WSD);8U'/]\[N4
M]A85JK]#'+Y;?AM8%W<H^N:GU\>@&RP*U*P!(L^_8#^8(.U:>DI?W7T5]*;-
M2N&\*=K!Y[<-F!KX8J^2<[$;9I9%-JE>S]YU44.R.;H.5>QT8"O8I<$MQAD_
MS@M4;HZ>K.KJBKKSK^SNS0:X$,RY-AJX#+<H4:* BS+A KQ082CYF/+(B#&'
M$CEE>P>"&%&1MX@YJVN:Q==2%L:PP0LG$M(&4D*@)K380+&8 989G(C$F1%S
M,_MBE5?6IU*UB_:OOKUD(=>L#66^ZY2@6RV]=:NBL#K)B3FA72E F9"I2UP(
M1F8]V3W*O.WQ^ZK-@.68^TXKSVI(HFU_62<6)H(M-I$%.-/IZ?2V\FAPUU26
M%44*2^OL\W5:4<@65K*X)E:^SN.Y^G.QMI9NA%S(V0REQGF@\<-HT2A,$ @Q
MJ%PBVIH,$A[K>RN0G')GY/&'/]V[CSN.L2FJLJ2!)<!9FN+/(SJ1$(-9Y$&!
M"43U)0,B1G@8Z=RS:],[GT?N>GTFXZU:5VUW6KL!;.WVAM#2U>CF)#&8#$U3
M<\%3QSB)7PBU\0!PY@(008D-:.&H\3F=_P 5AZ&(KHJ8Q;*E2L!K74![F5^I
MEWF>CS;U/R23)-9 9F92R3[3$\;RN0M7W-?<('O<0F;R4L'20CU^24*^P]8@
M($X(1$1@('K'"/K9'Q3QRQ/?')&Z*2.2-SF21O8]KF/8]JHYCV.1'-<U4<UR
M(J*BI\^I1G$CQ,1,3S$Q,1,3$Q,3$Q/,3$Q\3$ZK;/CM,?$P',3_  F"YB8_
MG$_,:M=\-O<\\A_&Z[H*G2="Z%T+C5<R44KGI=U06!04*L8@CL[<[7-:XNI%
MKWQHK:.N(J0B8'S#P%5<LJ&Q\ZW9Z<X'<";#*U"A0R[)@EWP0]8$7SW]PFG8
MJ@TSB?E[!:8E$$0MB)";'@-^9K;]A ,N7;F+""AE G).8'XZRAMNO:)0A,1/
MA62ED/88)1%Y(T'<^]UGQ$Z+5C7\EC9/M[>&Y!Z)A>@W<.*FK:D;/V%S#;4N
M0V.SLN5:L>5,[!1$@YO5KK)3K""6OH"GW!%<[AU[TPW9CVRCQ!*EREE"[025
MP&-*P"94VU4IADZI1[B7B=FK%4064&\(4+(ZQ5]4-K7%"\Y=W;YU9"E?>%25
M)&LU\-35MW&8JV)>W%!*K6YN2;1E=8_*2]>"-I?:(\AX[5U@-X\98?99A"HX
MUSU3R;H(!L,D)I<[+>KMZJP'OHIGQ?B#CI!+&PD0@%I5X#(8!ZV9K^K& )7C
MG<-@J=F0F1L-RV/,9B0 92Q3E&B8[3)2TUA]+)!)P#-116/1S<0MBP.W*47J
ML% FA.&R2V#(&9"U;DL"P)2 P(I%K)[*@["B->O9H/;!X&B9S1<.\I>S9"NA
MN:NTQ,%-T"DMJD'0Q"'V:RU4(H=.:MJ346!<\<,1<5B*"7:2R+,*>3'Z^'>I
MN<GW-;-;9PMQDJ:JX3Z#U.-!&"NK))C0\(N6 D765L8"XCJ2QG6%7I!MPXJV
M\!O#/X]</2^A[;(UFI"U -=#$B"4,]P2&L(.&0T%FTI[+8P9G;08KRFS!3B+
M[J^-["#=WX,-W5%9M_(I\QEVV1ZE%X>TSL>O?.=^TS5\!='I(B3K L4PNNZ!
MG5)$A!I#[>V+0]48N[AF(KG*'+L_BXVK/B7T"\JR5.!"7"V1L5I$% 8"S'VN
MARR^5L=OBBWO8SN-W"BU;2-JLVE.WSHTO.WRMQ=FG&2EC(K$D3IWEFU[ <:L
MS1\BH5)$^:4. 4>"G-NH9E<,0R"<![X(&#2.;,4ZX/$_5,E?&P9WUEG(=+.R
M25BPI/-'70B#DB)H*F/J&9$X@BDHB8'Q 728B9..8$8@9B)[=1FXM(EB A6;
M9$ID#@#3R PLB@F>X<OO!D,+G@C.38)%'3N8L-91W5QN]%F[[QJH+'G=G^6S
M_F\X["VQ&MU6?!0BF*M,U)'*\5L[(&UM%;WA?ZD0J*)A:U4+A4EGE$E%"M:K
M;E>K)*_)]DL,@F*=2PR1<*;8\"7$EY;"$# F!%(>8H/5+L+LV\SD,??]/Z5G
M!6>UF<JUN$MGE,G02)5&6L<SDU]P7%>C;MLEB6  N]J!+Y9F.^\@JQ;"XY5X
M:XK$Z&(83.2$WU[SP6PL*JG%$B#JIC\YH:IW[($]KDIIA;"[!0.(>-H81#)X
M1YZ*^W&2M&8WK>OU9,[,#5KY,EK<\SDW"%RLW\\XXE\&E#).2GNP)$SHYWM_
M5O-;VGZ/X7#9&%)QQOR%[;PO?4IK2":C&XW(TS]DB8F*<JM74PD%#"$,$U+4
M,=UYFW;ZYED+R[G0AQPX,S#%KZ^\;)(V171U1\>FZY3GER-8Z0826D9).R-?
MM^#XD^N D;'K^64LRV2-:R8/3R-K3QQ$>9<U,)86$3/UF-C@>8B.\S\98M^M
MU\JHV%;3VXA]A:&PZ$ULB/:#DII/#*[RH/=,#,J0VA!,B)DI7U*-=/1\6TVR
M,>!K]IVGJ -C^GH[BC6X'Y/BA!AKZMLC+>R*K *,JQ_0ST[$JR\?GT.M("/T
MRS+3'EG0*F=K40AE.A@\4Q7>PFQ[<\O>,RK.2"5"]MD%PP;$^8+MB5J(/) ^
M=0++YR6Q\GF'2C,9[?.[*]J5XZY0F]7VC@TI5D:MIUVT=*KC76"KG0'V;L-C
MIL6P;*);-&RZPJ"5]U.EXKK :6V/Q_(L#SC8&BC\H\<]"_2],Z<VD-E( ?TK
M>$V01=3FVD1@.GKM.967%P"=:#R9]?PB$"]$KX=^?I,>E5[-Y++45F>:W16]
MIB,1-@(%D8G'"EH6+4A+!%M1;D(-:3"Q'8P/@-[=5'8V711MV<-LS;VV<X]:
M]H^F61G)[KW5^'V).O\ O7N)MQ#:F+%@U_+6RSZEZ_7?=4>+X6AR7/V?N)8W
M-/*QW*!8*RIL*9ER=O[^SN=I;4&MO)23[VGK,LQA@>GLJQKV1@%ILP< ^QF=
M"M]" *R Z(Q_IC?M"-W+R3&KL377C:RT4%6:=<077L.NE('44Z>9-<T&9.%#
MVBJ1E)JM6=_:1PN+(\-M)05ZMFD-RQN')6+V;MXW+Y FVK]*KB0%U?*VJ@S
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M_K=^ $."-SW?+Y'HZ1ZN>YRJTU&#^&Q9]?:IY<[_ .)U#M[U_P ?]71+:/\
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M)%GZ:_MGQJDA$J--*/V7\Y=>X1[DOF)[L>_K")L7F='=<P\>1KALKYJ4RVK
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MOAQC-CX1^:'+^*^/QFKZ")G\#J+4D.XK[VNUEB)JCIX8N$;UGXK2\C*.'?\
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%U=M?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
